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ABSTRACT 
 
Plant natural products have played a pivotal role in the discovery and 
development of many new drugs for the treatment of various infectious diseases and 
cancers. The present study was therefore aimed at isolation and identification of novel 
bioactive compounds from selected plants collected in Malaysia with anti-cancer 
activity. Plant crude extracts were obtained using solvent extraction methods, while 
various chromatographic and spectroscopic methods were employed for compound 
isolation and structure elucidation. Evaluation of pure compounds and crude extracts for 
anti-cancer activity involved the use of Neutral Red assay (NR), acradine orange – 
ethidium bromide (AO/EB) staining and cell cycle analysis. 
Phytochemical investigations of five Malaysian plants, namely, Ficus hispida, F. 
fistulosa, F. schwarzii, Artocarpus heterophyllus x integer and Macaranga hypoleuca, 
with the focus on alkaloids and flavonoids, have resulted in the isolation of a total of 24 
compounds, of which six are new. The leaf and stem-bark extracts of Ficus hispida 
yielded two new alkaloids, hispidacine (1) and hispiloscine (2), and a known alkaloid, 
13a(S)-(+)-deoxypergularinine (3). Hispidacine represents the first example of an 8,4'-
oxyneolignan incorporated an unusual 2-hydroxyethylamine moiety, while hispiloscine 
represents the first naturally occurring phenanthroindolizidine alkaloid with acetoxy 
substitution. The leaf and bark extracts of Ficus fistulosa provided two new septicine 
alkaloids, fistulopsines A and B (4 and 5), together with four known 
phenanthroindolizidine alkaloids, 13a(R)-(–)-3,6-didemethylisotylocrebrine (6), 13a(S)-
(+)-tylocrebrine (7), 13a(S)-(+)-tylophorine (8) and 13a(S)-(+)-septicine (9), and one 
known non-alkaloid (vomifoliol, 10). The leaves of Ficus schwarzii gave two novel tri-
nor-sesquilignan alkaloids, schwarzinicines A and B (11 and 12). The bark of 
Artocarpus heterophyllus x integer  yielded five known compounds, of which four are 
v 
 
prenylated flavonoids, namely, cudraflavone C (13), artocarpetin A (14), 
cycloheterophyllin (15) and artonin J (16), and one natural xanthone, lichexanthone 
(17). The leaves of Macaranga hypoleuca provided seven known compounds, of which 
three are flavonoid glycosides, namely, quercetin-3-O--L-arabinopyranoside (18), 
quercetin-3-O--L-arabinofuranoside (19) and quercetin-3-O-β-D-galactoside (20), 
three are flavonoid aglycones, namely, quercetin (21), kaempherol (22), and 5,7-
dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one (23), and one 
sterol 3-epi-taraxerol (24). Preliminary screening by NR assay found that the crude 
extracts (except for Artocarpus heterophyllus x integer) showed growth inhibitory 
activities against human breast (MDA-MB-231 and MCF-7), lung (A549), and colon 
(HCT-116) cancer cell lines. Of the 24 pure compounds obtained, hispiloscine (2), 
fistulopsine A (4), fistulopsine B (5) and cudraflavone C (13) were found to show 
growth inhibitory activity against colon (HCT-116) and breast (MCF-7) cancer cells. 
Furthermore, 4 and 5 were found to dominantly arrest cells in G1 phase of the cell cycle 
without the induction of apoptosis. Cell cycle perturbation of these compounds was 
found to be reversible for HCT-116 cells at the onset of 72 hours. These results suggest 
that 4 and 5 have the potential to be further exploited for the development of new anti-
cancer agents.  
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 1 
Chapter 1: Introduction 
1.1  Bioactive compounds from natural sources 
Plants have a long history of uses in the treatment of diseases throughout the world 
as they are the most exclusive therapy accessible to humans. Today, most of the 
populations in developing countries still rely on traditional medicines for basic healthcare.
1
 
This has brought the shift of focus towards ethnopharmacological intervention in 
addressing the current need to treat emerging health related issues such as drug resistance, 
relapses and incurable diseases. The diversity of compounds found in plants have provided 
a variety of lead structures that are suitable for further modification during drug 
development.
2
 This holds true as a large proportion of drugs that are currently available are 
derived from the diverse structures and the intricate carbon skeletons of natural products.
2
 
For instance, the therapeutic areas of infectious diseases and oncology have benefitted from 
the numerous drugs that are derived from natural sources. These include paclitaxel (anti-
cancer) from the plant Taxus brevifolia, artemisinin (anti-malaria) from the plant Artemisia 
annua, doxorubicin (anti-cancer) from the bacteria Streptomyces peucetius and lovastatin 
(cholesterol lowering) from the mold species Aspergillus terreus (Figure 1.1).
3,4
 However, 
only a fraction (5-15%) of the approximately 250, 000 higher plants have been investigated 
for biological potential.
3
 In light of this, the plant kingdom remains an essential source of 
new molecules with therapeutic potentials.
5
  
Although the term natural product refers to any naturally occurring substance, it is 
generally taken to mean secondary metabolites.
6
 In a natural environment, these 
compounds are produced by higher plants (and other organisms) as an evolution 
mechanism for protection, adaptation and overall survival but play little role in the growth 
 2 
and development, or other primary functions of the producing organisms.
6,7
 The palette of 
secondary metabolites can be divided into three broad groups which are the alkaloids, 
terpenoids and phenolics.
6
 Since secondary metabolites from natural sources are found 
within living systems, arguably they are often perceived as showing more biological 
friendliness, with relatively non-toxic nature and defined mechanism of actions as 
compared to predominantly synthetic compounds.
2,3,8
 The purpose of this study is therefore 
to identify novel secondary metabolites and their potential as medicinal agents from three 
plant genera, namely Ficus, Artocarpus and Macaranga, which are laden with alkaloids 
and flavonoids. 
 
 
Figure 1.1: Examples of natural product derived drugs 
 3 
 
1.2  Alkaloids 
Alkaloids are nitrogen-containing organic substances of natural origin with greater or 
lesser degree of basic character where the nitrogen is derived from an amino acid.
9,10
 
Alkaloids and alkaloid-containing plant extracts are often biologically active and have 
prominent purpose as medicine, poisons and psychoactive drugs.
11
 Well known plant 
families that are marked as alkaloid producers include Rubiaceae, Papaveraceae and 
Apocyanaceae.
12
 The distribution of an alkaloid can differ greatly where some alkaloids are 
present only in selected genera while others are commonly found across more than one type 
of plant.
13
 For example, cocaine is specific to the genus Coca (Erythroxylaceae) while 
caffeine which is common to the genus Coffea (Rubiaceae) can also be found in the genus 
Camellia (Theaceae) (Figure 1.2).
13
 Although mainly found in higher plants, alkaloids have 
also been found in fungi, marine organisms, insects, micro-organisms and mammals.
14
 
Most alkaloids are chiral molecules which means the optical isomers may show different 
physiological activities.
15,16
 Alkaloids are also naturally basic and the degree of basicity 
may vary depending on the number and position of nitrogen atoms, electron withdrawing 
(reduce basicity) or electron enhancing (enhance basicity) groups surrounding the nitrogen 
atom. It is believed that the basic character of alkaloids makes them unstable to heat, light 
and oxygen.
15
 
Alkaloids constitute one of the most diverse structure classes of secondary 
metabolites showing a great variety in structural type. The main classification of alkaloids 
based on their structural types are shown in Figure 1.3.
17
 Among these alkaloid classes, 
phenanthroindolizidine alkaloids are among those which have been identified for their 
significant therapeutic potential such as anti-microbial, anti-inflammatory and particularly 
 4 
anti-cancer activity. This goes to show that there are much more to be discovered about the 
bioactivities of this class of compounds in the search of potential treatments for 
malignancy.
18–20
 
 
 
Figure 1.2: Alkaloids: cocaine and caffeine 
 
 
Figure 1.3: Classification of alkaloids based on structure 
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 1.2.1  Phenanthroindolizidine alkaloids 
Indolizidine alkaloids are classed as such when the alkaloid posses the indolizidine 
ring as a dominant heterocyclic system. With the addition of the phenanthrene ring system 
to the core indolizidine ring, they are classed as phenanthroindolizidine alkaloids (Figure 
1.4). The phenanthrene portion is generally substituted with three to five methoxy or 
hydroxy groups.
19,21
 Phenanthroindolizidines have been found in the plant families of 
Asclepiadaceae (genus Cycnanchum, Pergularia, Vincetoxicum) and Moraceae (genus 
Ficus).
22
 Tylocrebrine (7), tylophorine (8) and tylophorinine (25) were the first few 
phenanthroindolizidine alkaloids to be identified (Figure 1.5).  
 
Figure 1.4: Basic skeleton of phenantroindolizidine alkaloid 
 
 
Figure 1.5: Structures of first discovered phenantroindolizidines 
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1.3  Flavonoids 
Flavonoids are a group of polyphenolic compounds with variable phenolic 
structures, occurring in virtually all plant parts particularly as a major colouring component 
of flowering plants.
23
 They represent the largest and most diverse group comprising of 
more than 3000 varieties, many of which are responsible for a variety of biological 
activities.
24
 Flavonoids and their polymers constitute a large class of food constituents and 
are thought to have health promoting properties due to their high antioxidant capacities 
both in vitro and in vivo.
25,26
  
Chemically, flavonoids consist of two aromatic rings (rings A and B) that are 
connected through a three-carbon unit, which in most cases also forming part of the 
heterocyclic pyran ring C (Figure 1.6). They can be further divided into a variety of classes 
where each flavonoid class differed in the level of oxidation and pattern of substitution of 
the C-ring (Figure 1.7), while individual compounds within each class differ in the 
substitution pattern of the A and B rings.
27
 Flavonoids are usually hydroxylated in 
positions-2, -3, -5, -7, -3', -4' and -5'.
23
 Occasionally, aromatic and aliphatic acids, 
sulphates, and prenyl, or methelenedioxy groups are also attached to the flavonoid 
nucleus.
27
 Flavonoids can occur as aglycones, glycosides and methylated derivatives. In 
most cases, flavonoids are present as glycosides in vacuoles of flowers, leaves, stems or 
roots, while flavonoid aglycones were reported as farinose exudates or wax on the leaves, 
bark and buds.
27
 The basic flavonoid structure is an aglycone (Figure 1.6). However, when 
glycosides are formed, the glycosidic linkage is normally attached in position-3 or -7 and 
the carbohydrate can be L-rhamnose, D-glucose, glucorhamnose, D-galactose or L-
arabinose.
23
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Figure 1.6: Basic structure of a flavonoid skeleton 
 
Figure 1.7: Structures of flavonoid classes 
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1.4  Genus Ficus  
Globally, the genus Ficus consists of more than 800 species (more than 100 occurring 
in Peninsular Malaysia) of deciduous trees, shrubs, vines, epiphytes and semi-epiphytes in 
the family Moraceae.
28
 Collectively known as “Fig trees”, they are distributed primarily in 
sub-tropical and tropical regions.
29
 Although, great majority of the species grow in 
lowlands, some can be found in altitudes that reach up to approximately 2000 meters above 
sea level.
30
 Ficus are keystone species in the tropical rainforests that play an important role 
in the ecosystem as their fruits provide a source of nutrition to insects, birds and animals 
throughout the year.
31
 
A number of Ficus species are used as food and for medicinal properties in ayurvedic 
and traditional Chinese medicine (TCM) where different plant parts ranging from roots, 
bark, leaves, latex and fruits are used for specific reasons. In ayurvedic medicine, figs are 
used as treatment for eczema, leprosy, rheumatism, sores, ulcers and pains.
32
 In TCM, 
cooked figs are used for the treatment of diarrhea and as a gargle for sore throats, while the 
leaves are used as poultice for hemorrhoids.
33,34
 In addition, the Ficus plants are also used 
to treat benign neoplasia such as warts and as an anti-inflammatory agent for boils and 
pains, which are suggestive of potential anti-cancer and anti-inflammatory actions of this 
plant genus.
34
 
1.4.1  Phytochemicals and bioactivities of Ficus species 
Some Ficus species have been evaluated for biological activities related to cancer, 
revealed promising anti-cancer activities. This include in vitro anti-proliferative activities 
against several cancer cell lines and in vivo inhibition of hepatic carcinoma xenographs in 
 9 
mice.
34
 In addition to that, a fraction from the extract of F. citrifolia have been found to 
induce accumulation and cytotoxicity of chemotherapeutic drugs such as vinblastine and 
daunomycin in cancer cells, thus, suggesting possible complementary role in cancer 
chemotherapy and addressing multidrug resistance of cancer cells.
35
 Despite the significant 
pharmacological activities shown by the Ficus extracts, there are limited reports on the 
biologically active metabolites from the Ficus plants.  
Previous phytochemical investigations involving eight Ficus species had led to the 
identification of over 100 compounds.
34
 A substantial number of these compounds are 
phenanthroindolizidine alkaloids (from the leaves and stems of F. septica and F. hispida) 
and flavonoids,
36
 along with several coumarins,
37
 and triterpenoids.
38
 The most promising 
cytotoxic class of compounds found in these Ficus species are the triterpenes and 
phenanthroindolizidine alkaloids.
34
 The phenantroindolizidines are however found 
primarily in the genera, Cynanchum, Pergularia, and Tylophora of the Aspiadaceae 
family,
39
 although they have also been previously isolated from F. hispida, F. septica and 
F. fistulosa.
19,34,40,41
 
A significant number of novel and known alkaloids  (Table 1.1, Figure 1.8) from 
five different alkaloid subclasses have been isolated from F. septica and F. hispida which 
include ficuseptine A (26), ficuseptines E-N (30-39), (+)-tylophorine (8), and a mixture of 
(+)-antofine (50) and (+)-isotylocrebrine (49), and O-methyltylophorinidine (62) all of 
which exhibited potent cytotoxic activity against several cancer cell lines.
19,21,40
 To date, 
phytochemical studies on F. fistulosa have resulted in the isolation of a new 
benzopyrroloisoquinoline alkaloid, fistulosine (59) which accounted for the anti-fungal 
activities observed in the crude alkaloidal extract.
41
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Table 1.1: Alkaloids from the genus Ficus. 
Plant  Alkaloid class Alkaloid name Ref 
F. septica Phenanthroindolizidine Ficuseptine A (26) 
41
 
  Ficuseptine B (27) 
Ficuseptine C (28) 
Ficuseptine D (29) 
18
 
  Ficuseptine E (30) 
Ficuseptine F (31) 
Ficuseptine G (32) 
Ficuseptine H (33) 
Ficuseptine I (34) 
Ficuseptine J (35) 
Ficuseptine K (36) 
Ficuseptine L (37) 
Ficuseptine M (38) 
Ficuseptine N (39) 
19
 
  10R,13aR-tylophorine-N-oxide (40) 
10R,13aR-tylocrebrine-N-oxide (41) 
10S,13aR-tylocrebrine-N-oxide (42) 
10S,13aR-isotylocrebrine-N-oxide (43) 
10S,13aS-isotylocrebrine-N-oxide (44) 
18
 
  Dehydrotylophorine (45) 
10S, 13aR-tylophorine-N-oxide (46) 
10S, 13aR-antofine-N-oxide (47) 
 
  Tylophorine (8) 
14-α-hydroxyisocrebine-N-oxide (48) 
 
 
 
Isotylocrebrine (49) 
Antofine (50) 
 
  14-Hydroxy-2,3,4,6,7-
pentamethoxyphenanthroindolizidine (51) 
14-Hydroxy-,3,4,6,7-
tetramethoxyphenanthroindolizidine (52) 
 
 Seco-phenanthroindolizidine  Septicine (9) 
Secoantofine (53) 
42
 
 Aminocaprophenone Ficuseptamine A(54) 
Ficuseptamine B (55) 
 
 Pyrolidine Ficuseptamine C (56) 
Norruspoline (57) 
Phyllosterone (58) 
 
F. fistulosa Benzolopyrroloindolizidine Fistulosine (59) 
39
 
 Phenanthroindolizidine  Antofine (50) 
Secoantofine (53) 
14β-Hydroxyantofine (60) 
 
F. hispida Seco-phenanthroindolizidine Hispidine (61) 
38
 
 Phenanthroindolizidine O-Methyltylophorinidine (62)  
Bold highlights denote novel compounds isolated from respective plants. 
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 12 
 
Figure 1.8: Alkaloids from Ficus spp. 
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1.5  Genus Artocarpus 
The Artocarpus genus evergreen and deciduous trees from the of Moraceae family 
which covers approximately 60 genera of 1400 species.
43
 They are distributed in the 
tropical and sub-tropical regions of Asia, and are native to South and Southeast Asia, New 
Guinea and the Southern Pacific.
43
 The Artocarpus comprises mainly of jackfruit and 
breadfruit trees and are known as economic sources of food and widely used in traditional 
medicine, agriculture and industry. The use of the Artocarpus plants in traditional medicine 
included treatment of inflammation, malarial fever, diabetes, and other minor ailments such 
as diarrhea, ulcer and asthma.
43
 This genus received great scientific interest as they contain 
important secondary metabolites possessing useful biological activities.  
 „Nangka‟ (A. heterophyllus), „cempedak‟ (A. integer) and breadfruit or „sukun‟ 
(A. communis) are among the local variety of Artocarpus fruits found in Malaysia and 
Indonesia which have been thoroughly investigated due to their significant bioactivities. 
Consequently, a hybrid between A. heterophyllus and A. integer has been developed to 
enhanced disease resistance, fruits that are larger in size with better texture and taste.
44
 
Owing to the vast medicinal potential of the parent plants, the phytochemical constituents 
within the hybrid plant are worth to be explored. A preliminary study on the hybrid plant 
was undertaken by Panthong et al.,
44
 which uncovered a new prenylated flavone and was 
found to show significant antioxidant and antibacterial activities. Coincidentally, work on 
the hybrid plant extract was carried out by the author when Panthong et al. published their 
findings in 2013. 
44
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1.5.1  Phytochemicals and bioactivity of Artocarpus flavonoids 
The Artocarpus species are rich in phenolic compounds including flavonoids, 
stilbenoids and arylbenzofurans. The Artocarpus flavonoids constitute a relatively 
homogenous group of compounds, almost all derivatives are from the basic tricyclic 
structure of a flavone and differ only in the nature of substituents and substitution patterns 
of the A and B rings (Figure 1.6). Isoprenyl substituents at C-3 (3-prenylflavones) are 
mostly present in the form of a carbocyclic ring or an oxygen-bearing ring fused with rings 
B and C forming cyclic derivatives such as oxypinoflavones, pyranoflavones, 
dihydrobenzoxanthones, furanobenzoxanthones, and pyranodihydrobenzoxanthones (Figure 
1.9).
45
 The occurrence of an isoprenyl substituent at C-3 and a 2',4'-dioxygenated or 2',4',5'-
trioxygenated B-ring in the flavone skeleton was deemed to be of chemotaxonomic 
significant and are broadly believed to be the requirements for cytotoxic activity.
46
 
Known and novel flavonoids from selected Artocarpus plants are shown in Table 
1.2 and Figure 1.10. Interesting biological activities have been described for many phenolic 
metabolites from the  Artocarpus, which include anti-inflammatory, anti-viral, anti-
bacterial and anti-platelet effects.
43
 Certain members of these metabolites also displayed 
cytotoxic activity against various human cancer cell lines. Phytochemical investigations on 
A. integer yielded several new flavonoids, namely, artocarpones A (63) and B (69),
47
 
cyclochempedol (66),
48
 artoindonesianins A (71) and B (72),
49
 and artoindonesianins U-T 
(73-78)
50,51
 along with other known flavonoids. Artoindonesianins B (72), U (73), V (74) 
and T (78) together with two known flavonoids, heterophyllin (65) and cudraflavone C (13) 
showed strong cytotoxic activity against murine leukemia P-388 cells with IC50 values 
below 10 μM.52  Similarly, a new oxepinoflavone artoindonesianin E1 (126), isolated from 
the wood of A. elasticus, also showed cytotoxic activity against P388 cells.
53
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A. heterophyllus wood extract was found to exhibit strong tyrosine kinase inhibition 
activity, which is the key target involved in melanin biosynthesis.
54
 Alterations in 
melanogenesis occur in many diseases including malignant melanoma. Bioassay guided 
fractionation of the extract yielded artocarpanone (80), which proved to inhibit tyrosine 
kinase activity and melanin production in B16 melanoma cells with potent antioxidant 
activity.
54
 Furthermore, a series of structurally related isoprenoid-substituted flavonoids 
was also isolated from the wood of A. heterophyllus and were tested on B16 melanoma 
cells.
55
 Among the tested compounds, artocarpin (83), cudraflavone C (13), kuwanon C 
(86), cudraflavone B (84) and brosimone I (87) were the most active, possibly due to the 
position and number of isoprenoid moieties per molecule, which is believed to influence 
flavonoid cytotoxicity.
55
 In a separate study, artocarpanone (80), artonin B (88) and 
cycloheterophyllin (15) were shown to exert anti-inflammatory activity by their inhibitory 
effects on chemical mediators released from inflammatory cells (mast cells, neutrophils and 
macrophages).
56
 
Given the potency of A. integer and A. heterophyllus, a hybrid of these two plants 
naturally prompted the investigation of its constituents. A recent report identified a novel 
prenylated flavone (96) from the roots of a hybrid between A. integer and A. heterophyllus 
along with 24 other known compounds.
44
 The known compounds isolated from the hybrid 
plant were among those that were novel to its parent plants such as artocarpanone (80) and 
norartocarpetin (82) from A. heterophyllus and artoindonesianin S (77) from A. integer. 
Bioactivity study of the novel flavone (96) demonstrated potent antioxidant activity and 
strong anti-bacterial activity against Acenetobacter baumannii.
44
  
Three new geranyl chalcone derivatives from A. communis, namely, isolespeol 
(117), 5'-geranyl-2',4',4-trihydroxychalcone (118) and 3,4,2',4'-tetradyhydroxy-3'-
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geranyldihydrochalcone (119) were tested for in vitro anti-cancer activity against a panel of 
human cancer cell lines. The results indicated that 117 was the most potent against SW 872 
human lipocarcinoma cells where treatment with the compound induced apoptosis in the 
cells through mitochondria-mediated pathways.
57
 The novel prenylflavonoids, artoflavone 
A (111) and cyclogeracommunin (112) showed protective effect on DNA damage which 
serve as effective antioxidant agents that may provide chemopreventive measures against 
carcinogenesis.
58
  
Phytochemical studies from the root bark of A. rotunda yielded new prenylated 
flavone artoindonesian L (122) along with known phenolic compounds identified as artonin 
M (124) and E (123), cycloartobiloxanthone (120) and artonin O (125). These compounds 
were found to show potent cytotoxicity against murine leukemia cells P-388 with IC50 
values less than 10 μg/mL.59 The prenylflavonoids 120, 124 and 125 , which were also 
isolated from the stem-bark of A. kemando showed cytotoxicity against human oral 
epidermoid carcinoma KB cells, all of which showed IC50 values less than 4 μg/mL.
60
 In a 
separate study, 120 showed cytotoxicity against breast cancer and human small cell lung 
cancer (NCI-H187) cell lines.
61
  
Investigation of the twigs of A. rigida yielded four new prenylated flavonoids which 
were evaluated for their cytotoxicity against human colon cancer cell line HT-29. Among 
the novel prenylated flavonoids, artorigidin B (132) was found to be cytotoxic against HT-
29 with IC50 value of 3.4 μM, while artorigidin A (130) exhibited NF-κB inhibitory 
activity.
62
 Evidence suggested that activation of NF-κB contributes to the development of 
several types of human cancers; in as such NF-κB presents a good target for cancer therapy.  
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Figure 1.9: Distinct classes of flavonoids from Artocarpus
45
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Table 1.2: Flavonoids from Artocarpus 
Plant Class Compound Ref. 
A. champedem 
(Synonym: A. 
integer) 
Prenylflavone Artocarpones A (63) 
Artoindonesianin R (64) 
Heterophyllin (65) 
47
 
 Pyranoflavone Cyclochempedol (66) 
48
 
 Flavanone Artoindonesianin E (67) 
Heteroflavanone C (68) 
 
 Furanodyihydroxybenzoxantho
ne flavone 
Artocarpones B (69) 
Artonin A (70) 
 
 Pyranoflavones Cycloheterophyllin (15)  
 Furanodyihydroxybenzoxantho
ne flavone 
Artoindonesianin A (71) 
49
 
 Oxepinoflavone Artoindonesianin B (72)  
 Prenylflavone Artoindonesianin U (73) 
51
 
 Dihydrobenzoxanthone flavone Artoindonesianin V (74)  
 Prenylflavones Artoindonesianin Q (75) 
Artoindonesianin R (76) 
50
 
 Dihydrobenzoxanthone flavone Artoindonesianin S (77) 
Artoindonesianin T (78) 
 
A. 
heterophyllus 
Flavanone Artocarpanone A (79) 
Artocarpanone (80) 
63
 
 Flavone Artocarpetin A (14) 
Artocarpetin (81) 
Norartocarpetin (82) 
 
 Prenylflavone Artocarpin (83)  
  Cudraflavone B (84) 
Cudraflavone C (13) 
6-prenylapigenin (85) 
Kuwanon C (86) 
55
 
 Pyranoflavone Brosimone I (87) 
64
 
 Furanodyihydroxybenzoxantho
ne flavone 
Artonin A (70) 
65
 
 Dihydrobenzoxanthone flavone Artonin B (88)  
 Furanodyihydroxybenzoxantho
ne flavone 
Artonin J (16) 
Artonin K (89) 
Artonin L (90) 
66
 
  Artonin Q (91) 
Artonin R (92) 
67
 
 Oxepinoflavone Artonin S (93)  
 Furanodyihydroxybenzoxantho
ne flavone 
Artonin T (94)  
 Flavone Artonin U (95)  
A. 
heterophyllus 
x integer 
Pyranoflavone 2,8-Dihydroxy-3,10-dimethoxy-6-
(2-methyl-1-propen-1-yl)-6H,7H-
[1]benzopyrano[4,3-b]-
[1]benzopyran-7-one (96) 
44
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Table 1.2 continued 
  Isocyclomulberin (97) 
Cyclocommunol (98) 
Cycloheterophyllin (15) 
 
 Chalcone Flavokawain A (99) 
Gemichalcone A (100) 
 
 Flavonone Dihydromorin (101) 
Sakuranetin (102) 
Naringenin (103) 
Artocarpanone (80) 
 
 Flavone Isosinensetin (104) 
Norartocarpetin (82) 
Artonin Y (105) 
Morusin (106) 
Artocarpin (83) 
 
 Furanodihydroxybenxoxanthon
e 
Artopeden A (107) 
Artonin A (88) 
Artonin F (108) 
 
 Dihydroxybenzoxanthone Artoindonesianin S (77)  
 Isoflavone 5,3‟,4‟-trimethoxy-6,7-methylene 
dioxyisoflavone (109) 
 
A. altilis  
Synonym:  
A. communis) 
Prenylflavone Hydroxyartocarpin (110) 
Morusin (106) 
Artocarpin (83) 
68
 
  Artoflavone A (111) 
58
 
 Pyranoflavone Cyclogeracommunin (112)  
  Cycloartocarpin A (113) 
68
 
 Flavanone Arcommunol C (114) 
Arcommunol D (115) 
69
 
 Chalcone 5’-geranyl-3,4,2’,4’-
tetradyhydroxydihydrochalcone 
(116) 
 
  Isolespeol (117) 
5’-geranyl-2’,4’,4-
trihydroxychalcone (118) 
3,4,2’,4’-tetradyhydroxy-3’-
geranyldihydrochalcone (119) 
57
 
 Furanodihydrobenzoxanthone Cycloartobiloxanthone (120) 
Artoindonesianin V (74) 
68
 
A. gomezianus Prenylflavone Artogomezianone (121) 
70
 
A. rotunda Prenylflavone Artoindonesianin L (122) 
Artonin E (123) 
59
 
 Furanodihydrobenzoxanthone Cycloartobiloxanthone (120) 
Artonin M (124) 
 
 Quinonoxanthone Artonin O (125)  
A. elasticus  Oxipinoflavone Artoindonesianin E1 (126) 
53
 
 
 
Prenylflavone Artocarpin (83) 
Cycloartocarpin (127) 
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Table 1.2 continued   
 Pyranoflavone Cudraflavone A (128) 
53
 
A. rigida Pyranoflavone Cyclorigidol (129) 
62
 
 Quinonoxanthone Artorigidin A (130) 
Artorigidin C (131) 
Artonin O (125) 
 
 Pyranoflavone Artorigidin B (132)  
Bold highlights denote novel compounds isolated from respective plants. 
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Figure 1.10: Flavonoids from Artocarpus spp. 
1.6  Genus Macaranga 
Macaranga is the largest genera of the Euphobiaceae family, comprising of 
approximately 300 species, 40 of which are found growing in the secondary forests of 
Malaysia.
71,72
 Native to tropical Africa, Madagascar, South-East Asia, Australia and the 
Pacific region, they recolonize almost any undisturbed terrestrial habitat.
73
 These plants are 
noted for their mutualistic association with ants due to the plant‟s hollow stems which serve 
as shelter and sometimes provide nectar for the ants, while the plant in return receives 
protection from herbivorous insects.
74
 Traditionally, various species of Macaranga are used 
to treat swellings, cuts and boils.
75
 The sap of the young shoots of M. triloba and M. 
gigantea are used to treat fungal infections while the leaf decoction is consumed for 
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stomachaches.
76
 M. hypoleuca has been used as a febrifuge, expectorant and anti-
spasmodic.
77
 
1.6.1  Phytochemicals and bioactivity of Macaranga flavonoids 
The Macaranga genus encompasses a wide variety of species, many of which still 
remain unexplored in regards to phytochemical and biological studies. To date 
approximately 26 Macaranga species (out of 300 plant species) have been studied, and 
resulted in the identification of close to 190 secondary metabolites.
74
 Most of the isolated 
compounds have been reported from the leaves while approximately 10% of the isolated 
compounds were from other plant parts.
74
 Phytochemical investigation revealed that 
flavonoids, particularly the isoprenylated and geranylated flavonoids and stilbenes, are the 
major phenolic constituents of Macaranga plants hence, are most likely responsible for 
most of the biological activities found in the plants of this genus.
78,79
  
Known and novel flavonoids from the selected Macaranga plants are shown in 
Table 1.3 and Figure 1.11. A majority of the flavonoids isolated from the Macaranga plants 
were flavonoids of the flavanone variety. The occurrence of dihydroflavonol and flavones 
in the Macaranga genus are limited.
80
 To date, dihydroflavonol derivatives have been 
isolated only from M. alnifolia
78
, M. conifera
81
, M. pruinosa
82
 and M. lowii
80
 while the 
presence of flavone was reported in M. lowii
80
 and M. gigantea
83
. Therefore, the presence 
of these flavonoids may serve as a form of markers for a certain group of Macaranga. 
Phytochemical and biological studies on the wide array of compounds from various 
Macaranga species have uncovered many bioactive constituents, particularly as potential 
anti-cancer agents. Phytochemical investigation of the leaves of M. tanarius yielded seven 
novel prenylflavones which were characterized as macaflavones A-G (140-146). Biological 
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evaluation of the isolated compounds showed that macaflavone G (146) was the most 
active (IC50 ~ 10 μM) against oral and lung cancers, KB and A549 cell lines, respectively.
79
 
Cytotoxic evaluation of the flavonoids macagigantin (167), glysperin A (168) and apigenin 
(169) from M. gigantea showed that 168 and 169 possessed moderate cytotoxicity, while 
167 was only weakly active. This suggests that the presence of a farnesyl substituent at A-
ring of the flavonoid structure (Figure 1.6) in 167 may be the cause of reduced cytotoxicity, 
while the presence of the isoprenyl substituent in the B-ring in 168 and 169 enhances 
cytotoxicity.
83
 Cytotoxicity of the flavonoid macakurzin C (175) isolated from M. kurzii 
showed cytotoxicity against KB cells, while possessing moderate acetylcholisnestrace 
(AChE) inhibitory activity.
84
 AChE inhibitors are therapeutic agents for the treatment of 
neurological disorders by preventing the hydrolysis of acetylcholine (neurotransmitter) thus 
making more acetylcholine avalaible at the cholinergic synapses. 
In a study of bioactive compounds from M. triloba, three quercetin derivatives (161-
163) were found to show specific cancer fighting potential, where 162 showed cytotoxicity 
towards murine hepatoma Hepa 1c1c7 cells, while compounds 161 and 162 showed 
promising activities in the Quinone Reductase (QR) assay indicating their potential as 
chemopreventive agents.
85
 Lonchocarpol A (150), a prenylated flavanone from the leaves 
of M. conifera showed strong inhibitory activities in both cyclooxygenase-1 (COX-1) and 
cyclooxygenase-2 (COX-2) and also exhibited significant inhibitory activities in the 
development of 7,12-dimethyl-benz(a)anthracene (DMBA)-induced pre-neoplastic lesions 
in mouse mammary organs, rendering this compound as a potential cancer 
chemopreventive agent.
81
 The COX pathway is responsible for the regulation of 
prostaglandin under acute inflammation conditions hence, regulation of this pathway is a 
promising approach for cancer chemoprevention.
86,87
 Flavan and stilbenoid derivatives have 
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been known to exhibit COX-1 and COX-2 inhibitory activites.
88,89
 Since flavanones make 
up the major constituents of the Macaranga plants, they are potentials chemopreventive 
agents. 
Many terpenoids are known to be biologically active.
74,90
 Likewise, a wide range of 
bioactivities are described for flavonoids.
91–93
 As a result, the combination of these two 
types of compounds could potentially lead to more active hybrid compounds, or 
compounds with new biological properties. Denticulaflavonol (165) isolated from M. 
deticulata is the first natural hybrid compound constituting a diterpene and a flavonol.
94
 
The synthesis of 165 along with macarangin (166) and several prenylflavonoids were 
attempted by Basabe et al.
53
 whom later reported that the synthesized hybrid compounds 
showed moderate anti-tumorial activity towards the lung cancer (A549), colon cancer (HT-
29), cervical cancer (HeLa) and human leukemia (HL-60) cell lines.  
Table 1.3: Flavonoids from Macaranga plants 
Plant Class Compound Ref. 
M. tanarius Prenyl flavanone Tanariflavanone A (133) 
Tanariflavanone B (134) 
95
 
 
 Tanariflavanone C (135) 
Tanariflavanone D (136) 
Nymphaeol A (137) 
Nymphaeol B (138) 
Nymphaeol C (139) 
Tanariflavanone B (134) 
96
 
 
 Macaflavanone A (140) 
Macaflavanone B (141) 
Macaflavanone C (142) 
Macaflavanone D (143) 
Macaflavanone E (144) 
Macaflavanone F (145) 
Macaflavanone G (146) 
79
 
M. conifera Prenyl flavanone 5-Hydroxy-4′-methoxy-2″,2″-
dimethylpyrano-
(7,8,6″,5″)flavanone (147) 
 
81
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Table 1.3 continued   
  5,4′-Dihydroxy-[2″-(1-hydroxy-1-
methylethyl)dihydrofurano]-
(7,8,5″,4″)flavanone (148) 
5,7-Dihydroxy-4′-methoxy-8-(3-
methylbut-2-enyl)flavanone (149) 
Lonchocarpol A (150) 
Sophoraflavanone B (151) 
5,7-Dihydroxy-4′-methoxy-8-(2-
hydroxy-3-methylbut-3-
enyl)flavanone (152) 
Tomentosanol D (153),  
Lupinifolinol (154), 
 
 
 (2S)-5,7,3'-Trihydroxy-4'-
methoxy-8-(3''-methylbut-2''- 
enyl)-flavonone (155) 
(2S)-5,7,3',5'-Tetrahydroxy-6,8-
(3'',8''-dimethylobut-2'',7''-
dienyl)flavanone (156) 
97
 
 Flavonol Isolicoflavonol (157) 
81
 
M. triloba Flavanone Malaysianone A (158) 
98
 
 Prenylated flavanonne 6-Prenyl-3'-methoxy-eriodictyol 
(159) 
6-Farnesyl-3',4‟,5,7-
tetrahydroxyflavanone (160) 
Nymphaeol B (138) 
Nymphaeol C (139) 
 
99
 
 Flavone 3,7,3',4'-Tetramethylquercetin 
(161) 
3,7,3'-Trimethylquercetin (162) 
3,7-Dimethylquercetin (163) 
 
85
 
M. 
denticulata 
Prenylated flavone  3-O-Methyl-macarangin (164) 
Denticulaflavonol (165) 
Macarangin (166) 
94
 
 Flavonone Sophoraflavanone B (151)  
M. gigantea Farnesyl flavonol Macagigantin (167) 
Glyasperin (168) 
Apigenin (169) 
83
 
M. lowii Isoprenylated 
dihydroflavonol 
Macalowiinin (170) 
80
 
 Flavonone 4'-O-Methyl-8-isoprenylnaringenin 
(171) 
 
 Flavone 4'-O-Methyl-5,7,4'-
trihydroxyflavone (172) 
 
M. kurzii Flavonol Macakurzin A (173) 
84
 
  Macakurzin B (174) 
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Table 1.3 continued   
M. kurzii Flavonol Macakurzin C (175) 
84
 
M. pruinosa Flavonol Macapruinosin D (176) 
Macapruinosine E (177) 
Macapruinosine F (178) 
Papyriflavonol A (179) 
100
 
M. sampsonii Prenylflavanol Macaranones A (180) 
Macaranones B (181) 
Macaranones C (182) 
Macaranones D (183) 
101
 
M. anifolia Geranylated diydroflovonol  Anifoliol (184) 
Bonnaniol A (185) 
Diplacol (186) 
78
 
 Geranylated flavanones Bonnanione A (187)  
Bold highlights denote novel compounds isolated from respective plants. 
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Figure 1.11: Flavonoids from Macaranga spp. 
1.7  Anti-cancer activity of phenanthroindolizidine alkaloids and flavonoids 
Phenanthroindolizidine alkaloids and flavonoids have been touted as promising anti-
cancer agents because of their potent cytotoxicity with a broad range of cellular targets. The 
phenanthroindolizidine alkaloid, tylocrebrine (7), was one of the first members of its class 
to advance into clinical trial soon after its discovery in the early 1960‟s but was later 
aborted due to central nervous system (CNS) toxicity which manifested as disorientation 
and ataxia.
102
 However, medicinal interest in the phenanthroindolizidines was revived in 
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1990‟s when a number of these compounds were found to be highly potent with GI50 values 
in the low nanomolar to picomolar range. The National Cancer Institute (NCI) screening 
data from a panel of 60 tumor cell lines indicated that most of the alkaloids showed little 
discrimination between malignant and normal cells. However, the NCI collective data also 
found that these alkaloids retained their potency on drug sensitive and multidrug resistant 
(MDR) cell lines.
18
 
Contrary to alkaloids, flavonoids have little toxicity and are common components in 
the human diet particularly in fruits, vegetables and seeds, therefore presenting a good 
oppurtunity as chemopreventive agents. They have been shown to dislay a remarkable 
spectrum of biochemical and pharmacological activities such as anti-inflammatory, 
antioxidant, anti-viral and anti-cancer.
102
 Epidemiology studies showed lower risk of colon, 
prostate and breast cancers in Asians who generally consume more vegetables, fruits and 
tea than populations in the West hence, implicating that the flavonoid components in Asian 
diets may play a role as natural chemopreventive and chemotherapeutic agents.
104
 The 
encouraging results of anti-cancer effects in preclinical studies have encouraged the clinical 
trials of flavonoids in humans. Most recent is the emergence of flavopiridol, a novel 
semisynthetic flavone analogue (flavonoid alkaloid) of rohitukine, a leading anti-cancer 
compound from an indigenous tree from India.
105
 Flavopiridol was reported to inhibit  
cyclin-dependent kinases (CDKs) with cell cycle arrest at G1/S and G2M, induce apoptosis, 
promote differentiation, inhibit angiogenesis and modulate transcriptional events.
105
 
Flavopiridol, marketed under the name Alvocidib, is currently under clinical trial by 
Sanofi–Aventis for refractory/relapsed chronic lymphocytic leukaemia. If licensed, 
Alvocidib will be the first CDK inhibitor and may serve as an additional option for patients 
who generally have poor prognosis. 
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1.8  Structure-activity relationships 
Structure activity studies have demonstrated common features of compounds that are 
highly important to their different activities. Due to their diverse and potent 
pharmacological actions, flavonoids and alkaloids continue to be targets for synthesis, 
modification, and structure-activity relationship (SAR) studies. The most recent SAR of 
phenanthroindolizidine alkaloids were conducted by Wang et al.
106
 and Chemler.
20
 Notable 
key features highlighted by Chemler
20
 were the effect of the phenanthrene substitution 
pattern, the presence or lack of indolizidine ring fusion, the presence or lack of C-14-
hydroxy groups on the indolizine ring and the oxidation state of the amine (e.g., N-oxides 
vs. free amine counterpart). These features were later supported by Wang et al.
106
 who 
synthesized a series of phenanthroindolizidine alkaloids and their 14-amino derivatives for 
further evaluation of their anti-tumor activities against A549 and HL60 cell lines. Figure 
1.12 shows the comparison of SAR between antofine and the effect on the cytotoxic 
activity of the different structural features of its analogues. Collectively, their findings 
indicated that: (1) hydroxy or alkoxy substituents in the phenanthrene system are 
mandatory for biological activity (e.g, 133 and 50) but introducing hydroxy group at C-14 
reduces its effectiveness (e.g., 60), (2) Seco-analogues are substantially less active in vitro 
hence suggesting the importance of phenanthrene ring fusion (e.g., 50 vs 53), (3) the 
oxidation state of phenanthroindolizidine amines (N-oxides) (e.g., 50 vs 46) affects in vitro 
growth negatively, (4) introducing amino groups at C-14 was found to reduce cytotoxic 
activity (e.g., 50 vs 134) which may be due to steric effects of the phenanthrene unit, 
however, this increased polarity may be beneficial to offset CNS side effects despite slight 
reduction in activity.
106
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GI50 (μM) compiled from Wang et al.
106
: A549 = human lung adenocarcinoma, HL-60 = human 
promyelocytic leukemia cell line. 
a 
GI50 (μM) values measured from Stærk et al.
39
, 
b
GI50 (μM) from 
Stærk et al
18
: KB-3-1 = cervix carcinoma (HeLa deravative), KB-V1 = multidrug resistant cervical 
carcinoma. 
 
 
Figure 1.12: Structure activity relationship of antofine analogues 
 
Extensive research has been conducted on the potential anti-cancer effect of 
flavonoids. The underlying mechanisms of the different activities exhibited by flavonoids 
were alleged to be highly associated with specific structural features of the molecules.
107
 
Among the features identified include the presence of isoprenoid substituents in the 
flavonoid structure where an increasing number of such substituents showed enhanced 
cytotoxicity.
55
 The enhanced biological activity with the presence of isopenoid moieties is 
believed to be due to the increase hydrophobicity of the molecule which enhances the 
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overall affinity for biological membranes and protein interaction.
55,107
 Contrarily, 
flavonoids with sugar substituents (flavonoid glycosides) are generally rendered ineffective 
irrespective of the nature and position of the sugar moiety due to its reduced hydrophobicity 
which hinders them from entering the cytoplasm, hence decreasing its efficacy.
55
 The 
presence of the C-2–C-3 double bond in the C-ring are considered as a general feature that 
contributes to the anti-cancer activity of flavonoids.
91,107
 Accordingly, flavones and 
flavonols generally have better anti-cancer effects as compared to other sub-classes. 
Furthermore, Depint et al. inferred that role of the heterocyclic C-ring in the flavonoid 
structure is so crucial that any variation to its structure may lead to loss of the planarity of 
the flavonoid structure and thus reducing potency, such as in the case of flavanones and 
chalcones. The comparisons of activity observed by the structurally related flavonoids are 
shown in Figure 1.13. 
Although there seem to be consistent relationships between flavonoids and 
phenanthroindolizidine structures and their cellular activities in accordance with literature, 
the innate differences in cell lines, anti-cancer mechanisms, test systems and the lack of 
internal standards used in most SAR studies makes generalization of SAR properties 
virtually impossible. As such, this information may serve only as a suggestive indicator of 
possible bioactivity. 
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a
IC50 (μM) compiled from Arung et al.
55
 on B-16 bmelanoma cell line; 
b
Percentage of cell viability (vs 
control) of HT-29 colon adenocarcinoma cell line following treatment with 60 μM of the selected compounds 
as reported by Agullo  et al.
108
. 
 
Figure 1.13: Comparison of cytotoxic activity between structurally related flavanoids 
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1.9  Anti-cancer mechanisms of action  
The anti-cancer properties of phenanthroindolizidine alkaloids and flavonoids have 
been explored up to the biochemical level and several targets have been proposed. Given 
the complexity of cancer as a disease, the multi-targeted approach of these compound 
classes may be beneficial in controlling the onslaught of tumorigenesis. Among major 
targets evoked by phenanthroindolizidine alkaloids and flavonoids are as follows: 
1.9.1  Anti-proliferation/cytotoxicity 
The inhibition of protein biosynthesis is the most extensively studied mechanism for 
phenanthroindolizidine‟s anti-cancer activity aside from its inhibitory action on RNA and 
DNA synthesis. Since protein synthesis is more potently inhibited than nucleic acid 
synthesis, this is probably the primary mode of growth inhibition for the 
phenanthroindolizidines. This was supported by Donaldson et al.
109
 who first reported that 
tylocrebrine (7) and tylophorine (8) inhibited protein synthesis in Ehlich ascites-tumor cells 
by inhibiting the incorporation of leucine into protein. RNA synthesis was however not 
markedly affected.
109
 In a separate study, tylocrebrine (7) was on the contrary found to 
inhibit both RNA and DNA synthesis by the lack of thymidine and uridine incorporation, 
respectively.
110
 More recently, the phenanthroindolizidine derivative, YPC-100157, showed 
significant correlation between protein synthesis and its growth inhibition in A549 and HT-
29 cancer cell lines.
111
 It was postulated that YPC-100157 inhibited protein synthesis by 
blocking chain elongation, similar to tylophorine analogues.
110
 Aberrantly, protein 
synthesis highly contributes to tumerogenesis where there is a higher threshold for protein 
synthesis in transformed cells which positively correlates to higher rate of translation thus, 
higher rate of cell proliferation. As such, it can be assumed that phenanthroindolizidines 
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exert their cytotoxic effect primarily, but not necessarily exclusive, through protein 
synthesis inhibition. 
In flavonoids, the molecular mechanism of anti-proliferation may involve the 
inhibition of pro-oxidant process. This is because growth promoting oxidants (reactive 
oxygen species, ROS) are generally believed to be major catalysts of tumor promotion and 
progression.
112
 The production of ROS is triggered in the events of inflammation where it is 
responsible for causing DNA damage, increased rate of mutations and over-secretion of 
growth factors. In light of this, inhibitors that target the production of ROS or mediators of 
inflammation are important therapeutic strategies for malignancy. Flavonoids are good 
candidates in this sense as they are effective in inhibiting xanthine oxidase (an enzyme that 
generates ROS),
113
 COX-2 or LOX (inflammation mediators),
114
  and therefore inhibit 
tumor cell proliferation. 
1.9.2  Cell cycle arrest 
The cell cycle is composed of G1 (cells that are committed to the cell cycle), S 
(synthesis of DNA), G2 (DNA damage checkpoints), and M (separation of daughter cells) 
phases where entry into each phase is controlled by a series of checkpoint pathways. 
Progression throughout the cell cycle is driven by cyclin-dependent kinases (CDK). Tumor-
assosicated cell cycle perturbations are often linked to defective CDKs. Therefore, 
modulators of these components could potentially correct the faulty regulation that leads to 
uncontrolled cell proliferation in cancer. Checkpoints at G1/S and G2/M in the cell cycle 
have been found to be perturbed by both phenanthroindolizidine alkaloids such as antofine 
(53)
115
  and tylophorine (11),
116
 and flavonoids such as quercetin (24)
117
, kaempherol (22)
118
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and silymarin,
119
 while flavopiridol, a flavonoid-derived chemotherapy drug is known as the 
first CDK inhibitor currently in clinical trial.
105
  
1.9.3  Induction of apoptosis 
Apoptosis is an induced cell death which is essential in the elimination of damaged 
or unwanted cells hence, keeping the damaged cells from proliferating and passing the 
damage to succeeding generation of cells. Deregulation of apoptosis plays a critical role in 
tumor oncogenesis. Literature suggests that the anti-cancer activities induced by flavonoids 
may be due to  the induction of apoptosis selectively towards certain cancer cells but 
sparringly in normal cells.
112
 Although the molecular mechanisms in which flavonoids 
induce apoptosis have not been established,  several mechanisms which are thought to be 
involved include the release of cytochrome C, activation of caspases-3 and 9, alteration in 
Bax/Bcl2 (proapoptotic protein/oncogene-derived protein) ratio, and the down regulation of 
nuclear transcription factor kappaB (NF-kappaB) expression.
112,120
 Apigenin (104), 
quercetin (21), and kaempherol (22) were among several other flavonoids which are able to 
induce apoptosis.
120–122
 However, no evidence of apoptosis was observed for antofine (53) 
(in A549 and Col2), tylophorine (8) and its analogues (in HepG2 and KB) although the 
compounds showed potent inhibition of growth.
115,123
 From these data, it is suggestive that 
the induction of apoptosis is not a significant target for the phenanthroindolizidines.  
1.9.4  Cellular promotion and differentiation 
Differentiation is the process which immature cells become mature cells that are 
capable of carrying out specific functions. In cancer, deregulation of growth control 
ultimately leads to a selection of cells that replicate and yet fail to respond to differentiation 
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and maturation signals.
112
 As such, the induction of differentiation is a useful target for 
cancer therapy and prevention as this may lead to the eventual elimination of tumorigenic 
cells. Both phenanthroindolizidines and flavonoids were found to induce differentiation in a 
panel of cell lines. Tylophorine (11) 
123
 and its analogues have been reported to induce cell 
differentiation in HepG2 cells while the flavones genistein, apigenin (104), luteolin, 
quercetin (24), and phloretin were found to induce cell differentiation in human acute 
mylelogenous leukemia HL-60 cell into granulocytes and monocytes.
117
  
1.9.5  Inhibition of angiogenesis 
Angiogenesis is a process of growth of new blood vessels and is regulated by a 
variety of angiogenic and angiostatic factors. It is prominent in embryos but rather 
infrequent in adults, except in the case of tumor growth. When deprived of proper 
vascularization, tumor cells can no longer maintain its high proliferation rate due to lack of 
nutrients and oxygen. Targeting angiogenesis is therefore a highly effective way to 
suppress tumor growth. Tylophorine (8) (phenanthroindolizidine alkaloid) and flavonoids 
have been reported to potently inhibit angiogenesis by distruption of blood vessels, 
proliferation and migration of endothelial cells or inhibiting the binding of vascular 
endothelial growth factor (VEGF) to its receptors.
124,125
 VEGF is an inducer of 
angiogenesis that results in the proliferation, migration and the formation of new blood 
vessels hence, the modulation of VEGF expression creates new therapeutic avenues to 
address malignancy.
126
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1.11  Research objectives 
Ficus, Artocarpus and Macaranga have been regarded as plant genera that are 
associated either with phenanthroindolizidine alkaloids or flavonoids. 
Phenanthroindolizidine alkaloids and flavonoids have been regarded as potent anti-cancer 
metabolites hence, these plant genera represent potential sources of useful anti-cancer 
agents. As such, the aims of this research are to: 
1) Extract and isolate alkaloids from F. hispida, F. fistulosa and F. schwarzii, and 
flavonoids from A. heterophyllus x interger and M. hypoleuca. 
2) Elucidate the structures of the isolated compounds via various spectroscopic 
methods. 
3) Screen the isolated compounds for biological activity, with the focus on cytotoxic 
activity against breast (MDA-MB-231 and MCF-7), lung (A549), colon (HT-116) 
cancer cell lines as well as a non-cancer cell line (MRC-5). 
4) Propose on the anti-cancer mechanism of the active compounds. 
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Chapter 2: Isolation of alkaloids from Ficus hispida, Ficus 
fistulosa and Ficus schwarzii 
 
Preliminary screening by thin layer chromatography (TLC) of the basic crude 
extracts of the leaves and/or stem-bark/bark of F. hispida, F. fistulosa and F. schwarzii 
following acid-base treatment of the crude ethanolic extracts showed a series of orange 
spots when sprayed with Dragendorff‟s reagent, indicating the presence of alkaloids. Acid-
base extractions of the crude ethanolic extracts of the leaves and/or stem-bark/bark of the 
three Ficus species gave different percentage yields of the crude alkaloid mixtures, as 
summarized in Table 2.1. The crude alkaloid mixtures were subjected to repeated 
chromatography using column chromatography and preparative centrifugal thin layer 
chromatography (CTLC) techniques on silica gel until pure compounds were obtained. 
 
Table 2.1: Percentage yield of crude alkaloid mixture. 
Plant  Part  Dry weight (kg) Yield (g) (%) 
F. hispida Leaves 3 1.67 (0.06) 
 Stem-bark 3 0.67 (0.02) 
F. fistulosa Leaves 8 8.38 (0.28) 
 Bark 8 1.87 (0.06) 
F. schwarzii Leaves 4 0.88 (0.02) 
 
2.1  Alkaloids from F. hispida 
Three alkaloids were isolated from the leaves and stem-bark of F. hispida, two of 
which are new. The new compounds were identified as hispidacine (1) isolated from the 
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bark and hispilosine (2) from the leaves.
127
 The known alkaloid, which was isolated from 
the leaves was determined to be 13a(S)-(+)-deoxypergularinine (3).  
2.1.1 Hispidacine  
 
Hispidacine (1) was obtained in minute amounts from the stem-bark of Ficus 
hispida as a colourless oil, []D
25
 20 (c 0.28, CHCl3). The IR spectrum (Appendix 8) 
showed absorption bands due to OH/NH functions (3385 cm
-1
) and aromatic rings (1585 
and 1505 cm
-1
). The UV spectrum (Appendix 7) showed absorption maxima at 228 and 271 
nm, confirming the existence of aromatic rings. The ESIMS showed a pseudo-molecular 
ion at m/z 494 [M + H]
+
, and HRESIMS measurements established the molecular formula 
as C25H35NO9, requiring nine degrees of unsaturation.  
The 
13
C NMR data (Table 2.2, Figure 2.4) showed the presence of 19 discrete 
carbon signals, six of which are due to six pairs of equivalent carbons. The total number of 
carbon resonances was therefore 25, comprising of five methoxy, four methylene, eight 
methine, and eight quaternary carbon atoms, in agreement with the molecular formula. The 
six pairs of chemically equivalent resonances were due to two pairs of oxygenated aromatic 
O
OR2HN
OR3
MeO
MeO
OMe
OR1
OMe
MeO
1"
2"
1
4
7S
8S
9
3'
5'
1'
7'
8'
9'
1    R1 = R
2 = R3 = H
1a  R1 = R
2 = R3 = COOH
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carbons (C-3/C-5 and C-3'/C-5'), two pairs of aromatic methine carbons (C-2/C-6 and C-
2'/C-6') and two pairs of aromatic methoxy groups (3-OMe/5-OMe and 3'-OMe/5'-OMe). 
This, coupled with the presence of four other substituted aromatic carbons, strongly 
suggested the presence of elements of symmetry in two tetrasubstituted aromatic rings, with 
each possessing a pair of equivalent aromatic methine and methoxy-substituted aromatic 
carbons. This was further supported by the presence of two 2H aromatic singlets (δH 6.57 
and 6.61) and two 6H methoxy singlets (δH 3.81 and 3.82) in the 
1
H NMR data (Table 2.2, 
Figure 2.3). The above observations established the presence of two 1,3,4,5-tetrasubstituted 
aromatic rings with a mirror plane of symmetry passing through C-1 and C-4 as well as C-
1' and C-4', and requiring the pair of equivalent methoxy groups to be placed either at 
positions -3 and -5 or -2 and -6. The HMBC three-bond correlations from H-2/H-6 to C-7 
and H-2'/H-6' to C-7' confirmed the placement of the two methoxy pairs at C-3/C-5 and C-
3'/C-5', respectively (Figure 2.1).  
The 
1
H NMR data also showed the presence of a rather deshielded methylene signal 
at δH 4.30 (dd, J = 5.5, 1.6 Hz) and two olefinic signals at δH 6.28 (dt, J = 16, 5.5 Hz) and 
δH 6.52 (dd, J = 16, 1.6 Hz), which readily established the occurrence of a 3-
hydroxypropenyl moiety that corresponds to the Ar-C-7'–C-8'–C-9'–OH partial structure in 
1. The large coupling constant observed between H-7' and H-8' (16 Hz) indicated the E 
geometry of the C-7'/C-8' double bond. This was also supported by the NOESY data that 
showed a correlation between H-7' and H-9' (Figure 2.1). On the other hand, the 
1
H NMR 
signals at δH 4.07 (d, J = 5 Hz), 4.11 (td, J = 5, 3 Hz), 3.64 (dd, J = 12, 3 Hz) and 3.91 (dd, 
J = 12, 5 Hz), aided by the COSY data, established the occurrence of a CHCH(O)CH2OH 
fragment, corresponding to the Ar-C-7–C-8–C-9–OH partial structure in 1 (Figue 2.1). 
Additionally, the presence of a 2-hydroxyethylamine fragment corresponding to the -NH-
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C-1''–C-2''–OH partial structure in 1 was also shown by the COSY data (Figure 2.1, 
Apendix 3). From the observations disclosed thus far, it was evident that 1 consisted of two 
C6-C3 units and a 2-hydroxyethylamine moiety. Three-bond correlations from H-8' to C-1', 
H-7' to C-2'/C-6' and H-2'/H-6' to C-7' in the HMBC spectrum (Appendix 5) confirmed the 
attachment of the 3-hydroxypropenyl side chain at C-1', while correlations from H-2'/H-6' 
and H-8 to C-4' suggested attachment of C-8 to C-4' via an ether linkage. The C-7–C-8–C-
9–OH fragment was deduced to be linked to the aromatic C-1 at C-7, from two- and three-
bond correlations from H-7 to C-1, C-2/C-6 and H-2/H-6 to C-7. The three-bond 
correlations from H-1'' to C-7 and H-7 to C-1'' indicated the attachment of the 2-
hydroxyethylamine side chain to C-7. This left the remaining methoxy group which must 
be linked to C-4, which was confirmed by the observed three-bond correlations from 4-
OMe to C-4 and H-2/H-6 to C-4. The proposed structure of hispidacine (1) is entirely 
consistent with the HMBC and NOESY data (Figure 2.1, Appendix 5 and 6).  
 
Figure 2.1: Selected HMBC, NOESY and COSY correlations of 1 
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The presence of the three primary hydroxy groups in 1 was shown by acetylation, 
which yielded the triacetate derivative 1a. The 
1
H NMR spectrum of 1a (Figure 2.5) 
showed the characteristic presence of 3 x COCH3 signals at H 1.94, 2.08 and 2.11, while in 
the IR spectrum (Appendix 12) a strong absorption band was observed at 1738 cm
-1
. 
HRESIMS established the molecular formula of the triacetate derivative 1a as C31H41NO12. 
Additionally, the absence of the hydroxy groups in 1a was clearly indicated by the 
disappearance of the broad IR band at 3385 cm
-1
 observed for 1, which was replaced 
instead by a weaker but sharper band at 3325 cm
-1
 due to the secondary amine NH. 
Although acetylation could occur to hydroxy and amine groups, in the case of hispidacine, 
the amine group was not acetylated likely due to steric congestion. The positions of the 
three hydroxy groups at C-9, C-9' and C-2'' were further confirmed by the three-bond 
correlations from H-9, H-9' and H-2'' to the respective acetyl carbons observed in the 
HMBC data of 1a (Appendix 10).  The two germinal hydrogens of C-1'', as well as C-2'' in 
1, unexpectedly gave rise to two pairs of non-equivalent signals (H-1'': δH 2.57 and 2.66; H-
2'': δH 3.64 and 3.71), suggesting restricted C-1''–N bond rotation. This could be due to the 
occurrence of intramolecular hydrogen bonding between the hydroxy (H donor) and 
secondary amine (H acceptor) groups within the 2-hydroxyethylamine side chain. 
Alternatively, the hydroxy group could form a hydrogen bond with the proximate aromatic 
methoxy group at C-3'/5'. This supposition is somewhat supported by the observation of 
two sets of equivalent geminal hydrogens due to H2C-1'' and H2C-2'' at δH 2.65 and 4.16, 
respectively, in the 
1
H NMR data of the triacetate derivative 1a (Table 2.2, Figure 2.5). 
This suggested free rotation about the C-1''–N bond due to the absence of intramolecular 
hydrogen bonding following replacement of the hydroxy group at C-2'' with an O-acetyl 
group. 
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The structure of hispidacine (1) constitutes an 8,4'-oxyneolignan skeleton
128
 
featuring an unprecedented incorporation of a 2-hydroxyethylamine moiety at C-7. Due to 
the presence of two adjacent stereocentres (C-7 and C-8) in the molecule, there are two 
possible 8,4'-oxyneolignan diastereomers (erythro or threo). The relative configurations at 
the two stereocentres can be determined by analogy to the typical 8,4'-oxyneolignan system 
via examination of the magnitude of the coupling constant between H-7 and H-8. 
Accordingly, based on the energetically favourable staggered conformer with 
intermolecular hydrogen bonding between the benzylic hydroxy (at C-7) and aryloxy 
groups present in a typical 8,4'-oxyneolignan, large J7,8 values (associated with dihedral 
angles of approx. 180°) correspond to threo configuration, while small J7,8 values 
(associated with dihedral angles of approx. 60°) correspond to erythro configuration.
129–133
 
The main difference between 1 and the typical 8,4'-oxyneolignans is that the C-7 hydroxy 
group has now been replaced with a 2-hydroxyethylamine side chain. Examination of 
models suggested that the benzylic NH group in 1 is also able to form a similar 
intramolecular hydrogen bond with the adjacent aryloxy group (Figure 2.2). Since a small 
coupling constant 
3
J7,8 = 5 Hz was observed in 1, an erythro relative configuration was 
suggested for C-7 and C-8. Finally, the configuration of C-8 can be deduced by comparing 
the CD spectra of 1 and 1a with those of 8,4'-oxyneolignans or related compounds with 
known absolute configurations.
129,131,132,134
 In as such, the configuration of C-8 was 
proposed to be 8S by the negative Cotton effects observed at 237 and 235 nm in the CD 
spectra of 1 and 1a, respectively. Consequently, an S configuration must be assigned to C-7 
since the relative configuration between C-7 and C-8 was determined as erythro. Therefore, 
the structure of 1 was elucidated as (+)-(7S,8S,7'E)-3,3',4,5,5'-pentamethoxy-7-(2-
hydroxyethylamino)-8,4'-oxyneolign-7'-ene-9,9'-diol. 
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Figure 2.2: Staggered conformer of 1 with the lowest energy (viewed along the axis of the 
C-7–C-8 bond). Dotted bond shows intermolecular hydrogen bond between benzylic NH 
and adjecent aryloxy groups.
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Table 2.2: 
1
H and 
13
C NMR data of hispidacine (1) and the triacetate derivative (1a)
a 
Position 1   1a  
1
H (J in Hz) 
13
C 
1
H (J in Hz) 
13
C 
1 - 135.19  - 135.3 
2 6.57 s 104.8 6.60 s 104.9 
3 - 153.35  - 153.3 
4 - 137.2  - 137.1 
5 - 153.4  - 153.3 
6 6.57 s 104.8  6.60 s 104.9 
7 4.07 d (5) 64.6  3.88 m 63.9 
8 4.11 td (5, 3) 86.6  4.56 dt (7, 3) 82.9 
9 3.64 dd (12, 3) 61.5  4.29 m 63.2 
 3.91 dd (12, 5)   4.51 dd (12, 7)  
1' - 133.1  - 132.2 
2' 6.61 s 103.6  6.65 s 103.8 
3' - 153.41  - 153.5 
4' - 135.18  - 134.7 
5' - 153.41  - 153.5 
6' 6.61 s 103.6  6.65 s 103.8 
7' 6.52 dt (16, 1.6) 130.6  6.60 d (16) 134.1 
8' 6.28 dt (16, 5.5) 128.8  6.24 dt (16, 6.5) 123.0 
9' 4.30 dd (5.5, 1.6) 63.4  4.73 dd (6.5, 1.3) 64.9 
1'' 2.57 ddd (12, 6, 3.8) 
 
49.8  2.65 m 42.3 
 2.66 ddd (12, 6.9, 4)     
2'' 3.64 ddd (10.5, 6, 4) 62.0  4.16 m 64.7 
 3.71 m     
3-OMe 3.81 s 56.18  3.84 s 56.1 
4-OMe 3.80 s 60.9  3.83 s 60.8 
5-OMe 3.81 s 56.18  3.84 s 56.10 
3'-OMe 3.82 s 56.24  3.87 s 56.11 
5'-OMe 3.82 s 56.24  3.87 s 56.11 
3 x OH / 1 x 
NH 
2.76 br s -  Not observed - 
9-OCOCH3 - -  1.94 s
d
 20.8
b
 
9-OCOCH3     170.7
5
c
 
9'-OCOCH3 - -  2.08 s
d
 20.9
b
 
9'-OCOCH3     170.8
3
c
 
2''-OCOCH3 - -  2.11 s
d
 21.0
b
 
2''-OCOCH3     171.0
c
 
a
 CDCl3, 600 MHz; 
bd
 Assignments are interchangeable 
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Figure 2.3: 
1
H NMR spectrum (CDCl3, 600 MHz) of hispidacine (1) 
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1
 
 
Figure 2.4: 
13
C NMR spectrum (CDCl3, 150 MHz) of hispidacine (1) 
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2
 
 
Figure 2.5: 
1
H NMR spectrum (CDCl3, 600 MHz) of hispidacine acetate (1a) 
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3
 
 
Figure 2.6: 
13
C NMR spectrum (CDCl3, 150 MHz) of hispidacine acetate (1a) 
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2.1.2 Hispiloscine  
 
       2 
Hispiloscine (2) was a minor alkaloid obtained from the leaves of F. hispida as a 
light yellowish oil, []D
25
 +1 (c 0.40, CHCl3). The UV spectrum showed absorption 
maxima at 260, 286, 313 and 338 nm indicating the presence of a substituted phenanthrene 
chromophore,
135
 while the IR spectrum (Appendix 16) showed a strong absorption band at 
1736 cm
-1
 suggesting the presence of an ester carbonyl function. The ESIMS of 2 showed a 
pseudo-molecular ion at m/z 422 [M + H]
+
, and HRESIMS measurements established the 
molecular formula as C25H27NO5, requiring 13 degrees of unsaturation.  
The 
13
C NMR data of 2 (Table 2.3, Figure 2.11) indicated the presence of 25 carbon 
signals consisting of four methyl, four methylene, seven methine and 10 quaternary 
carbons, in agreement with the molecular formula. The most downfield carbon resonance at 
C 171.0 supported the presence of an ester function as indicated by the IR spectrum. In 
addition, the carbon resonances at C 149.1, 149.6 and 157.5 suggested the presence of 
three oxygenated aromatic carbons. The 
1
H NMR data of 2 (Table 2.3, Figure 2.10) 
indicated the presence of a 1,2,4-trisubstituted aromatic ring from the 
1
H signals observed 
at H 7.15 (dd, J = 9, 2 Hz), 7.62 (d, J = 9 Hz), and 7.86 (d, J = 2 Hz), while the two 
aromatic singlets at H 7.14 and 7.88 indicated the presence of a 1,2,4,5-tetrasubstituted 
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aromatic moiety. The four methyl singlets at H 2.03, 3.99, 4.04, and 4.09, were readily 
assigned to an acetyl and three aromatic methoxy groups, respectively. In addition to a pair 
of AB doublets (J = 14.7 Hz) observed at H 3.73 and 4.48, readily attributable to the 
isolated benzylic aminomethylene group (H-9), the 
1
H NMR data also revealed the 
presence of a profoundly deshielded aliphatic signal at H 6.62 (d, J = 7.4 Hz), which is 
characteristic of the benzylic methine H-14 when an acetoxy substituent is present at C-
14.
136,137
  
 In addition to the isolated methylene (H-9) and aromatic CH=CH fragment noted 
previously, the COSY and HSQC data (Appendix 9 and 10) also revealed a 
CH2CH2CH2CHCH(O) fragment corresponding to the N-C-11–C-12–C-13–C-13a–C-14–
Ar partial structure in 3, indicating the presence of an indolizidine moiety with oxygenation 
at C-14. The substitution pattern of the phenanthrene moiety was established by detailed 
analysis of the NOE data (Figure 2.7). Reciprocal NOEs between H-14 and the aromatic 
doublet at  7.62 confirmed the latter signal to be due to H-1. This in turn allowed the 
aromatic signals at H 7.15 (dd, J = 9, 2 Hz) and 7.86 (d, J = 2 Hz) to be assigned to H-2 
and H-4, respectively. Similarly, reciprocal NOEs between H-9 and the aromatic singlet at 
H 7.14 confirmed the assignment of the latter signal to H-8, and the other aromatic singlet 
at H 7.88 to H-5. Thus, C-3, C-6 and C-7 were deduced to be the sites of methoxylation, 
which were confirmed from the NOEs observed between H-2, H-4/3-OMe, H-5/6-OMe, 
and H-8/7-OMe. Finally, attachment of the indolizidine moiety to the trimethoxylated-
phenanthrene moiety was established by the HMBC data (Figure 2.7, Appendix 15). Two- 
and three-bond correlations from H-9 to C-8a, C-8b and C-14a, and H-14 to C-14a and C-
8b, allowed the linking of C-9 to C-8b and C-14 to C-14a, respectively, while three-bond 
 56 
correlation from H-14 to the ester carbonyl carbon confirmed the attachment of the acetoxy 
group at C-14.  
 
 
Figure 2.7: Selected HMBCs and NOEs of hispilocine (2) 
 
 The proposed structure of hispiloscine (2), which was entirely consistent with the 
HMBC data, is identical to those of O-methyltylophorinidine acetate (62a) and 
tylophorinine acetate (187a), both of which are semi-synthetic alkaloids derived from O-
methyltylophorinidine (62) and tylophorinine (187).
135,137,138
 The 
1
H NMR data of 2 
presented a general similarity to those of 62a and 187 (Table 2.3), except that the chemical 
shifts of H-1 (H 7.62), H-9 (H 4.48), H-11 (H 3.35), H-13 (H 2.05 and 2.21), and H-13a 
(H 2.56) in 2 differed substantially from those of 62a and 187a, suggesting possible 
stereochemical variations at C-13a, C-14 and N (orientation of lone pair electrons) in 2. 
Further confirmation of this view was the observation that the coupling constant observed 
for the aliphatic doublet of H-14 in 2 was 7.4 Hz, compared to 2 Hz in 62a and 187a.
135
 
Hispiloscine (2) was therefore deduced to be a diastereomer of 62a and 187a. 
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Indolizidine heterocycles that contain three stereocentres at C-13a, C-14 and N can 
essentially yield four possibilities of the relative stereochemistry between the two methine  
 
Figure 2.8: Structures of 2, 62, 62a, 187 and 187a 
 
hydrogens and the N lone pair electrons, i.e., H-14,H-13a / H-13a,N-Lp: trans/trans, 
cis/trans, trans/cis or cis/cis (Figure 2.8).In addition to 62a and 62, other naturally 
occurring phenanthroindolizidine alkaloids bearing oxygenation at C-14 such as 3-
demethyl-14-hydroxyisotylocrebrine139and 14-hydoxy-3,6-didemethylisotylocrebrine,140 
were previously shown to possess the cis/trans relative stereochemistry. On the other hand, 
187a and 187 as well as the naturally occurring tylophoricidine E
141
 were shown to possess 
the trans/cis relative stereochemistry. The 
3
J13a,14 coupling constants reported for 
phenanthroindolizidine alkaloids with oxygenation at C-14 and possessing either the 
cis/trans or trans/cis stereochemistry were shown to be 0-2 Hz. This is entirely consistent 
with the coupling constants calculated by a vicinal coupling constant calculator that uses 
the equation of Haasnoot and co-worker
142
 and based on the dihedral angles obtained from 
energy-minimized models generated by MM2 calculations (ChemBioDraw 3D software): 
62a,  = 57°, calcd. 3J13a,14 = 1.5 Hz; 187a,  = 84°, calcd. 
3
J13a,14 = 1.2 Hz (Figure 2.9). By 
invoking the same argument that the calculated 
3
J13a,14 values corresponded well with the 
N
H
O
MeO
OMe
MeO
N
H
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N
H
OR
N
H
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2 (trans/trans)
62    R = H
62a  R = Ac
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187    R = H
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(trans/cis)
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actual coupling constants, the relative stereochemistry of 2 can possibly be deduced 
accordingly. Since 2 is a diastereomer of 62a and 187a, it can either assume the trans/trans 
or cis/cis relative stereochemistry. Consequently, the energy-minimized models for the 
trans/trans and cis/cis systems were constructed revealing dihedral angles (trans/trans,  = 
152°; cis/cis,  = 41°) that corresponded to the calculated 3J13a,14 values of 7.0 and 3.2 Hz, 
respectively (Figure 2.9). This strongly suggested that the indolizidine heterocycle in 2 
assumed the trans/trans relative stereochemistry, since the doublet of H-14 showed a 
coupling constant of 7.4 Hz. 
With regards to the configuration at C-13a, it appeared that phenanthroindolizidine 
alkaloids with the S configuration exhibited a positive optical rotation (the opposite was 
observed for alkaloids with the R configuration).
19,143
 Furthermore, variation in the 
substituents and substitution pattern in both the phenanthrene and indolizidine moieties did 
not seem to significantly alter the optical rotational properties of the alkaloids.
39,144–148
 On 
this basis, since a positive optical rotation was observed for 2, the C-13a configuration of 2 
can be assigned as S. Taken together, the trans/trans relative stereochemistry and the S-
configured C-13a, revealed the configuration at C-14 as R and N as S (-oriented lone pair 
electrons). Thus, hispiloscine (2) represents the first naturally occurring acetoxy-substituted 
phenanthroindolizidine, which is diastereomeric with both the semi-synthetic acetates of O-
methyltylophorinidine and tylophorinine. 
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Figure 2.9: Energy-minimized structures of the four possible relative stereochemistry of a 
C-14-oxygenated phenanthroindolizidine alkaloid, viewed along the axis of the C-13a–C-
14 bond and showing the dihedral angles between H-13a and H-14. 
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Table 2.3:
 1
H and 
13
C NMR data of hispiloscine (2)
a
 and selected 
1
H NMR data of O-
methyltylophorinidine acetate (62a)
136
 and tylophorinine acetate (187a).
137
 
Position 2  62a  187a 
13
C 
1
H (J in Hz) 
1
H (J in Hz) 
1
H (J in Hz) 
1 125.7 7.62 d (9)  7.84 d (9)  7.86 d (9) 
2 103.6 7.15 dd (9, 2)  7.20 dd (9, 2)  7.22 dd (9, 2) 
3 157.5 -  -  - 
4 104.7 7.86 d (2)  7.85 d (2)  7.90 d (2) 
4a 131.0 -  -  - 
4b 124.0 -  -  - 
5 103.8 7.88 s  7.88 s  7.91 s 
6 149.6
b
 -  -  - 
7 149.1
b
 -  -  - 
8 115.0 7.14 s  7.16 s  7.19 s 
8a 124.5
c 
-  -  - 
8b 129.4 -  -  - 
9 53.5 3.73 d (14.7)  3.57 d (16)  3.62 d (16) 
  4.48 d (14.7)  4.75 d (16)  4.78 d (16) 
11 54.5 2.54 q (8) 
( 
 f 
 2.45 m
 
  3.35 t (8) 
 f
  3.53 m
 
12 21.7 1.88 m 
 f
  1.94 m
 
  1.99 m 
 f
  2.02 m
 
13 30.1 2.05 m 
 f
  1.69 m
 
  2.21 m 
 f
  2.08 m
 
13a 66.0 2.56 m 
 f
  2.71 m
 
14 73.5 6.62 d (7.4)  6.66 d (2)  6.71 br d 
14a 125.9 -  -  -
 
14b 124.7
c
 -  -  -
 
3-OMe 55.4 3.99 s  3.97 s  4.01 s 
6-OMe 55.9
d
 4.09 s
e
  4.09 s  4.11 s 
7-OMe 56.0
d
 4.04 s
e
  4.04 s  4.06 s 
14-OCOCH3 21.2 2.03 s  2.13 s 
 f
 
14-OCOCH3 171.0 -  -  - 
a
 CDCl3, 600 MHz; 
b-e
 Assignments are interchangeable; 
f 
Data not reported 
 
 6
1
 
 
 
Figure 2.10: 
1
H NMR spectrum (CDCl3, 600 MHz) of hispiloscine (2) 
 6
2
 
 
Figure 2.11: 
13
C NMR spectrum (CDCl3, 150 MHz) of hispiloscine (2)
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2.1.3 13a(S)-(+)-Deoxypergularinine 
 
        3 
13a(S)-(+)-Deoxypergularinine (3) was isolated in minute amounts from the leaves 
of F. hispida as a colourless oil, with []D
25
  (c 0.11, CHCl3). The ESIMS of 3 showed a 
pseudo-molecular ion at m/z 364 [M+H]
+ 
and HRESIMS measurements established the 
molecular formula as C23H25NO3, requiring 12 degrees of unsaturation. The UV spectrum 
showed absorption maxima at 228, 261 and 287nm, while the IR spectrum showed 
absorption bands at 1609 and 1512 cm
-1
 due to aromatic moieties. The 
1
H NMR spectrum 
(Table 2.4, Figure 2.13) showed characteristic patterns of a phenathroindolizidine alkaloid 
substituted with three methoxy groups from the presence of three 3H singlets at δH 4.02, 
4.06 and 4.11, and five aromatic hydrogens. The aromatic hydrogens consist of a pair of 
ortho-coupled hydrogens (δH 7.96, d, J = 8 Hz and 7.22, dd, J = 8, 2 Hz), one meta-coupled 
hydrogen (δH 7.90, d, J = 2 Hz), and two isolated hydrogens (δH 7.92 and 7.16), clearly 
indicating the existence of a trisubstituted phenanthroindolizidine moiety in 3. The distinct 
pair of AB doublets observed at δH 3.66 and 4.61 with J = 14.4 Hz can be readily assigned 
to the isolated aminomethylene group (NCH2) at C-9. Additionally, the COSY data (Figure 
2.12) disclosed the presence of a NCH2CH2CH2CHCH2 fragment, which together with the 
aminomethylene group at C-9, confirmed the presence of an indolizidine moiety in 3. 
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The structural information obtained thus far allows the identity of 3 to be narrowed 
down to either deoxypergularinine or antofine, which are the 3,6,7-trimethoxy and 2,3,6-
trimethoxy regioisomers, respectively. Due to scarcity of compound, NOE experiments 
were not carried out for 3. However, the 
1
H NMR data of 3 showed a close resemblance to 
those of deoxypergularinine, previously reported in the literature
149
 providing support that 3 
was indeed deoxypergularinine. Using the same argument invoked for hispiloscine (2) (vide 
supra), the positive optical rotation observed for 3 revealed that the configuration at C-13a 
is S.
18,143
 Therefore, 3 is determined as 13a(S)-(+)-deoxypergularinine. 
 
 
Figure 2.12: COSY correlations (bold bonds) of 13a(S)-(+)-deoxypergularinine (3) 
N
MeO
OMe
MeO
H
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Table 2.4: 
1
H NMR data of 13a(S)-(+)-deoxypergularinine (3)
a
 obtained from literature 
and those from the present study. 
Position Deoxypergularinine
149
  3 
  
1
H (J in Hz) 
1
H (J in Hz)
 
1 7.91 d (9.2)  7.96 d (8) 
2 7.21 dd (9.2, 2.5)  7.22 dd (8, 2) 
4 7.86 d (2.5)  7.90 d (2) 
5 7.88 s  7.92 s 
8 7.09 s  7.16 s 
9 4.62 d (14.5)  4.61 d (14.4) 
 3.72 d (14.5)  3.66 d (14.4) 
11 3.47 td (8.1, 2)  3.48 t (9) 
 2.58 q (8.1)  2.47 q (9) 
12 2.06 m  2.03 m 
 1.96 m  1.92 m 
13 2.22 m  2.24 m 
 1.82 m  1.78 m 
13a 2.59 m  2.5 m 
14 3.40 dd (16.5, 3)  3.45  dd (16, 2.5) 
 3.00 dd (16.5, 10.5)  2.95 dd (16, 10.9) 
3-OMe 4.01 s  4.02 s 
6-OMe 4.03 s  4.06 s 
7-OMe 4.09 s  4.11 s 
a
 CDCl3, 600 MHz 
 6
6
 
 
Figure 2.13: 
1
H NMR spectrum (CDCl3, 600 MHz) of 13a(S)-(+)-deoxypergularinine (3) 
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2.2  Alkaloids from F. fistulosa 
Two new septicine alkaloids, fistulopsines A (4) and B (5), together with four known 
alkaloids, 13a(R)-(-)-3,6-didemethylisotylocrebrine (6), 13a(S)-(+)-tylocrebrine (7), 13a(S)-
(+)-tylophorine (8), 13a(S)-(+)-septicine (9), and a non-alkaloid, vomifoliol (10) were 
isolated from the leaves and bark of F. fistulosa. The structures of the isolated compounds 
were determined by spectroscopic methods as well as comparison with literature data. 
2.2.1 Fistulopsine A 
 
       4 
Fistulopsine A (4) was obtained in minute amounts from the bark of F. fistulosa as a 
colourless oil, with []D
25
 47 (c 0.30, CHCl3). The IR spectrum (Appendix 22) showed 
absorption bands corresponding to the presence of hydroxy (3375 cm
-1
) and aromatic 
moieties (1583 and 1515 cm
-1
).  The UV spectrum (Appendix 21) showed absorption 
maxima at 225, 265, and 282 (sh) nm, while on addition of aqueous sodium hydroxide the 
UV spectrum displayed a bathochromic shift, suggesting the presence of unsubstituted 
phenolic hydroxy group. The ESIMS of 4 showed a pseudo-molecular ion at m/z 412 and 
HRESIMS measurements established the molecular formula as C24H29NO5, requiring 11 
degrees of unsaturation.  
N
OMe
MeO
HO
OMe
MeO
1
2
3
4
4a
14b
8a
4b
5
6
7
8
8b
14
9
13a
13
12
11
14a
H
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The 
13
C NMR data of fistulopsine A (Table 2.5, Figure 2.17) indicated the presence 
of 24 carbon signals consisting of four methoxy, five methylene, six methine, and nine 
quaternary carbons, in agreement with the molecular formula. The 
1
H NMR spectrum 
(Table 2.5, Figure 2.16) showed the presence of a 1,3,4,5-tetrasubstituted aromatic ring 
from the two aromatic doublets observed at H 6.05 and 6.41 with J = 1.5 Hz, which 
implied that the two aromatic hydrogens were meta-coupled. The remaining three aromatic 
hydrogen signals present in the 
1
H NMR spectrum indicated the presence of a trisubstituted 
aromatic ring. On the other hand, the pair of distinct AB doublets in the upfield region at   
3.88 and 3.08 with J = 15.5 Hz can be readily assigned to the isolated aminomethylene 
group at C-9. In addition to this, the COSY and HSQC data (Appendix 17 and 18) revealed 
the presence of an NCH2CH2CH2CHCH2 fragment (Figure 2.14) corresponding to the N-C-
11–C-12–C-13–C-13a–C-14–Ar partial structure in 4. The partial structures disclosed thus 
far indicated that 4 constituted of an indolizidine moiety substituted only by two aryl 
groups at C-8b and C-14a. As a result, the four methyl singlets observed between H 3.51-
3.81 in the 
1
H NMR spectrum can be attributed to four aromatic methoxy groups. Since 
there are five oxygen atoms in the molecular formula of fistulopsine A (4), the fifth oxygen 
atom must therefore be associated to a phenolic hydroxy group. The substitution pattern of 
the two aryl rings was determined from the HMBC data (Figure 2.14, Appendix 19). Three-
bond correlations from H-1 to C-3 and C-4a; H-4a to C-1 and C-3; 2-OMe to C-2; and 3-
OMe to C-3 allowed the 1,3,4,5-tetrasubstituted aromatic ring to be identified as a 3-
hydroxy-4,5-dimethoxyphenyl moiety, which was subsequently linked to C-14a of the 
indolizidine portion by the H-4a to C-14a HMBC correlation. On the other hand, the 
trisubstituted aromatic ring was determined to be a 3,4-dimethoxyphenyl moiety from the 
HMBC three-bond correlations from H-4b to C-8; H-5 to C-7 and C-8a; H-8 to C-4b and 
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C-6; 6-OMe to C-6; and 7-OMe to C-7. This aromatic moiety was linked to the indolizidine 
portion at C-8b by the three-bond correlations from H-4b and H-8 to C-8b. In addition, the 
13
C NMR data of the 3-hydroxy-4,5-dimethoxyphenyl and 3,4-dimethoxyphenyl moieties, 
which corresponded well with reported data,
150–152
 provided further support for the 
substitution patterns proposed. The NOESY spectrum which showed correlations between 
H-1/2-OMe, H-5/6-OMe and H-8/7-OMe (Figure 2.15, Appendix 20), also supported the 
methoxylation pattern of the two aromatic moieties, while NOESY correlations between H-
14/H-1, H-4a and H-9/H-4b, H-8 further confirmed the attachment of the two aromatic 
moieties at C-8b and C-14a. With regards to the configuration at C-13a, it appeared that 
seco-phenanthroindolizidine alkaloids with R configuration exhibited negative optical 
rotations (the opposite was observed for alkaloids with S configuration).
18,146
 Accordingly, 
the negative optical rotation observed for fistulopsine A (4) suggested that the configuration 
at C-13a in 4 is R.
18,19
 Therefore, fistulopsine A (4) was elucidated as 13a(R)-(-)-4-
hydroxysepticine.  
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Figure 2.14: Selected HMBCs and COSY correlations (bold bond) of fistulopsine A (4) 
 
 
Figure 2.15: NOESY correlations of fistulopsine A (4) 
N
OMe
MeO
HO
OMe
MeO
N
OMe
MeO
HO
OMe
MeO
H
H H
H H H
H
H H
 7
1
 
 
Figure 2.16: 
1
H NMR spectrum (CDCl3 CD3OD, 600 MHz) of fistulopsine A (4) 
 7
2
 
 
Figure 2.17: 
13
C NMR spectrum (CDCl3, 150 MHz) of fistulopsine A (4) 
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2.2.2 Fistulopsine B 
 
 5 
Fistulopsine B (5) was obtained as a light yellowish oil and subsequently as 
colourless needles (mp 209-210 °C) from CHCl3/MeOH, with []D
25
 +18 (c 0.32, MeOH). 
The IR spectrum (Appendix 28) showed absorption bands due to hydroxy (3350 cm
-1
) and 
aromatic moieties (1594 and 1508 cm
-1
). The UV spectrum showed absorption maxima at 
225, 239, 263 and 286 nm, while as in the case of 4, a bathochromic shift was also 
observed in the UV spectrum of 5 (Appendix 27), upon addition of aqueous sodium 
hydroxide indicating the presence of unsubstituted phenolic hydroxy. The ESIMS showed a 
pseudo-molecular ion at m/z 368, and HRESIMS measurements established the molecular 
formula as C22H25NO4, requiring 11 degrees of unsaturation.  
Similar to fistulopsine A (4), the 
1
H and 
13
C NMR data of 5 (Table 2.5, Figures 2.21 
and 2.22) showed the presence of an identical indolizidine moiety. This was confirmed by 
the COSY and HSQC spectra (Appendix 23 and 24) which also disclosed the presence of 
the two partial structures, i.e., isolated NCH2 and NCH2CH2CH2CHCH2, that constituted 
the indolizidine moiety present in fistulopsine A (4). On the other hand, the molecular 
formula of fistulopsine B (5) was 44 mass units lower than that of fistulopsine A (4), 
suggested the replacement of a methoxy and methyl group in 4 with two hydrogen atoms in 
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5, which must have taken place within the two aromatic rings. Inspection of the downfield 
region of the 
13
C NMR spectrum of 5 revealed the presence of four oxygenated aromatic 
carbon resonances at C 144.3, 144.5, 146.4 and 146.6, which are consistent with the 
presence of four oxygen atoms in the molecular formula of 5. The observation of only two 
aromatic methoxy singlets in the 
1
H NMR spectrum therefore suggested the presence of 
two phenolic OH groups in the aromatic rings. The presence of two 1,3,4-substituted aryl 
moieties was deduced from the observation of two ABX systems in the 
1
H NMR spectrum: 
H 6.44 (1H, d, J = 1.6 Hz), 6.45 (1H, d, J = 1.6 Hz), 6.62 (2H, dd, J = 8.0, 1.6 Hz), 6.70 
(1H, d, J = 8.0 Hz), 6.71 (1H, d, J = 8.0 Hz). Finally, the substitution pattern of the two aryl 
rings, i.e., 3-hydroxy-2-methoxyphenyl, was revealed by the HMBC data (Figure 2.18, 
Appendix 25), which showed three-bond correlation from H-1 to C-3 and C-4a; 2-OMe to 
C-2; H-4 to C-2 and C-14b; H-4a to C-1 and C-3; H-4b to C-6 and C-8; H-5 to C-7 and C-
8a; 7-OMe to C-7; H-8 to C-4b and C-6. Subsequently, the two 3-hydroxy-2-
methoxyphenyl moieties were shown to be connected to C-8b and C-14a by the HMBC 
three-bond correlations from H-9 to C-8a and H-14 to C-14b, respectively. This conclusion 
was further supported by the NOESY spectrum that showed correlations (Figure 2.19, 
Appendix 26) between H-1/H-14, H-14; H-4a/H-14, H-14; H-8/H-9, H-9; and H-
4b/H-9, H-9. Finally, the positive optical rotation of 5 suggested that the configuration at 
C-13a is S.
18,143
 Since suitable crystals of 5 were available, X-ray diffraction analysis was 
carried out (Figure 2.20), which confirmed the structure deduced from the NMR data. 
Therefore, the structure of 5 was elucidated as 13a(S)-(+)-3,6-didemethylsepticine.  
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Figure 2.18: Selected HMBCs and COSY correlations (bold bonds) of fistulopsine B (5) 
 
 
Figure 2.19: NOESY correlations of fistulopsine B (5) 
 
 
Figure 2.20: X-ray crystal structure of fistulopsine B (5) 
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Figure 2.21: 
1
H NMR spectrum (CDCl3/CD3OD, 600 MHz) of fistulopsine B (5) 
 7
7
 
 
Figure 2.22: 
13
C NMR spectrum (CDCl3/CD3OD, 150 MHz) of fistulopsine B (5)
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Table 2.5:
 1
H and 
13
C NMR data of fistulopsines A (4) and B (5)
a
 
Position 4
 
  
5
   
 
1
H (J in Hz) 
13
C   
1
H (J in Hz) 
13
C 
1 6.05 d (1.5) 106.0  6.44 d (1.6)
i
 113.0
b
 
2 - 151.6  - 146.4
c
 
3 - 133.9  - 144.3
d
 
4 - 148.9  6.70 d (8.0)
j
 114.3
e
 
4a 6.41 d (1.5) 108.2  6.62 dd (8.0, 1.6)
k
 121.3
f
 
4b 6.69 br s 120.8  6.62 dd (8.0, 1.6)
k
 121.5
f
 
5 6.69 br s 110.6  6.71 d (8.0)
j
 114.4
e
 
6 - 147.6  - 144.5
d
 
7 - 148.2  - 146.6
c
 
8 6.53 br s 113.1  6.45 d (1.6)
i
 113.2
b
 
8a - 133.6  - 132.8
g
 
8b - 133.0  - 132.3 
9α 3.08 d (15.5)  57.6  3.09 d (16.0) 57.6 
9β 3.88 d (15.5)    3.86 d (16.0)  
11α 2.26 q (9)  54.3  2.28 q (9) 54.2 
11β 3.31 t (9)    3.29 t (9)  
12α 1.83 m 21.6  1.86 m 21.4 
12β 1.94 m    1.94 m  
13β 1.56 m 30.8  1.57 m 30.6 
13α 2.10 m    2.11 m  
13a 2.40 m  60.4  2.45 m 60.7 
14β 2.39 m  38.6  2.42 m 38.0 
14α 2.69 d (13)    2.73 d (16)  
14a - 133.2  - 134.3 
14b - 138.7  - 132.9
g
 
2-OMe 3.51 s 55.65  3.55
l 
55.7
h 
3-OMe 3.81 s 61.0  - - 
6-OMe 3.81 s 55.8  - - 
7-OMe 3.59 s 55.70  3.57 s
l
 55.8
h
 
a
 CDCl3/CD3OD, 600 MHz; 
b-l
 Assignments are interchangeable
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2.2.3 13a(R)-(-)-3,6-Didemethylisotylocrebrine 
 
        6 
13a(R)-(-)-3,6-Didemethylisotylocrebrine (6) was obtained from the leaves of  F. 
fistulosa as a light yellowish oil, with []D
25
 -113 (c 0.13, CHCl3/MeOH). The IR spectrum 
showed absorption bands corresponding to the presence of hydroxy (3385 cm
-1
) and 
aromatic moieties (1601 and 1514 cm
-1
). The UV spectrum showed absorption maxima at 
262, 279, 304, and 317 nm. The ESIMS of 6 showed a pseudo-molecular ion at m/z 366 [M 
+ H]
+ 
and HRESIMS measurements established the molecular formula as C22H23NO4, 
requiring 12 degrees of unsaturation. The 
13
C NMR data of 6 (Table 2.6, Figure 2.25) 
indicated the presence of 22 carbon signals (consisting of two methoxy, five methylene, 
five methine, and ten quaternary carbons), which are in agreement with the molecular 
formula. The 
1
H NMR spectrum (Table 2.6, Figure 2.24) showed the distinct presence of a 
pair of ortho-coupled hydrogen signals (δH 7.22 and 7.69, J = 9 Hz), two aromatic singlets 
due to two para-positioned hydrogens of a tetrasubstituted benzene ring (δH 7.14 and 9.01), 
and two methoxy signals at δH 3.85 and 4.06. Due to the presence of four oxygen atoms in 
the molecular formula of 6, the phenanthrene moiety must therefore be substituted with two 
hydroxy groups in addition to the two methoxy groups mentioned earlier. The profoundly 
deshielded aromatic singlet observed at δH 9.01 was characteristic of paramagnetic 
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deshielding of an aromatic hydrogen that is spatially proximate to an oxygen lone pair 
electrons, a case which is only possible if hydroxy substitution occurs at C-4 while C-5 
remains unsubstituted or vice versa. The characteristic AB doublets observed at δH 3.66 and 
4.58 (J = 14 Hz) were readily assigned to the isolated aminomethylene group (NCH2) at C-
9. The presence of an unsubstituted indolizidine moiety was confirmed by COSY and 
HSQC data which revealed the presence of an NCH2CH2CH2CHCH2 fragment 
corresponding to the N-C-11-C-12-C-13-C-13a-C-14-Ar partial structure (Figure 2.23, 
Appendix 29 and 30). The substitution pattern of the phenanthrene moiety was determined 
to be 3,6-dihydroxy-4,7-dimethoxy, deduced from the HMBC data (Figure 2.23, Appendix 
31), which showed correlations from H-1 to C-3 and C-4a; H-2 to C-3, C-4 and C-14b; H-5 
to C-4b, C-6 and C-7; H-8 to C-6 and C-7; 4-OMe to C-4; 7-OMe to C-7. This 
tetraoxygeated-phenanthrene moiety is linked to the indolizidine fragment at C-8b and C-
14a by three bond correlations from H-1 to C-14a and H-8 to C-8b. The negative optical 
rotation observed for 6 suggested that the configuration at the C-13a stereocentre is R.
18,21
 
Therefore, the structure of 6 was elucidated as 13a(R)-(-)-3,6-didemethylisotylocrebrine. 
The structure of 6 is consistent with COSY, HSQC and HMBC data as well as with 
published data.
140
 
 
 
 
Figure 2.23: Selected HMBC and COSY correlations (bold bonds) of 13a(R)-(-)-3,6-
didemethylisotylocrebrine (6) 
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Figure 2.24: 
1
H NMR spectrum (CDCl3/CD3OD, 400 MHz) of 13a(R)-(-)-3,6-didemethylisotylocrebrine (6) 
 8
2
 
 
Figure 2.25: 
13
C NMR spectrum (CDCl3/CD3OD, 100 MHz) of 13a(R)-(-)-3,6-didemethylisotylocrebrine (6) 
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2.2.4 13a(S)-(+)-Tylocrebrine  
 
        7 
13a(S)-(+)-Tylocrebrine (7) was obtained from the bark of F. fistulosa as a light 
yellowish oil, with []D
25
 +19 (c 0.15, CHCl3). The IR spectrum showed absorption bands 
corresponding to the presence of aromatic moieties (1600 and 1515 cm
-1
). The UV 
spectrum showed absorption maxima at 244, 264, 276, 309 and 321 nm. The ESIMS of 7 
showed a pseudo-molecular ion at m/z 394 [M + H]
+ 
and HRESIMS measurements 
established the molecular formula as C24H27NO4, requiring 12 degrees of unsaturation. The 
13
C NMR data (Table 2.6, Figure 2.28) indicated the presence of 24 carbon resonances 
(consisting of four methoxy, five methylene, five methine, and ten quaternary carbons), 
which was in agreement with the molecular formula. The 
1
H NMR spectrum (Table 2.6, 
Figure 2.27) showed signals due to four aromatic hydrogens and four methoxy groups (δH 
3.48, 3.48, 3.44, 3.51). The two aromatic doublets observed at δH 7.30 and 7.79 with J = 9 
Hz, was attributed to a pair of ortho-coupled aromatic hydrogens, while the remaining two 
aromatic singlets at δH 7.15 and 9.34 were due to a pair of para-positioned hydrogens of a 
tetrasubstituted benzene ring. Additionally, the aromatic singlet that was profoundly 
deshielded at δH 9.34 was characteristic of paramagnetic deshielding of an aromatic 
hydrogen that is spatially proximate to an oxygen lone pair electron. This is only possible if 
oxygenation occurs at C-4 while C-5 remains unsubstituted or vice versa. A distinct pair of 
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AB doublets observed at δH 3.71 and 4.63 with J = 16 Hz can be readily assigned to the 
isolated aminomethylene group (NCH2) at C-9. Furthermore, the COSY data (Figure 2.26, 
Appendix 32) confirmed the presence of an NCH2CH2CH2CHCH2 fragment which 
corresponds to the N-C-11-C-12-C-13-C-13a-C-14-Ar partial structure of an unsubstituted 
indolizidine moiety. The 
1
H, 
13
C NMR and COSY data obtained suggested two possible 
gross structures for 7, which corresponds to the known phenanthroindolizidine alkaloids, 
tylocrebrine and isotylocrebrine (49). However, further comparison with literature data
153
 
confirmed the identity of 7 as tylocrebrine. The positive optical rotation observed for 7 
suggested that the configuration at the C-13a stereocentre is S.
18,143
 Therefore, the structure 
of 7 was elucidated as 13a(S)-(+)-tylocrebrine. 
 
 
Figure 2.26: COSY correlations of 13a(S)-(+)-tylocrebrine (7) 
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Figure 2.27: 
1
H NMR spectrum (CDCl3, 400MHz) of 13a(S)-(+)-tylocrebrine (7) 
 8
6
 
 
Figure 2.28: 
13
C NMR spectrum (CDCl3, 100MHz) of 13a(S)-(+)-tylocrebrine (7) 
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Table 2.6: 
1
H and 
13
C NMR data of 13a(R)-(-)-3,6-didemethylisotylocrebrine (6)
c
 and 
13a(S)-(+)-tylocrebrine (7)
a 
Position   6 
  
7   
 
1
H (J in Hz) 
13
C   
1
H (J in Hz) 
13
C 
1 7.69 d (9) 120.3  7.15 s  102.7  
2 7.22 d (9) 115.9  - 151.0 
3 - 147.7
 
 - 148.9 
4 - 144.0  9.34 s 109.4 
4a - 127.4  - 127.2 
4b - 126.5  - 126.9 
5 9.01 s 112.5  - 146.3 
6 - 145.1  - 148.0 
7 - 148.0
 
 7.30 d (9) 112.2 
8 7.14 s 102.6  7.79 d (9) 120.0 
8a - 125.9  - 126.5 
8b - 123.3  - 123.8 
9α 4.58 d (14) 54.1  4.63 d (16) 53.6 
9β 3.66 d (14)   3.71 d (16)  
11α 3.67 t (8) 55.1  3.54 m  55.0 
11β 2.49 q (8)   2.54 m  
12α 1.99 m 21.5  2.04 m 21.6 
12β 2.02 m   1.68 m  
13α 1.77 m 31.0  2.27 m 29.8 
13β 2.29 m   1.96 m  
13a 2.54 m 60.6  2.58 m 60.4 
14α 3.38 dd (16, 1) 33.5  3.40 dd (16, 4) 31.1 
14β 2.91 dd (16, 8)   2.97 dd (16, 10)  
14a - 123.4  - 123.3
b 
14b - 124.9  - 123.3
b
 
2-OMe -   3.48 s 55.85 
3-OMe -   3.48 s 56.5 
4-OMe 3.85 s 59.8  -  
5-OMe -   3.44 s 60.2 
6-OMe -   3.51 s 55.91 
7-OMe 4.06 s 55.8  -  
a
 CDCl3, 400 MHz;
c
 CDCl3/CD3OD, 400MHz; 
b
Overlapping signals. 
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2.2.5  13a(S)-(+)-Tylophorine 
 
          8 
13a(S)-(+)-Tylophorine (8) was isolated from the leaves of F. fistulosa as white 
amorphous, with []D
25
 +44 (c 0.12, CHCl3). The UV spectrum showed absorption maxima 
at 240, 257, 288, 304 and 399 nm. The IR spectrum showed absorption bands 
corresponding to the presence of aromatic moieties (1619 and 1515 cm
-1
). The ESIMS of 8 
showed a pseudo-molecular ion at m/z 394 [M + H]
+
 and HRESIMS measurements 
established the molecular formula as C24H27NO4, requiring 12 degrees of unsaturation.  
The 
13
C NMR data of 8 (Table 2.7, Figure 2.31) indicated the presence of 24 carbon 
signals consisting of four methoxy, five methylene, five methine, and ten quaternary 
carbons, in agreement with the molecular formula. The 
1
H NMR spectrum (Table 2.7, 
Figure 2.30) showed the presence of four sharp aromatic singlets at δH 7.12, 7.28, 7.80, 
7.80, indicating the presence of a 2,3,6,7-tetrasubstituted phenanthrene moiety. In addition 
to this, the characteristic AB doublets observed at δH 4.57 and 3.65 with J=14.4 Hz can be 
readily assigned to the isolated aminomethylene group (NCH2) at C-9. The COSY and 
HSQC data on the other hand confirmed the presence of the isolated NCH2 group and the 
NCH2CH2CH2CHCH2 fragment that constituted the indolizidine moiety (Figure 2.29, 
Appendix 33 and 34). The four methyl singlets occurred between δH 4.05 - 4.11 were 
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attributed to four aromatic methoxy groups. HMBC correlations (Figure 2.29, Appendix 
35) deduced that these methoxy groups are attached to the phenanthrene moiety at C-2, C-
3, C-6 and C-7, thus revealing the presence of a 2,3,6,7-tetramethoxylated phenanthrene 
moiety. This phenanthrene moiety was linked to the indolizidine portion at C-8b and C-14a 
by the observed three bond correlations from H-1 to C-14a and H-8 to C-8b in the HMBC 
spectrum. The positive optical rotation observed for 11 suggested that the configuration at 
C-13a is S.
18,143
 Therefore, the structure of 8 was elucidated to be 13a(S)-(+)-tylophorine. 
The structure of 8 is consistent with COSY, HSQC and HMBC data as well as with 
published data.
139,154
  
 
  
Figure 2.29: Selected HMBCs and COSY correlations (bold bonds) of 13a(S)-(+)-
tylophorine (8) 
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Figure 2.30: 
1
H NMR spectrum (CDCl3, 400MHz) of 13a(S)-(+)-tylophorine (8) 
 9
1
 
 
Figure 2.31: 
13
C NMR spectrum (CDCl3, 100MHz) of 13a(S)-(+)-tylophorine (8) 
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2.2.6 13a(S)-(+)-Septicine  
 
           9 
13a(S)-(+)-Septicine (9) was isolated as a light yellowish oil from the bark of F. 
fistulosa, with []D
25
 +7 (c 0.28, CHCl3). The UV spectrum showed absorption maxima at 
204, 235, 263, 280 and 353 nm indicative of a seco-phenanthroindolizidine 
chromophore.
18,155
 The ESIMS of 9 showed a pseudo-molecular ion at m/z 396 [M + H]
+ 
and HRESIMS measurements established the molecular formula as C24H29NO4, requiring 
11 degrees of unsaturation. 
The 
13
C NMR data of 9 (Table 2.7, Figure 2.34) indicated the presence of 24 carbon 
signals consisting of four methoxy, five methylene, seven methine, and eight quaternary 
carbons, in agreement with the molecular formula. The six carbon resonances at δC 113.0, 
110.6, 120.7, 121.0, 110.7 and 112.9 were readily assigned to the aromatic methines in 9, 
while the quaternary aromatic carbon signals observed between δC 132.7–135.2 are 
characteristic of C-8a, C-8b, C-14a, and C-14b of seco-phenanthroindolizidine alkaloids. 
The 
1
H NMR spectrum (Table 2.7, Figure 2.33) showed signals due to six distinct 
aromatic hydrogens and four methoxy groups (δH 3.55, 3.57, 3.78, 3.78), which indicated 
the presence of two dimethoxylated benzene rings. Characteristic AB doublets in the 
upfield region at δH 3.07 and 3.87 with J=16 Hz was assigned to the isolated 
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aminomethylene group (NCH2) at C-9. Furthermore, the COSY and HSQC data revealed 
the presence of the NCH2CH2CH2CHCH2 partial structure of the indolizidine moiety, i.e., 
N-C-11-C-12-C-13-C13a-C-14 (Figure 2.32, Appendix 36 and 37). The substitution pattern 
of the two aryl rings was determined by HMBC data (Figure 2.32, Appendix 38). Three-
bond correlations from H-1 to C-3 and C-4a; H-4a to C-1 and C-3; 2-OMe to C-2; 3-OMe 
to C-3; H-4b and H-8 to C-6; H-5 to C-7 and C-8a; 6-OMe to C-6; 7-OMe to C-7, 
established the substitution pattern of the two aryl rings to be 2,3-dimethoxyphenyl. HMBC 
correlations from H-9 and H-4a to C-14a, and H-8 and H-9 to C-8b established the 
attachment sites of the two dimethoxylated aryl rings as C-8b and C-14a. The positive 
optical rotation observed for 9 suggested an S configuration at the C-13a stereocentre.
18,143
 
Therefore, the structure of 9 was elucidated to be 13a(S)-(+)-septicine. The structure of 9 is 
entirely consistent with the COSY, HSQC and HMBC data and the 
1
H and 
13
C  NMR data 
are identical to published data.
156
 
 
 
Figure 2.32: Selected HMBCs and COSY correlations (bold bonds) of 13a(S)-(+)-septicine 
(9) 
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Figure 2.33: 
1
H NMR spectrum (CDCl3, 400 MHz) of 13a(S)-(+)-septicine (9) 
 9
5
 
 
Figure 2.34: 
13
C NMR spectrum (CDCl3, 100 MHz) of 13a(S)-(+)-septicine (9)
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Table 2.7:
 1
H (CDCl3, 400 MHz) and 
13
C (CDCl3, 100 MHz) NMR data of 13a(S)-(+)-
tylophorine (8) and 13a(S)-(+)-septicine (9)
a 
 Position 8 
  
9   
 
1
H (J in Hz) 
13
C   
1
H (J in Hz) 
13
C 
1 7.28 s 104.0  6.25 d (2)
b 
113.0
b 
2 - 148.54
b 
 - 148.1
c 
3 - 148.46
b 
 - 147.3
d 
4 7.80 s 103.4  6.66 m
c 
110.6
e 
4a - 123.7  6.65 m
d 
120.7
f 
4b - 123.4  6.65 m
d 
121.0
f 
5 7.80 s 103.3  6.63 m
c 
110.7
e 
6 - 148.1  - 147.4
d 
7 - 148.7  - 148.2
c 
8 7.12 s 103.1  6.50 d (2)
b 
112.9
b 
8a - 125.9
j 
 - 135.2 
8b - 124.3  - 132.7
g 
9α 4.57 d (14) 55.2  3.07 d (16) 57.6 
9β 3.65 d (14)   3.87 d (16)  
11α 3.47 td (7, 6) 54.0  2.24 m  53.4 
11β 2.49m   3.29 t (8.5)  
12α 2.04 m 21.6  1.82 m 21.5 
12β 1.93 m   1.93 m  
13α 2.24 m 31.2  1.54 30.8 
13β 1.78 m   2.07 m  
13a 2.47 m 60.3  2.40 m  60.4 
14α 3.31 dd (15, 3) 33.7  2.40 m 38.6 
14β 2.89 dd (15, 10)   2.73 dd   
14a - 125.9
j
  - 132.8
g 
14b - 126.3  - 133.7 
2-OMe 4.05 s 56.1
k
  3.55 s
e 
57.6
h 
3-OMe 4.11 s 55.9
l
  3.78 s 55.60
i 
6-OMe 4.11 s 55.9
l
  3.78 s 55.55
i 
7-OMe 4.05 s 56.1
 k
  3.57 s
e 
54.2
h 
a
 CDCl3, 400 MHz; 
b-h
Assignments are interchangeable; 
k-l
Overlapping signals 
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2.2.7 Vomifoliol 
 
  10 
Vomifoliol (10) was isolated from the bark of F. fistulosa as colourless needles, mp 
105-109 
o
C (lit., 107-109 
o
C)
157
 with []D
25
 +117 (c 0.41, CHCl3). ESIMS of 10 showed a 
pseudo-molecular ion at m/z 225 [M + H]
+ 
and HRESIMS measurements established the 
molecular formula as C13H20O3, requiring four degrees of unsaturation. The UV spectrum 
showed absorption maxima at 237 nm, while the IR spectrum showed absorption bands due 
to OH (3369 cm
-1
) and conjugated ketone function (1663 cm
-1
).  
The 
1
H NMR spectrum (Table 2.8, Figure 2.35) showed the distinct presence of 
three 3H singlets and one 3H doublet. The two 3H singlets at δH 1.02 and 1.08 were 
attributable to the gem dimethyl group at C-1, while the 3H singlet at δH 1.91 can be 
assigned to the methyl group attached to the olefinic C-5 and the 3H doublet at δH 1.30 (J = 
5.8) to the oxymethine C-9. The large coupling constant observed between δH 5.78 and δH 
5.85 (16 Hz) implied a trans geometry of the C-7/C-8 double bond. Comparison between 
the NMR spectral data of 10 with those in the literature revealed 10 to be either (+)-(6S,9S)-
vomifoliol or (-)-(6R,9R)-vomifoliol. Since a positive optical rotation value was obtained 
for 10, it is therefore (+)-(6S,9S)-vomifoliol.
157
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Table 2.8: 
1
H NMR data (CDCl3, 400 MHz) of vomifoliol (10)
 
Position  10  Vomifoliol
157
 
1
H (J in Hz) 
1
H (J in Hz) 
1-Me 1.02 s  1.00 s 
 1.08 s  1.07 s 
2 2.24 d (17.1)  2.23 d (17) 
 2.45 d (17.1)  2.45 d (17) 
4 5.91 br s  5.90 br s 
5-Me 1.91 s  1.90 s 
7 5.78 d (15.6)  5.77 d (15.5) 
8 5.85 dd (15.7, 5)  5.87 dd (15.5, 5) 
9 4.40 quintet-like  4.41 quintet-like 
9-Me 1.30 d (5.8)  1.30 d (6.5) 
 9
9
 
 
Figure 2.35: 
1
H NMR spectrum (CDCl3, 400 MHz) of vomifoliol (10)
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2.3  Alkaloids from F. schwarzii 
A preliminary study on the leaves of F. schwarzii has resulted in the isolation of two 
major alkaloids, namely, schwarzinicines A (11) and B (12), which represent the first 
members of a novel class of plant alkaloids, i.e., tri-nor-sesquilignan alkaloids. The 
structures of the isolated compounds were determined by spectroscopic methods. 
2.3.1 Schwarzinicine A 
 
         11 
Schwarzinicine A (11) was obtained from the leaves of F. schwarzii as a light 
yellowish oil with []D
25
 +24 (c 0.50, CHCl3). The UV spectrum (Appendix 42), which 
showed absorption maxima at 228 and 280 nm, is characteristic of a 3,4-dimethoxylated 
benzene chromophore. The ESIMS showed a pseudo-molecular ion at m/z 524 [M + H]
+
, 
and HRESIMS measurements established the molecular formula as C31H41NO6, requiring 
12 degrees of unsaturation. 
 The 
13
C NMR data (Table 2.9, Figure 2.38) showed the presence of 31 carbon 
signals, comprising of three dioxygenated aromatic rings (6C x 3), five methylene, one 
methine, one N-methyl and six methoxy carbons, in agreement with the molecular formula. 
Additionally, the 18 carbon resonances found within the region of δC 110-150 were seen to 
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cluster in four distinct chemical shift ranges, i.e., δC 146-149 (six signals), δC 132-136 (three 
signals), δC 120-122 (three signals) and δC 111-113 (six signals), which were indicative of 
the presence of three units of trisubstituted 3,4-dioxygenated aryl ring. Comparison of the 
aromatic carbon shifts with those of natural products containing 3,4-dioxygenated aryl 
moieties,
158,159
 readily allowed the assignment of the four distinct clusters of carbon 
resonances to the corresponding aromatic carbon types. The three quaternary carbons 
resonated between δC 132-136 were assigned to C-1, -1' and -1''. The three methine carbons 
resonated between δC 120-122 were readily assigned to C-6, -6', -6'', while the remaining 
six methine carbons that resonated between δC 111-113 are characteristic of aromatic 
carbons adjacent to an oxygenated aromatic carbon, and thus were attributable to C-2, -2', -
2'', C-5, -5' and -5''. Finally, the six highly deshielded quaternary carbon resonances at δC 
146.9, 147.1, 147.3, 148.6, 148.7 and 148.8 suggested that these carbons are sites of 
oxygenation, which coupled with the presence of six methoxy groups (δC 55-56), indicated 
the presence of three 3,4-dimethoxylated aryl moieties. 
 The 
1
H NMR spectrum (Table 2.9, Figure 2.37) showed the presence of nine 
aromatic protons, six aromatic methoxy groups, an N-methyl, and eleven aliphatic protons. 
The presence of the 1,3,4-trisubstituted aromatic rings were further supported by the 
splitting patterns observed for the aromatic proton signals for H-2/2'/2'' [δH 6.73 m, 6.62 (d, 
J = 8 Hz), 6.56 (d, J = 2 Hz)], H-5/5'/5'' [δ 6.79 (d, J = 8 Hz), 6.76 (d, J = 8 Hz), 6.73m] 
and H-6/6'/6'' [δ 6.74 m, 6.65 (dd, J = 8, 2 Hz), 6.57 (dd, J = 8, 2 Hz)]. The six methoxy 
singlets were detected between δH 3.80 – 3.87 while the NMe singlet at 2.38 ppm.  
The HSQC and COSY data revealed the presence of CH2CH2 and CH2CHCH2CH2 
fragments which correspond to the C(7)-C(8) and C(7')-C(8')-C(8'')-C(7'') partial structures, 
respectively (Figure 2.36, Appendix 39 and 40). The most important information provided 
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by the HMBC data (Figure 2.36, Appendix 41) are those that linked the three aryl rings 
deduced above to C-7/7'/7'' of the aliphatic backbone. The attachment of one of the aryl 
rings to C-7 was supported by the long range correlations observed from H-8 to C-1; H-7 to 
C-2 and C-6; H-2 and H-6 to C-7. The attachment of the second aryl ring to C-7' was 
supported by the correlations observed from H-7' to C-2' and C-6'; H-2' to C-7'. Finally, the 
last aryl ring was deduced to be attached to C-7'' from the correlations observed from H-8'' 
to C-1''; H-7'' to C-1'', C-2'' and C-6''; H-2'' to C-7''. The HMBC data have therefore 
successfully connected the three 3,4-dimethoxybenzene rings to the aliphatic carbon 
skeleton. Therefore the structure of schwarzinicine A (11) was elucidated to be N-(3,4-
dimethoxyphenethyl)-1,4-bis(3,4-dimethoxyphenyl)-N-methylbutan-2-amine. However, 
because of severe overlapping of signals in the 
1
H and 
13
C NMR spectra, the unambiguous 
assignments of some aromatic signals were not possible, and these are indicated in Table 
2.9. 
 
 
Figure 2.36: Selected HMBCs and COSY correlations (bold bonds) of (11)
 1
0
3
 
 
Figure 2.37: 
1
H NMR spectrum (CDCl3, 600 MHz) of schwarzinicine A (11) 
 1
0
4
 
 
Figure 2.38: 
13
C NMR spectrum (CDCl3, 150 MHz) of schwarzinicine A (11) 
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2.3.2 Schwarzinicine B 
 
                             12 
Schwarzinicine B (12) was obtained as a major alkaloid from the leaves of F. 
schwarzii as a light yellowish oil []D
25
 +2 (c 0.45, CHCl3). The IR spectrum (Appendix 
48) showed absorption band at 3587 cm
-1 
indicating the presence of a secondary amine. The 
UV spectrum (max 230 and 281 nm) of 12 (Appendix 47) was essentially identical to that 
of 11. The ESIMS showed a pseudo-molecular ion at m/z 510 [M + H]
+
, and HRESIMS 
measurements established the molecular formula as C30H39NO6, differing from 12 by 14 
mass units and suggesting that 12 differed from 11 in having a methyl group replaced with 
a hydrogen atom. 
Comparison of the 
1
H and 
13
C NMR spectra (Table 2.9) indicated a general 
similarity of 11 and 12, except for some notable differences in the aliphatic region. The 
1
H 
NMR spectrum of 12 (Figure 2.40) showed a distinct absence of the NMe signal (H 2.38) 
present in that of 11, replaced instead by a broad singlet at H 1.98 in 12, attributable to an 
NH group. Similarly the 
13
C NMR spectrum of 12 (Figure 2.41) showed the absence of the 
NMe signal present in that of 11. Analysis of HSQC, COSY and HMBC data (Figure 2.39, 
Appendix 44 - 46) revealed the presence of identical partial structures in both 11 and 12. 
Therefore, schwarzinicine B (12) was determined to be the N-demethyl derivative of 
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schwarzinicine A (11) or N-(3,4-dimethoxyphenethyl)-1,4-bis(3,4-dimethoxyphenyl)-N-
methylbutan-2-amine. 
 
 
Figure 2.39: Selected HMBCs and COSY correlations (bold bonds) of schwarzinicine B 
(12) 
 1
0
7
 
 
Figure 2.40: 
1
H NMR spectrum (CDCl3, 600 MHz) of schwarzinicine B (12) 
 1
0
8
 
 
Figure 2.41: 
13
C NMR spectrum (CDCl3, 150 MHz) of schwarzinicine B (12)
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Table 2.9: 
1
H and 
13
C NMR data of schwarzinicines A (11) and B (12)
a
 
 
a
CDCl3, 600 MHz; 
b-j
 Assignments are interchangeable. 
Position 11  12 
1
H (J in Hz) 
13
C 
1
H (J in Hz) 
13
C 
1 - 132.3
c
  - 132.13 
2 6.73 m 112.2  6.67 d (2)
b 
111.64
f 
3 - 147.3
d
 
 
- 147.17
g
 
4 - 148.6
d
  - 147.44
g
 
5 6.79 d (8)
 
111.12
e
  6.72 d (8)
c
 111.10
h 
6 6.74 m 120.6  6.66 dd (8, 2)
d
 120.43
i 
7 2.71 m 34.9  2.67 dt (11, 7) 35.75 
8 2.65 m 55.7  2.75 m 48.36 
 2.77 m   2.90 dt (11, 7)
 
 
1' - 133.4
c
  - 131.50 
2' 6.62 d (2)  112.4  6.66 d (2)
b
 111.82
f 
3' - 146.9
d
  - 147.45
g
 
4' - 147.1
d
  - 148.80
g
 
5' 6.76 d (8) 111.06
e
  6.72 d (8)
c
 111.15
g 
6' 6.65 dd (8, 2)
 
121.1  6.61 dd (8, 2)
d
 121.06
i 
7' 2.32 m 34.6  2.62 m 40.10 
 2.89 m   2.73m  
8' 2.73 m 64.5  2.73 m
 
58.70 
1'' - 135.3  - 134.77 
2'' 6.56 d (2) 111.7  6.62 d (2)
b
 112.25
f 
3'' - 148.68
d
  - 148.84
g
 
4'' - 148.75
d
  - 148.87
g
 
5'' 6.73 m 111.2  6.77 d (8)
c 
111.22
h 
6'' 6.57 dd (8, 2) 120.1  6.60 dd (8)
d
 120.07
 
7'' 2.39 m 32.47  2.62 m 31.57 
 2.59 m     
8'' 1.59 m 32.49  1.79 m 35.37 
 1.69 m   1.72 m  
3-OMe 3.80 s
b 
55.79
f 
 3.82 s
e 
55.77
j
 
3'-OMe 3.83 s
b
 55.79
f
  3.83 s
e
 55.77
j
 
3''-OMe 3.83 s
b
 55.82
f
  3.84 s
e
 55.81
j
 
4-OMe 3.85 s
b
 55.85
f
  3.85 s
e
 55.81
j
 
4'-OMe 3.85 s
b
 55.86
f
  3.85 s
e
 55.84
j
 
4''-OMe 3.87 s
b
 55.89
f
  3.86 s
e
 55.93
j 
N-Me 2.38 s 36.8  - - 
N-H - -  1.98 br s - 
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Chapter 3: Isolation of flavonoids from Artocarpus heterophyllus 
x integer and Macaranga hypoleuca 
 
Sequential extraction of the dried macerated bark of Artocarpus heterophyllus x 
integer and the leaves of Macaranga hypoleuca using solvents of varying polarity, namely 
hexane, ethyl acetate and ethanol, have afforded crude extracts as summarized inTable 3.1.  
Table 3.1: Percentage yield of plant crude extracts. 
Plant Part Dry weight   Extract Weight of extract  
(% Yield) 
 
A. heterophyllus x 
integer 
 
Bark 
 
4 kg 
 
Hexane 
 
77 g (1.93) 
  Ethyl acetate 60 g (1.50) 
  Ethanol 
 
51 g (1.28) 
M. hypoleuca Leaves 2.2 kg Hexane 93g (4.23) 
  Ethyl acetate 54 g (2.45) 
  Ethanol 226 g (10.27) 
 
Preliminary screening by TLC of the crude extracts of A. heterophyllus x integer 
and M. hypoleuca revealed a series of dark spots when visualized under UV254, indicating 
the presence of chromophoric compounds. Some of these compound appeared as bright 
yellow spots under UV365 when reacted with ethanolic aluminium chloride solution, thus 
indicating the presence of flavonoids. In general, only the ethyl acetate extracts showed 
strong presence of flavonoids. Determination of total phenolic and flavonoid contents of the 
crude ethyl acetate extracts of A. heterophyllus x integer and M. hypoleuca (Appendix 1) 
reinforced the presence of flavonoids in these extracts. The crude ethyl acetate extracts of 
A. heterophyllus x integer and M. hypoleuca were then subjected to repeated 
chromatographic separation, i.e., column chromatography (VLC, silica gel or Sephadex 
LH-20) and centrifugal thin layer chromatography (CTLC, silica gel). 
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3.1 Isolation of flavonoids from A. heterophyllus x integer 
Four prenylated flavonoids and a xanthone compound were isolated from the bark 
ethyl acetate extract of A. heterophyllus x integer. Analysis of spectroscopic data as well as 
comparison with literature identified these compounds as cudraflavone C (13), 
artocarpentin A (14), cycloheterophyllin (15), artonin J (16) and lichexanthone (17). 
3.1.1 Cudraflavone C  
  
        13 
Cudraflavone C (13) was obtained as a light orange oil. TLC of this compound gave 
a bright yellow colour with ethanolic aluminium chloride solution. ESIMS showed a 
pseudo-molecular ion peak at m/z 423 [M + H]
+
, and HRESIMS measurements gave the 
molecular formula C25H26O6. The UV spectrum showed absorption maxima at 201, 232, 
261, and 314 nm, similar to those of 3-prenylflavones,
160
 while the IR spectrum showed 
absorption bands at 3364 and 1649 cm
-1
 due to hydroxy and conjugated carbonyl functions, 
respectively.  
The 
1
H NMR spectrum (Table 3.2, Figure 3.2) of cudraflavone C (13) showed the 
distinct presence of four allylic methyl singlets (δH 1.42, 1.55, 1.63 and 1.77), two allylic 
methylene doublets (δH 3.09 and 3.34), and two vinylic methine triplets (δH 5.11 and 5.25), 
indicating the presence of two prenyl side chains. In addition to the isolated aromatic 
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hydrogen at δH 6.38 (due to a pentasubstituted aromatic ring), the 
1
H NMR spectrum 
showed three aromatic hydrogens at δH 6.54 (d, J = 2.3 Hz), 6.50 (dd, J = 8.3, 2.3 Hz), and 
7.17 (d, J = 8.3 Hz), clearly indicated the existence of a 1,2,4-trisubstituted benzene ring. 
Furthermore, the absence of alkoxy signal such as OMe suggested that all phenolic OH 
groups are free, while the signal observed at δ 13.50 is characteristic of the presence of the 
hydrogen bonded 5-OH at ring A. 
 The 
13
C NMR spectrum (Table 3.1, Figure 3.3) showed a total of 25 carbon signals 
(four methyl, two methylene, six methine, and thirteen quaternary carbons). As far as the 
number of carbon atoms is concerned, the structure of 13 constituted of only a flavone 
nucleus (9xC), a 1,2,4-trisubstituted benzene ring (6xC) and two prenyl moieties (10xC). 
The quaternary carbon signal observed at δC 182.3 (C-4) was readily attributed to the 
conjugated ketone carbonyl, while the signals at δC 155.1, 156.0, 158.97, 159.01, 159.57, 
and 161.3 suggested that these aromatic/olefinic carbons are sites of oxygenation.  
The presence of two prenyl side chains as well as a 1,2,4-trisubstituted benzene ring 
were further supported by the COSY and HSQC data (Figure 3.1, Appendix 49 and 50). 
Since there are a total of six oxygen atoms in 13, and two are due to ring C of the flavone 
nucleus, the remaining four oxygen atoms must be due to four phenolic hydroxy groups 
attached to both rings A and B. Attachment of the 1,2,4-trisubstituted benzene ring to C-2 
(δC 159.57) was deduced from the observed three-bond correlation from H-6' (δH 7.17) to 
C-2 in the HMBC spectrum (Figure 3.1, Appendix 51), while the ortho and para positions 
of this benzene ring (B) were hydroxy-substituted. The location of one of the two prenyl 
side chains at C-3 was deduced from three-bond correlations observed from H-9 (δH 3.12) 
to C-2 and C-4 (δC 182.3). The other prenyl side chain was deduced to be linked to C-7 
from the observed HMBC correlations from H-14 to C-6, and C-7. HMBC correlations 
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observed from H-8 to C-4a, C-6, C-7, and C-8a provided firm support that C-8 is 
unsubstituted, hence the final hydroxy group must therefore be attached to C-5 in ring A. 
The structure of 13 is consistent with the HSQC, COSY, HMBC and NOESY data, as well 
as literature data.
161
 
 
  
Figure 3.1: Selected HMBC, NOESY and COSY (bold bonds) correlations of cudraflavone 
C (13) 
 
 
 1
1
4
 
 
 
Figure 3.2: 
1
H NMR spectrum (CDCl3/CD3OD, 400 MHz) of cudraflavone C (13) 
 1
1
5
 
 
Figure 3.3: 
13
C NMR spectrum (CDCl3/CD3OD, 100 MHz) of cudraflavone C (13)
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3.1.2 Artocarpetin A 
  
        14 
Artocarpetin (14) was obtained in minute amounts as a yellowish amorphous. The 
ESIMS showed a pseudo-molecular ion at m/z 369 [M + H]
+
, and HRESIMS gave the 
molecular formula C21H20O6. IR spectrum showed absorption bands for hydroxy groups at 
3400 cm
-1
 and a conjugated carbonyl function at 1651 cm
-1
. The UV spectrum showed 
absorption maxima at 208, 253, 269 nm. 
The 
13
C NMR spectrum (Table 3.2, Figure 3.6) showed a total of 21 carbon signals, 
which is in agreement with the molecular formula. The quaternary carbon resonance 
observed at δC 182.9 (C-4) was readily attributed to the conjugated ketone carbonyl, while 
the resonances at δC 155.6, 161.6, 162.1, 162.7, 163.2, and 164.0 are due to six oxygenated 
aromatic/olefinic carbons. The 
1
H NMR spectrum (Table 3.2, Figure 3.5) of 14 showed the 
presence of a methoxy signal at δH 3.94, a set of signals due to a prenyl side chain at δH 1.64 
and 1.78 (each 3H, s), 3.51 (2H, d, 7.0 Hz) and 5.21 (1H, t, 7.0 Hz), and a chelated phenolic 
hydroxy signal at δH 13.17 attributed to the hydroxy group at C-5. HMBC correlations 
(Figure 3.4, Appendix 54) suggested that the aromatic proton signals at δH 6.62 (d, 1.9 Hz), 
6.55 (dd, 8.8, 1.9 Hz) and 7.84 (d, 8.8 Hz) corresponded to H-3', H-5' and H-6' of the 2',4'-
dihydroxylated ring B, while the three bond correlation from H-3 to C-1' established the 
attachment of the B ring at C-2. The two remaining aromatic proton singlets at δH 7.19 and 
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6.43 are attributable to the isolated H-3 and H-6, respectively. Attachment of the prenyl 
side chain to C-8 was deduced from the HMBC correlations observed from H-9 to C-8 and 
C-7, while a three bond correlation from the methoxy group to C-7 established C-7 as the 
site of methoxylation. The structure of 14 is entirely consistent with the COSY, HSQC and 
HMBC data (Apendix 52-54) as well as by comparison with literature.
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Figure 3.4: Selected HMBCs and COSY (bold bonds) correlations of artocarpetin A (14)
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Figure 3.5: 
1
H NMR spectrum (CDCl3/CD3OD, 400 MHz) of artocarpetin A (14) 
 1
1
9
 
 
Figure 3.6: 
13
C NMR spectrum (CDCl3/CD3OD, 100 MHz) of artocarpetin A (14)
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Table 3.2: 
1
H and 
13
C NMR data of cudraflavone C (13) and artocarpetin A (14)
a
 
Position 13 
 
 14 
 
1
H (J in Hz) 13C  1H (J in Hz) 13C 
2 - 159.57
 
 - 162.7
b 
3 - 121.2  7.19 s 109.6 
4 - 182.3  - 182.9 
4a - 104.8  - 104.4 
5 - 158.97
b 
 - 162.1 
6 - 109.9  6.43 s 95.6 
7 - 161.3  - 164.0 
8 6.38 s 93.8  - 108.1 
8a - 156.0  - 161.6 
9 3.09 d (7.1) 24.4  3.51 d (7.0) 21.4 
10 5.11 t (7.1) 120.9
c
  5.21 t (7.0) 123.5 
11 - 133.2  - 131.2 
12 1.42 s 17.7  1.64 s 17.1 
13 1.55 s 25.6  1.78 s 24.9 
14 3.34 d (7.2) 21.5  - - 
15 5.25 tt (7.2, 1.4) 121.2
c
  - - 
16 - 135.8  - - 
17 1.77 s 25.8  - - 
18 1.63 s 17.9  - - 
1' - 112.6  - 111.5 
2' - 155.1
 
 - 155.6 
3' 6.54 d 2.3 103.8  6.62 d (1.9) 105.5 
4' - 159.01
b
  - 163.2
b 
5' 6.50 dd (8.3, 2.3) 108.4  6.55 dd (8.8, 1.9) 108.8 
6' 7.17 d (8.3) 131.6  7.84 d (8.8) 129.9 
5-OH 13.50 s -  13.17 s - 
7-OH Not observed -  - - 
2'-OH Not observed -  Not observed - 
4'-OH Not observed -  Not observed - 
7-OMe - -  3.94 s 55.7 
a
 CDCl3/CD3OD, 400 MHz; 
b-c 
Assignments are interchangable 
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3.1.3 Cycloheterophyllin  
 
              15 
Cycloheterophyllin (15) was obtained as yellow powder. The ESIMS showed a 
pseudo-molecular ion peak at m/z 501 [M - H]
-
, which corresponds to the molecular 
formula C30H30O7, requiring 16 degrees of unsaturation. The IR spectrum showed 
absorption bands at 3346 cm
-1
 and 1652 cm
-1 
due to hydroxy and conjugated carbonyl 
groups, respectively. Additionally, the IR absorption bands at 1375 and 1346 cm
-1
 were 
attributable to the gem-dimethyl group attached to C-16. The UV spectrum showed 
absorption maxima at 273, 299, and 405 nm resembling those of cycloheterophyllin 
reported in the literature and other flavone derivatives such as artonin A and 
cyclochampedol.
48,65
  
The 
13
C NMR spectrum (Table 3.3, Figure 3.10) gave a total of 30 carbon resonances (six 
methyls, a conjugated ketone carbonyl, 12 aromatic carbons, eight olefinic carbons, a 
methylene carbon, a methine carbon and a quaternary carbon) consistent with the molecular 
formula. The 
1
H NMR spectrum (Table 3.3, Figure 3.9) of cycloheterophyllin showed 
characteristic pattern of a dimethylchromene system with the presence of two singlets 
integrated for three protons each at δH 1.40 (H-17) and 1.43 (H-18) (Figure 3.7). The two 
AB doublets at δH 5.57 and 6.66 (1H each, J = 10 Hz) were assigned to the olefinic H-14 
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and H-15, respectively, while the two singlets at δH 7.21 and 6.45 were attributable to the 
isolated aromatic protons in ring B, i.e., H-2' and H-5', respectively.  
 
 
Figure 3.7: A dimethylchromene partial structure in 15 
 
The two vinylic methyls observed at δH 1.63 (H-13) and 1.89 (H-12), coupled to the 
two doublets (J = 9.2 Hz) at δH 6.14 (H-9) and 5.43 (H-10), revealed an oxygenated prenyl 
partial structure where C-9 is linked to C-2' of ring B via an oxygen atom, and as a result 
formed the D ring. This was supported by the HMBC data which showed correlations from 
H-9 to C-3 and C-11; H-10 to C-12; H-12 to C-13; H-13 to C-12 (Figure 3.8, Appendix 
57). The 
1
H NMR spectrum also showed a set of signals characteristic of an unaltered 
prenyl side chain, i.e., δH 1.63 (3H, s, H-23), 1.80 (3H, s, H-22), 3.41 (2H, m, H-19) and 
5.19 (1H, t, J = 6.9 Hz, H-20). In addition to confirming the presence of the prenyl side 
chain, the COSY and HMBC data also confirmed that the prenyl unit is attached to the core 
structure at C-8. The relevant HMBC correlations include H-19 to C-7 and C-8a; H-19 to 
C-20; H-20 to C-23; H-22 to C-23; H-23 to C-20 and C-22. Full assignments of the 
1
H and 
13
C NMR data of cycloheterophyllin (15) were in complete agreement with the COSY, 
HSQC and HMBC data (Appendix 55-57) as well as comparison with literature. 
Cycloheterophyllin (15) is a known flavonoid previously isolated from the bark of A. 
heterophyllus.
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Figure 3.8: HMBC and COSY (bold bonds) correlations of cycloheterophyllin (15) 
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Figure 3.9: 
1
H NMR spectrum (CDCl3/CD3OD, 400 MHz) of cycloheterophyllin (15) 
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2
5
 
 
Figure 3.10: 
13
C NMR spectrum (CDCl3/CD3OD, 100 MHz) of cycloheterophyllin (15) 
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3.1.4 Artonin J 
 
             16 
Artonin J (16) was obtained in minute amounts from the bark of A. heterophyllus x 
integer as yellowish crystals, mp: 280 – 285 °C (lit., 281 – 282 °C)66.  ESIMS of 16 showed 
a pseudo-molecular ion peak at m/z 437 [M + H]
+
 and HRESIMS which corresponds to the 
molecular formula C25H24O7. The IR spectrum showed absorption bands at 3399 cm
-1
 and 
1713 cm
-1
 attributable to hydroxy and conjugated carbonyl groups, respectively. The UV 
spectrum showed absorption maxima at 380, 264, 231 and 210 nm, resembling those from 
molecules with similar chromophore such as cycloartobiloxanthone.
46
 
The 
13
C NMR spectra (Table 3.3, Figure 3.14) showed peaks accountable for 25 
carbons, comparable to data reported in the literature which are consistent with the 
molecular formula.
66
 Analysis of the 
13
C NMR data revealed the presence of four methyl 
carbons at δC 17.7 (C-18), 25.7 (C-17), 22.4 (C-13), and 28.0 (C-12); two methylene 
carbons at δC 22.6 (C-14) and 19.9 (C-9); a methine carbon at δC 46.1 (C-10); four olefinic 
carbons; 12 aromatic carbons; a conjugated ketone at δ 179.1 (C-4); and a quaternary 
carbon at δC 94.0 (C-11). 
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The 
1
H NMR spectrum (Table 3.3, Figure 3.13) showed the presence of a set of 
signals characteristic of a prenyl substituent: two methyl singlets at δH 1.70 (H-17) and 1.81 
(H-18), a 1-H olefinic signal at δH 5.26 (H-15), and a 2H doublet at δH 3.39 (H-14). The 
COSY spectrum (Figure 3.11, Appendix 58) of 16 revealed an ABX spin system at δH 2.39 
(1H, t, J = 15 Hz, H-9), 3.18 (1H, dd, J = 15, 7 Hz, H-9) and 3.39 (1H, dd, J = 15, 7 Hz, H-
10), which is a typical pattern for the furanoxanthone core structure that acquired its D ring 
from the linkage between C-3 of ring C and C-6' of ring B via a prenyl unit. Similar ABX 
spin systems were observed in compounds having the same furanoxanthone core structure 
such as artonin A and artoindosianin A.
65
 The gem-dimethyl group attached at C-11 of the 
furan moiety was observed as two methyl singlets at δH 1.34 (H-12) and 1.66 (H-13). The 
two singlet signals at δH 6.28 (H-6) and 6.39 (H-8) were readily attributable to the two 
isolated aromatic protons. 
Due to compound degradation and insufficient yield, HSQC and HMBC spectra 
could not be obtained. However, due to the presence of suitable crystals at hand, X-ray 
diffraction analysis was carried out, which revealed compound 16 as artonin J (Figure 
3.12). The spectroscopic data available including MS, 1D NMR, IR and UV spectroscopy 
are in good agreement with those of literature.
66
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Figure 3.11: COSY correlations of artonin J (16) 
 
 
Figure 3.12: X-ray diffraction crystal structure of artonin J (16) 
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Figure 3.13: 
1
H NMR spectrum (CDCl3/CD3OD, 400 MHz) of artonin J (16) 
 1
3
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Figure 3.14: 
13
C NMR spectrum (CDCl3/CD3OD, 100 MHz) of artonin J (16) 
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Table 3.3: 
1
H and 
13
C NMR data of cycloheterophyllin (15) and artonin J (16)
a
 
Position 15  
 
 16 
 
 
1
H (J in Hz) 
13
C 
1
H (J in Hz) 
13
C 
2 - 155.8  - 161.3 
3 - 109.6  - 111.8 
4 - 178.8  - 179.1 
4a - 105.4
b
  - 103.5 
5 - 154.3  - 160.7 
6 - 105.5
b
  6.28 s 99.6 
7 - 153.6
c
  - 163.7 
8 - 107.8  6.39 s 94.0 
8a - 156.6
c
  - 156.1 
9 6.14 d (9.2) 69.3  2.39 t (15)  
3.18 dd (15, 7) 
19.9 
10 5.43 d (9.2) 121.2  3.39 dd (15, 7) 46.1 
11 - 139.4  - 93.9 
12 1.89 s 18.7  1.34 s 28.0 
13 1.63 s 26.0  1.66 s 22.4 
14 6.66 d (10.1) 116.0  3.39 d (7) 22.6 
15 5.57 d (10.1) 128.0  5.26 t (7) 122.2 
16 - 77.8  - 132.3 
17 1.40 s 28.1  1.70 s 25.7 
18 1.43 s 28.3  1.81 s 17.7 
19 3.41 m 21.6  - - 
20 5.19 t (6.9) 122.1  - - 
21 - 131.8  - - 
22 1.80 s 18.1  - - 
23 1.63 s 25.9  - - 
1' - 107.7  - 104.0 
2' - 151.5  - 146.0 
3' 6.45 s 104.7  - 117.1 
4' - 150.3  - 144.3 
5' - 139.6  - 137.2 
6' 7.21 s 109.2  - 127.8 
a
 CDCl3/CD3OD, 400 MHz; 
b- c
 Assignments are interchangeable 
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3.1.5 Lichexanthone 
 
       17 
Lichexanthone (17) was obtained from the ethyl acetate bark extract of A. 
heterophyllus x integer as yellow needles, mp: 185-190 °C (lit., 188-190 °C)
162
 and was 
identified by X-ray diffraction analysis (Figure 3.15). 
1
H NMR spectrum of 17 (Figure 
3.16) showed the presence of a methyl signal at δH 2.83 (3H, s, H-8), and two methoxy 
groups at δH 3.84 (3H, s) and 3.88 (3H, s). A pair of aromatic doublet signals due to H-2 
and H-4 were seen at δ 6.28 (1H, d, J = 2.8 Hz) and 6.31 (1H, d, J = 2.8 Hz) respectively, 
while the signals for H-5 and H-7 appeared as singlet signals at δH 6.64 and 6.66, 
respectively. 
1
H NMR assignments were made by comparison with literature (Table 
3.4).
162,163
 
It is believed that lichexanthone (17) is not produced first hand by A. integer x 
heterophyllus. Since lichexanthone is a major metabolite produced by epiphytic lichens, 
which commonly grow on leaves, branches and bark of trees in rainforests and woodlands, 
isolation of lichexanthone in the present study is suspected to be the due to the epiphytic 
lichens that were found on the bark of A. integer x heterophyllus.
164
 
 
 
 
 133 
 
Table 3.4: Comparison of 
1
H NMR data of lichexanthone (17)a obtained with published 
data.  
Position Literature
162
 
 
 Literature
163 
 
 17 
 1H (J in Hz) 
 
1
H  
 
1
H (J in Hz) 
 
1-OH 13.36 s  13.39    
2 6.26 d (2.6)  6.29   6.28 d (2.8) 
4 6.28 d (2.6)  6.32   6.31 d (2.8) 
5 6.63 d (2.6)  6.65   6.64 s 
7 6.62  s  6.67   6.66 s 
8 -Me 2.81 s  2.84   2.83 s 
12 -OMe 3.85 s  3.86   3.84 s 
13 -OMe 3.87 s  3.89   3.88 s 
a
 CDCl3, 400 MHz 
 
 
Figure 3.15: X-ray diffraction crystal structure of lichexanthone (17) 
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Figure 3.16: 
1
H NMR spectrum (CDCl3, 400 MHz) of lichexanthone (17) 
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3.2  Isolation of flavonoids from the leaves of Macaranga hypoleuca 
Six known flavonoids and a triterpenoid were isolated from the leaf ethyl acetate 
extract of M. hypoleuca. These compounds were identified as quercetin-3-O--L-
arabinopyranoside (18), quercetin-3-O--L-arabinofuranoside (19), quercetin-3-O-β-D-
galactoside (20), quercetin (21), kaempherol (22), 5,7-dihydroxy-2-(4-methoxyphenyl)-8-
(3-methylbut-2-en-1-yl)chroman-4-one (23) and 3-epi-taraxerol (24) based on 
spectroscopic data as well as comparison with literature. 
3.2.1 Quercetin-3-O-α-L-arabinopyranoside  
 
18 
Quercetin-3-O-α-L-arabinopyranoside (18) was obtained as yellow crystals, mp: 
242-244 
o
C (lit., 250-260 
o
C).
165
 ESIMS of 18 showed a pseudo-molecular ion peak at m/z 
435 [M + H]
+
, while HRESIMS measurements gave the molecular formula C20H18O11. The 
IR spectrum showed broad absorption bands at 3476 and 1654 cm
-1 
attributable to the 
presence of hydroxy and conjugated carbonyl groups, respectively. The UV spectrum 
showed absorption maxima at 256 and 357 nm, resembling the UV spectra reported in 
literature for this compound and other similar flavonol monoglycosides.
166,167
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The 
13
C NMR spectrum (Table 3.5, Figure 3.20) showed a total of 20 carbon signals 
attributed to a flavonol nucleus (9xC), a 1',3',4'-trisubstituted aromatic ring (6xC) and an 
aldopentose moiety (5xC). The carbon signal observed at δC 179.1 was readily attributed to 
the conjugated ketone carbonyl, while the signals at δC 165.3, 163.0, 157.9, 149.4, and 
145.5 are due to aromatic carbons that are sites of oxygenation. Pyranose and furanose 
forms of a sugar moiety can be distinguished readily by considering the chemical shift of 
C-4'' as well as the hydrogen signals for H-5''. The C-4'' chemical shifts are distinctly 
different for both pyranose and furanose moieties, i.e., ca. δC 67 and 87, respectively.
168,169
  
On the other hand, the pyranose moiety normally possesses a pair of anisochronous C-5'' 
methylene hydrogen signals, while the furanose moiety shows an isochronous C-5'' 
methylene hydrogen signal.
169
 The pyranose form of the arabinoside in 18 was thus 
indicated by the chemical shift of C-4'' at δC 68.2 and the presence of a pair of 
anisochronous C-5'' methylene hydrogens at δH 3.46 and 3.79. 
The 
1
H NMR spectrum (Table 3.5, Figure 3.19) showed three aromatic hydrogen 
signals at δH 6.92 (d, J = 8.5 Hz), 7.63 (dd, J = 8.5, 2.2 Hz), and 7.88 (d, J = 2.2 Hz) 
attributed to the 1',3',4'-trisubstituted ring B, and two aromatic doublets at δH 6.25 (d, J = 
2.1 Hz) and 6.49 (d, J = 2.1 Hz) attributed to the two hydrogens in meta arrangements in 
ring A. These observations are consistent with the presence of the 5,7,3',4'-tetraoxygenated 
flavonoid core structure of 18. The broad singlet at δH 12.49 is readily attributed to 5-OH, 
which is hydrogen bonded to the oxygen atom of the ketone function at C-4. Not all 
hydroxy signals are visible, only those exchanging at a slower rate will be visible as in the 
case of flavonoids where 5-OH hydrogen is bonded to C=O at C-4. 
The 
1H NMR spectrum showed signals (δH 3.4-5.3 ppm) that are distinctive of the 
presence of a sugar moiety, with an anomeric hydrogen (H-1'') signal normally appearing 
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within δH 4.3-5.9 ppm.
168
 The coupling constant between the anomeric H-1'' and H-2'' of 
the sugar ring moiety is normally quite diagnostic of the stereochemistry at the anomeric 
carbon.
170
 This is because carbohydrates form relatively rigid ring conformations where the 
attached hydrogens adopt either the axial or equatorial orientation. Thus, according to the 
Karplus correlation a H-1''-H-2'' equatorial-axial relationship leads to a small coupling 
constant (J < 7 Hz, dihedral angle ca 60°), which is associated with -L-
arabinopyranosides, while the opposite is observed for a trans-diaxial relationship of H-
1''/H-2'' (J > 7 Hz, dihedral angle ca 180°), which is associated with -L-
arabinopyranosides.
168
 For 18, the anomeric H-1'' signal appeared as a well resolved 
doublet at δH 5.26 (d, J = 6.2 Hz) implying an equatorial-axial configuration with H-2'' and 
corresponding to an -anomer. This determined the sugar moiety in 18 to be an -L-
arabinopyranoside linked to the flavonol nucleus via an -glycosidic bond. On the other 
hand, the H-2''/H-3'' coupling constant of J = 7.9 Hz also indicated a trans-diaxial 
configuration between H-2''and H-3'', while the H-3''/H-4'' coupling constant of J = 4.0 Hz 
implied an axial-equatorial orientation between H-3'' and H-4''. These observations are 
entirely consistent with the configuration of -L-arabinopyranose.169,170   
The presence the 5,7,3',4'-tetraoxygenated flavonoid core structure, which was 
further supported by 2D NMR data, was identified as quercetin. The COSY, HSQC and 
HMBC data (Figure 3.17, Appendix 59 - 61) further supported the assignment of the 
arabinopyranose substituent. HMBC correlation between H-1'' to C-3 essentially confirmed 
the attachment of the -L-arabinopyranosyl moiety to the quercetin structure at C-3. The 
NMR data of 18 are in good agreement with those reported in literature.
166,169,171
 Since 
suitable crystals of 18 were obtained, X-ray diffraction analysis was carried out (Figure 
3.18) and re-confirmed the structure of 18 as quercetin-3-O-α-L-arabinopyranoside. 
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Figure 3.17: Selected HMBC and COSY (bold bonds) correlations of quercetin-3-O-α-L-
arabinopyranoside (18) 
 
 
Figure 3.18: X-ray crystal structure of quercetin-3-O-α-L-arabinopyranoside (18) 
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Figure 3.19: 
1
H NMR spectrum (acetone-d6,, 600 MHz) of quercetin-3-O-α-L-arabinopyranoside (18) 
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Figure 3.20: 
13
C NMR spectrum (acetone-d6,, 150 MHz) of quercetin-3-O-α-L-arabinopyranoside (18)
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3.2.2 Quercetin-3-O-α-L-arabinofuranoside  
 
            19 
Quercetin-3-O-α-L-arabinofuranoside (19) was obtained as a yellow amorphous. 
ESIMS of 19 showed a pseudo-molecular ion peak at m/z 435 [M + H]
+
 and HRESIMS 
gave the molecular formula C20H18O11.
 
The IR spectrum showed absorption bands due to 
the presence of hydroxy and carbonyl groups respectively at 3400 cm
-1
and 1613 cm
-1
. The 
UV spectrum showed absorption maxima at 258, 292 and 358 nm, resembling the UV 
spectra of similar flavonol monoglycosides.
166,167
 
The 
13
C NMR spectrum (Table 3.5, Figure 3.23) showed a total of 20 carbon signals 
attributed to a flavone nucleus (9xC), a 1',3',4'-trisubstituted aromatic ring (6xC) and an 
aldopentose moiety (5xC). The carbon signal observed at δC 178.9 was readily attributed to 
the conjugated ketone carbonyl, while the signals at δC 164.3, 161.8, 157.12, 157.06, 148.4 
and 144.9 suggested that these quaternary carbons are sites of oxygenation. In contrast to 
18, the furanose form of 19 was indicated by the carbon chemical shift of C-4'' at δC 88.4 
and the isochronous C-5'' methylene signal at δH 3.57 (2H, d, J = 3.9 Hz).
168,169
 
The 
1
H NMR spectrum (Table 3.5, Figure 3.22) showed three aromatic hydrogen 
signals at δH 6.97 (d, J = 8.4 Hz), 7.56 (dd, J = 8.4, 2.2 Hz), and 7.70 (d, J = 2.2 Hz) 
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attributed to the 1',3',4'-trisubstituted ring B, and two aromatic doublets at δH 6.26 (d, J = 
2.1 Hz) and 6.49 (d, J = 2.1 Hz) attributed to two hydrogens in meta arrangements in ring 
A. These observations are consistent with the 5,7,3',4'-tetraoxigenated flavonoid core 
structure of 19. The broad singlet at δH 12.48 is readily attributed to 5-OH, which is 
hydrogen bonded to the oxygen atom of the ketone function at C-4. The flavonol moiety 
was determined to be quercetin as in the case of 18, and was confirmed by comparison with 
published data.
172
 A comparison of the anomeric hydrogen chemical shifts and coupling 
constants for the sugar moiety in 19 with - and -arabinofuranosides suggested that the 
sugar moiety is an arabinose in the furanose form and -linked to the flavonoid 
structure.
173–175
 The attachment of the arabinofuranosyl moiety to C-3 was supported by 
HMBC correlation from H-1'' to C-3 (Figure 3.21). The structure of quercetin-O-α-L-
arabinofuranoside is consistent  with COSY and HMBC (Figure 3.2, Appendix 62 - 63) 
data as well as by comparison with literature data.
169,171
 Quercetin-3-O-arabinoside exists in 
M. hypoleuca in two sugar forms, i.e., as a pyranose (18) and furanose (19). 
 
 
Figure 3.21: Selected HMBCs and COSY (bold bonds) correlations of quercetin-3-O-α-L-
arabinofuranoside (19) 
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Figure 3.22: 
1
H NMR spectrum (acetone-d6, 600 MHz) of quercetin-3-O-α-L-arabinofuranoside (19) 
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Figure 3.23: 
13
C NMR spectrum (acetone-d6, 150 MHz) of quercetin-3-O-α-L-arabinofuranoside (19)
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3.2.3 Quercetin-3-O-β-D-galactoside 
 
             20 
Quercetin-3-O-β-D-galactoside (20) was obtained as a yellow amorphous. ESIMS 
showed a pseudo-molecular ion peak at m/z 465 [M + H]
+
 and HRESIMS gave the 
molecular formula C21H20O11. The IR spectrum showed absorption bands due to the 
presence of hydroxy and conjugated ketone groups at 3400 and 1608 cm
-1
, respectively. 
The UV spectrum showed absorption at 258, 306, 363 nm, resembling the UV spectra of 
similar flavonol monoglycosides.
166,167
 
The 
13
C NMR spectrum (Table 3.5, Figure 3.26) showed a total of 21 carbon signals 
attributed to a flavone nucleus (9xC), a 1',3',4'-trisubstituted aromatic ring (6xC) and an 
aldohexose moiety (6xC). The carbon signal observed at δC 178.3 was readily attributed to 
the conjugated ketone carbonyl, while the signals at δC 164.4, 161.7, 157.7, and 157.1 are 
due to aromatic carbons that are sites of oxygenation. The C-4'' carbon shift at δC 68.7 and 
the anisochronous C-5'' methylene hydrogen signals at δH 3.57 and 3.68, are consistent with 
those of β-flavonol gylcosides in the pyranose form.168,169 
The 
1
H NMR spectrum (Table 3.5, Figure 3.25) showed three aromatic hydrogen 
signals at δH 6.91 (d, J = 8.5 Hz), 7.80 (dd, J = 8.5, 2.2 Hz), and 8.03 (d, J = 2.2 Hz) 
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attributed to the 1',3',4'-trisubstituted ring B, and two aromatic doublets at δH 6.26 (d, J = 
2.1 Hz) and 6.5 (d, J = 2.1 Hz) attributed to the two hydrogens in meta arrangement in ring 
A. These observations are consistent with the 5,7,3',4'-tetraoxygenated flavonol core 
structure of 20. The broad singlet at δH 12.36 is readily attributed to 5-OH, which is 
hydrogen bonded to the oxygen atom of the ketone function at C-4. The flavonol moiety 
was determined to be quercetin by comparison with published data.
172
 The observation of 
an anomeirc hydrogen signal at δH 5.16 (d, J = 7.8 Hz) along with six hydrogen signals in 
the region δH 3.61 – 3.91 indicated the presence of a sugar unit. The large coupling constant 
(7.8 Hz) observed between H-1'' and H-2'' suggested both hydrogens are trans-diaxially 
oriented requiring the sugar moiety to be a -anomer. Comparison of the 1H and 13C NMR 
data of the sugar moiety with literature values revealed the presence of a β-
galactopyranose.
176
 The HMBC correlation (Figure 3.24) from H-1'' to C-3 confirmed the 
attachment of the galactopyranosyl moiety to the quercetin structure at C-3. Overall, the 
structure of 20 is consistent with COSY, HSQC, HMBC (Appendix 65 - 67) and literature 
data of 3-O-β-D-galactopyranoside flavonoids.167,169,176. 
 
 
Figure 3.24:  Selected HMBCs and COSY (bold bonds) correlations of quercetin-3-O-β-D-
galactoside (20) 
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Figure 3.25: 
1
H NMR spectrum (acetone-d6, 600 MHz) of quercetin-3-O-β-D-galactoside (20) 
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4
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Figure 3.26:
13
C NMR spectrum (acetone-d6, 150 MHz) of quercetin-3-O-β-D-galactoside (20) 
 149 
Table 3.5: 
1
H and 
13
C NMR data of quercetin-O-α-L-arabinopyranoside (18), quercetin-O-α-
L-arabinofuranoside (19) and quercetin-O-β-D-galactoside (20)a 
C 18 
 
 19    20  
 
1
H (J in Hz) 13C 1H (J in Hz) 13C 
1
H (J in Hz)
 13
C
 
2 - 157.9b   - 157.12c
  - 157.7 c 
3 - 135.5   - 133.6  - 134.8 
4 - 179.1   - 178.9  - 178.3 
4a - 105.5   - 104.4  - 104.5 
5 - 163.0   - 161.8  - 161.7 
6 6.25 d (2.1) 99.6  6.26 d (2.1) 98.7  6.26 d (2.1) 98.7 
7 - 165.3   - 164.3  - 164.4 
8 6.49 d (2.1) 94.6  6.49 d (2.1) 93.7  6.50 d (2.1) 93.7 
8a - 157.9b   - 157.06c
 
 - 157.1c 
  
  
  - 
 
   
1' - 122.8   - 121.6  - 122.2 
2' 7.88 d (2.2) 117.3  7.70 d (2.2) 115.4  8.03 d (2.2) 117.0 
3' - 145.5   - 144.9  - 144.3 
4' - 149.4   - 148.4  - 148.4 
5' 6.92 d (8.5) 116.0  6.97 d (8.4) 115.6  6.91 d (8.5) 114.8 
6' 7.63 dd (8.5, 2.2) 122.7  7.56 dd (8.4, 2.2) 121.8  7.80 dd (8.5, 2,2) 121.7 
  
  
   
 
   
1'' 5.26 d (6.2 Hz) 104.2  5.47 br s 108.3  5.18 d (7.8) 104.9 
2'' 3.91 dd (7.9, 6.2) 72.5  4.29 dd (2.0, 0.7) 81.4  3.80 dd (9.5, 7.8) 71.9 
3'' 3.71 dd (7.9, 4) 73.7  3.97 dd (3.7, 2.0) 77.9  3.61 dd (9.5, 3.3) 73.9 
4'' 3.85 td (4, 2.3) 68.2  4.07 q (3.7) 88.4  3.91 dd (3.4, 1.1) 68.7 
5'' 3.79 dd (12.2, 4) 66.1  3.57 d (3.7) 61.7  3.84 br t (8.7) 75.7 
 
3.46 dd (12.2, 
2.3)  
 
  
 
 
  
6'' - -  - -  3.68 dd (11, 6) 61.1 
 - -  - -  3.61 m - 
5-OH 12.49 s -  12.48 s -  12.36 br s - 
a
 Acetone-d6, 600 MHz; 
b
 Overlapping signals; 
c 
Assignments are interchangable  
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3.2.4 Quercetin  
  
            21 
Quercetin (21) was obtained as a yellow powder. ESIMS of 21 showed a pseudo-
molecular ion peak at m/z 303 [M + H]
+
 which corresponds to the molecular formula 
C15H10O7. The IR spectrum showed absorption bands attributable to the presence of 
hydroxy (at 3476 cm
-1
) and conjugated carbonyl (1614 cm
-1
). The UV spectrum showed 
absorption at 257, 303 and 374 nm. 
 The 
1
H NMR spectrum (Table 3.6, Figure 3.27) showed three aromatic hydrogen 
signals at δH 6.86 (d, J = 8.5 Hz), 7.57 (dd, J = 8.5, 2.0 Hz), and 7.70 (d, J = 2.0 Hz) 
attributed to the trisubstituted aromatic ring B, and two aromatic doublets at δH 6.13 (d, J = 
2.0 Hz) and 6.40 (d, J = 2.0 Hz), attributed to a pair of meta-coupled hydrogens in ring 
A.
177
 The absence of a singlet signal at approximately δH 6.3 ppm due to H-3 indicated that 
C-3 is substituted. These results agreed with a 3,5,7,3',4'-pentaoxygenated flavonoid. In 
addition, the signal at δH 12.04 indicated the presence of a hydroxy group at C-5. Although 
13
C NMR was not carried out, comparison of mass, IR, UV and 
1
H NMR data with 
literature was sufficient for the identification of quercetin (21).
166,169,172,178
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Figure 3.27: 
1
H NMR spectrum (acetone-d6, 400 MHz) of quercetin (21)
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3.2.5 Kaempferol 
  
           22 
Kaempherol (22) was obtained as a yellow powder. ESIMS showed a pseudo-
molecular ion peak at m/z 287 [M + H]
+
 which corresponds to the molecular formula 
C15H10O6. The IR spectrum showed absorption bands attributable to the presence of 
hydroxy and conjugated ketone groups at 3476 and 1614 cm
-1
, respectively. The UV 
spectrum showed absorption at 265 and 367 nm. 
The 
13
C NMR spectrum (Table 3.6, Figure 3.29) showed a total of 15 carbon signals 
(six methines and nine quaternary carbons). The quaternary carbon signal observed at δC 
176.6 was readily attributed to the conjugated ketone carbonyl, while the resonances at δC 
160.2, 162.5 and 165.5 suggested that these aromatic carbons are sites of oxygenation while 
the resonance at δC 136.7 is attributed to the C-3.
167,179
 
The 
1
H NMR spectrum (Table 3.6, Figure 3.28) showed two singlets at δH 6.28 (H-
6) and 6.54 (H-8), attributed to a pair of meta-coupled aromatic hydrogens in ring A, 
usually appear between δH 6.0-6.5.
177
 On the other hand, two sets of 2H aromatic doublets 
observed at δH 7.03 (d, J = 8.8 Hz, 2H) and 8.17 (d, J = 8.8 Hz, 2H) confirmed the presence 
of the para-disubstituted ring B. The more upfield signal (δH 7.03) was attributed to H-3' 
and H-5' due to the shielding effect from the OH at C-4', while the more downfield signal 
(δH 8.17) was attributed H-2' and H-6'. The absence of a singlet signal at approximately δH 
 153 
6.3 due to H-3 indicated a substitution at C-3, which is consistent with the structure of 
flavonol.
177
 Additionally, a broad signal at δH 12.20 is attributed to the presence of hydroxy 
group at C-5. The NMR (
1
H and 
13
C, HSQC), MS, IR, and UV data of 22 are in complete 
agreement with those of kaempherol, as available in the literature.
170,179
 
 
Table 3.6: 
1
H and 
13
C NMR data of quercetin (21) and kaempherol (22)
a
 
Position 21  22 
 
 
1
H (J in Hz) 
1
H (J in Hz) 
13
C 
2 -  - 147.1 
3 -  - 136.7 
4 -  - 176.6 
4a -  - 104.1 
5 -  - 162.5
b
 
6 6.13 d (2.0)  6.28  s 99.2 
7 -  - 165.5 
8 6.40 d (2.0)  6.54  s 94.5 
8a -  - 157.8 
  
 
 
  1' -  - 123.3 
2' 7.70  d (2.0)  8.17 d (8.8) 130.5
 
3' -  7.03 d (8.8) 116.3 
4' -  - 160.2
b
 
5' 6.86  d (8.5)  7.03 d (8.8) 116.3 
6' 7.57  dd (8.5, 2.0)  8.17 d (8.8) 130.5 
  
 
  5-OH 12.04  s  12.20 s - 
a
 Acetone-d6, 400 MHz; 
b
 Assignments are interchangeable 
 1
5
4
 
 
Figure 3.28: 
1
H NMR spectrum (acetone-d6, 400 MHz) of kaempherol (22) 
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5
5
 
 
Figure 3.29: 
13
C NMR spectrum (acetone-d6, 100 MHz) of kaempherol (22) 
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3.2.6 5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one 
 
          23 
 5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one (23) 
was obtained in minute amounts as yellow crystals, mp: 215-218 °C. ESIMS measurements 
showed a pseudo-molecular ion peak at m/z 355 [M + H]
+ 
and HRESIMS gave the 
molecular formula C21H22O5. IR spectrum showed absorption bands due to hydroxy (3241 
cm
-1
) and conjugated ketone (1643 cm
-1
) functions. The UV spectrum showed absorption 
maxima at 219, 296 and 336 nm.  
The 
13
C NMR spectrum (Table 3.7, Figure 3.32) showed a total of 21 carbon signals 
(three methyls, two methylenes, seven methines, and nine quaternary carbons). The 
quaternary carbon signal observed at δC 197.4 was readily attributed to the conjugated 
ketone carbonyl, while the signals at δC 160.9, 161.0, 163.0, and 165.0 suggested that these 
aromatic carbons are sites of oxygenation.  
The 
1
H NMR spectrum (Table 3.7, Figure 3.31) were indicative of a flavonone 
structure with three sets of doublet of doublets observed at δH 2.77 (dd, J = 17.0, 3.1 Hz), 
3.13 (dd, J = 17.0, 12.0 Hz) and 5.48 (dd, J = 12.0, 3.1 Hz) attributed to the H-3eq, H-3ax 
and H-2, respectively.
45
 Two typical 2H aromatic signals appearing as a pair of doublets at 
δH 6.98 (d, J = 9.0 Hz) and 7.49 (d, J = 9.0 Hz) suggested two pairs of equivalent aromatic 
O
O
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hydrogens, while the methoxy signal at δH 3.82, which is assignable to C-4' suggested a 
1',4'-disubstituted aromatic B-ring with a mirror plane of symmetry passing through C-1' 
and C-4'. The equatorial position of the B-ring was assigned based on the the coupling 
constant J2,3ax = 12.0 Hz, which requires H-2 and H-3ax to be trans-diaxial.
45
 The presence 
of two allylic methyl singlets at (δH 1.59 and 1.60), an allylic methylene doublet (δH 3.21) 
and a vinylic methine triplet (δH 5.18) were indicative of a prenyl side chain. HMBC 
correlations (Figure 3.30, Appendix 69) from H-9 to C-8 and H-6 to C-8 established the 
connectivity of the prenyl unit to C-8. The remaining singlet at δH 6.03 were attributed to 
H-6 while the signal observed at δH 12.12 are attributed to the hydroxy group at C-5. The 
structure of 23 is entirely consistent with COSY and HMBC data (Figure 3.30, Appendix 
67 and 68) as well as literature.
180,181
  
 
 
Figure 3.30: Selected HMBCs and COSY (bold bonds) correlations of 5,7-dihydroxy-2-(4-
methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one (23) 
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Figure 3.31: 
1
H NMR spectrum (acetone-d6, 600 MHz) of 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-
one (23) 
 1
5
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Figure 3.32: 
13
C NMR spectrum (acetone-d6, 150 MHz) of 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one 
(23) 
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Table 3.7: 
1
H and 
13
C NMR data of 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-
en-1-yl) chroman-4-one (23)
 a
 
Position  23
    Literature data
181
  
 
 1
H (J in Hz) 
 13
C 
1
H (J in Hz)
 13
C
 
2  5.48 dd (12, 3.1)  79.6  5.36 dd (12.9, 3) 78.7 
3ax  3.13 dd (17, 12)  43.5  3.06 dd (17.1, 12.9) 43.0 
3eq  2.77 dd (17, 3.1)    2.80 dd (17.1, 3) - 
4  -  197.4  - 196.5 
4a  -  103.2  - 103.1 
5  -  165.0  - 162.1 
6  6.03 s  96.4  6.02 s 96.7 
7  -  163.0  - 163.7 
8  -  108.3  - 106.4 
8a  -  161.0  - 159.8 
         
9  3.21 d (7.2)  22.3  Not available 21.7 
10  5.18 t (7.2)  123.7  Not available 121.6 
11  -  131.2  - 134.6 
12  1.59 s  17.9  Not available 17.8 
13  1.60 s   25.9  Not available 25.6 
        
1'  -  132.3  - 130.7 
2'  7.49 d (9)
 
 128.7
 
 7.37 d (8.7) 127.5 
3'  6.98 d (9)  114.8
 
 6.95 d (8.7) 114.1 
4'  -  160.9  - 159.8 
5'  6.98 d (9)  114.8
 
 6.95 d (8.7) 114.1 
6'  7.49 d (9)  128.7
 
 7.37 d (8.7) 127.5
 
 
        
4'-OMe  3.82 s  55.6  3.84 s 55.3 
5-OH  12.12 s   -  12.01 s - 
a
 Acetone-d6, 600 MHz 
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3.2.7 3-Epi-taraxerol 
 
                 24 
3-Epi-taraxerol (24) was obtained from the leaves of M. hypoleuca as colourless 
crystals, mp: 260-263 °C (lit., 261-263 °C)
182
. Since suitable crystals of 24 were at hand, X-
ray diffraction analysis was carried out (Figure 3.33) and revealed 24 as 3-epi-taraxerol. 
The 
1
H NMR spectrum (Figure 3.34) of 24 was also obtained which revealed seven singlets 
in the upfield region (δH 0.81 – 1.25), attributable to the seven methyl groups. Additionally, 
a carbinolic hydrogen was observed at δH 3.40 (t, 2.28 Hz) and an olefinic hydrogen at δH 
5.5 (dd, 8.2, 3.1 Hz), assignable to H-3 and H-13, respectively. Due to severe overlapping 
of the 
1
H NMR signals, detailed hydrogen assignment was not possible without 2D NMR 
analysis (not done due to insufficient compound). However, the 
1
H NMR data of 24 are 
largely similar to those of taraxerol and tarexerone (structurally similar compounds).
182,183
 
Epi-taraxerol (24) is commonly found in the Macaranga genus as it is one of the principal 
component of the epicutilar wax crystals that coats the stems of many Macaranga plants.
184
  
 
Figure 3.33: X-ray diffraction crystal structure of 3-epi-taraxerol (24) 
 1
6
2
 
 
Figure 3.34: 
1
H NMR spectrum (CDCl3, 600 MHz) of 3-epi-taraxerol (24)
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Chapter 4: Characterisation of anti-cancer properties of 
crude extracts and isolated compounds  
 
4.1  Introduction 
One of the distinct characteristics of cancer cells is their ability for uncontrolled 
cell proliferation by evading normal regulation in cell growth thus giving them the 
ability to resist apoptosis. As a result, cell proliferation assay which takes into account 
this trait is an effective preliminary screening tool that uncovers potential compounds 
which contribute to advances in cancer drug discovery. The present study yielded 24 
pure compounds from three plant genera, namely Ficus, Artocarpus and Macaranga, 
among which include known compounds that are well established for their anti-cancer 
properties. These are alkaloids: 13a(S)-(+)-tylocrebrine, 13a(S)-(+)-tylophorine (8), 
13a(S)-(+)-septicine (9), and flavonoids: quercetin (21) and kaempherol (22). The anti-
cancer studies of the named alkaloids dated back to the 1960s where tylophorine (8) and 
tylocrebrine (7) became clinical candidates only to be aborted due to central nervous 
system (CNS) toxicity.
102
 In comparison to tylophorine (8), septicine (9) was reported to 
be profoundly weaker in activity despite its structural similarities.
146
 Quercetin 
(21)
121,185
 and kaempherol (22)
122,186
 on the other hand are highly regarded for their 
therapeutic potential against several types of cancer by induction of apoptosis as well as 
the possibility to overcome resistance in tumor cell growth. Given the well established 
studies that have been carried out on these compounds, they were excluded from the 
preliminary anti-cancer screening in this study.  
13a(R)-(-)-3,6-Deoxypergularinine (3), artocarpetin A (14), quercetin-3-O-α-L-
arabinofuranoside (19), lichexanthone (17), 5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-
methylbut-2-en-1-yl)chroman-4-one (23) and 3-epi-taraxerol (24) can not be included in 
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the screening effort due to scarcity of the compounds. Similar to other 
phenanthroindolizidines, literature survey of 3 showed potent cytotoxicity against 
various tumor cell lines including the drug resistant variants.
149
 Contrary to other 
prenylated flavonoids, there were no reports of anti-cancer properties exhibited by 
artocarpetin A (14). Furthermore, 14 was found to show no effect as an antioxidant 
agent rendering this compound as possibly biologically inactive.
187
 No reports were 
found on the anti-cancer activities of lichexanthone (17) and 3-epi-taraxerol (24). The 
remaining compounds (1-2, 4-6, 10-13, 15-16, 18, 20) together with the crude extracts 
were screened for their anti-proliferative potential against four US National Cancer 
Institute (NCI) recognized human cancer cell lines, namely lung carcinoma (A549), 
breast carcinoma (estrogen receptor positive: MCF-7 and estrogen receptor negative: 
MDA-MB-231) and colon carcinoma (HCT-116) cell lines, in addition to one non-
cancer variant, i.e., human lung fibroblast (MRC-5). 
4.2  Anti-proliferative activity of crude extracts and the selected isolated 
compounds 
The anti-proliferative potential of the selected compounds and crude extracts were 
evaluated using the Neutral Red uptake (NR) assay. The NR assay measures lysosomal 
uptake and accumulation of NR dyes in the viable and uninjured cells. Since the amount 
of retained dye is proportional to the number of viable cells, it is thus possible to 
quantitate cell viability and can be used to measure cytostatic effects and cell death.
188
 
The anti-proliferative effects were measured in terms of IC50, which denotes the 
concentration required to reduce cell viability by 50% as compared to the control. IC50 
values are extracted from concentration-response curves by linear interpolation.
189
 
Based on the NCI guidelines, a crude extract is considered to have in vitro anti-
proliferative activity if the IC50 value in cancer cells following treatment between 48-72 
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hours is ≤ 20 µg/mL, while for a pure compound, the IC50 value should be ≤ 4 µg/mL to 
be considered active.
190
 Selectivity of a particular compound can be evaluated based on 
the calculated selectivity index (SI) which is defined as the ratio of cytotoxicity on non-
cancer cells to cancer cells. Samples with SI values > 3 is considered to be highly 
selective towards cancer cells.
191
 For ease of comparison of activity amongst the tested 
compounds within this study, IC50 values were categorized as active, moderately active 
and inactive according to Figure 4.1. 
 
 
Figure 4.1: Classification of anti-proliferative activity based on IC50 (µg/mL) 
concentration. (Information adapted from Boik, J., 2001190) 
 
The anti-proliferative activities of the crude extracts and the selected compounds 
are summarized in Tables 4.1 and 4.2. The most promising anti-proliferative activity 
was found to be the crude alkaloidal mixture of the Ficus species with IC50 values < 1.5 
µg/mL across all the tested cell lines (Table 4.1). Hispiloscine (2), obtained as a new 
alkaloid from the leaves of F. hispida, showed profound anti-proliferative activities 
against all the tested cancer cell lines with IC50 values ranging from 0.13 to 1.21 µg/mL. 
Although hispiloscine (2) also seemed to affect the non-cancer cell line MRC-5, the SI 
values calculated were all above 3, with the exception towards MDA-MB-231, 
indicating that the anti-proliferative activity of 2 is selective towards certain cancer cell 
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lines. The bark of F. hispida on the other hand yielded a new lignan-alkaloid, 
hispidacine (1), which essentially did not show any anti-proliferative activity against the 
cancer cell lines tested (IC50 > 10 µg/mL). Although found to be inactive for anti-
proliferative activity, 1 have been reported to induce moderate vasorelaxant activity in 
rat isolated aorta.
127
 
 The leaves and bark of Ficus fistulosa yielded two new septicine-like alkaloids, 
fistulopsines A and B (4 and 5), a known alkaloid 13a(R)-(-)-3,6- 
didemethylisotylocrebrine (6), and a non-alkaloid vomifoliol (10). Fistulopsine A (4) 
showed potent anti-proliferative activity against MCF-7 and HCT-116 cell lines (IC50 ≤ 
4 µg/mL) and moderate anti-proliferative activity against A549 and MDA-MB-231 cell 
lines. Among these compounds, SI indices showed that the anti-proliferative activity of 
4 was selective towards cancer cells with SI values ranging from 3.5 to 7.4 (Table 4.1). 
Fistulopsine B (5) also exerted anti-proliferative activity and selectivity towards MCF-7 
and HCT-116 cell lines. However, the potency of 5 can be considered only as 
moderately active as the IC50 values for all tested cell lines were ranged between 4.70 to 
8.54 µg/mL. On the other hand, 6 was shown to be active as an anti-proliferative agent 
with IC50 values in the nanogram range where it is the most potent and selective towards 
MCF-7 and HCT-116 cell lines. In contrast to the alkaloids, vomifoliol (10) was shown 
to have poor cytotoxic activity with IC50 values above the treatment range of 50 µg/mL. 
The two new lignan alkaloids, schwarzinicines A and B (11 and 12), obtained from the 
leaves of F. schwarzii were also shown to be inactive towards all the cancer cell lines 
tested.  
The potency of the Ficus plant extracts and the isolated compounds observed in 
the present study is in agreement with literature which states that Ficus plants are highly 
cytotoxic. The Ficus genus have been highly appraised for its efficacy in anti-cancer 
research where some of the most promising cytotoxic compounds in Ficus plants 
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include triterpenoids and phenanthroindolizidine alkaloids.
18,19,123
 The bioactivity of 
phenanthroindolizidines has been linked to its substitution nature and pattern of on the 
phenanthrene ring.
106
 The pronounced cytotoxic activity shown by hispiloscine (2) and 
(-)-3,6-didemethylisotylocrebrine (6) compared to fistulopsines A (4) and B (5) 
(septicine-like alkaloids), provided further support that a rigid phenanthrene structure 
favours higher cytotoxicity.
39
 The rigid phenanthrene structure is essentially lost in the 
structures of 4 and 5 due to the disconnection between C-4a in ring A and C-4b in ring 
C. A similar case was encountered previously which showed that septicine (9) exhibited 
less profound anti-cancer activity compared to its phenanthrene analogue, tylophorine 
(8), despite their overall structural similarities.
42,146
  
Biological studies have suggested that some flavonoids possess anti-tumour 
properties which somewhat justifies the use of flavonoid-rich plants in traditional 
medicine. Many phenolic compounds including flavonoids have been isolated from 
various plants including the Artocarpus and Macaranga genus. In the present study, 
three flavonoid aglycones, namely, cudraflavone C (13), cycloheterophyllin (15) and 
artonin J (16) obtained from the bark of A. heterophyllus x integer and two flavonoid 
glycosides, namely, quercetin-3-O-α-L-arabinopyranoside (18) and quercetin-3-O-β-D-
galactoside (20), which were isolated from the leaves of M. hypoleuca were evaluated 
for anti-proliferative activity. Both flavonoid glycosides were found to be inactive 
against all the cell lines tested. 
It is noteworthy that the crude extract of the hybrid species, A. heterophyllus x 
integer, showed inactive for anti-proliferative activity against the tested cancer cell lines 
(Table 4.2) (IC50 > 100 µg/mL). This was rather unexpected considering the fact that 
not only that the two parent species, namely, A. heterophyllus and A. integer, were 
shown to individually possess anti-proliferative property in the present study (Appendix 
2), but phytochemical screening also revealed a higher flavonoid content in the hybrid 
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species as compared to its parent plants (Appendix 1). It was presumed that flavonoids 
are the agents responsible for the observed anti-proliferative activity for the crude 
extracts of Artocarpus plants. Therefore having a crude extract of the hybrid plant that 
is more flavonoid-rich but possesses no cytotoxic effect is indeed rather surprising. 
Nonetheless, following repeated chromatographic separation, the crude extract of the 
hybrid species yielded three prenylflavonoids, cudraflavone C (13), cycloheterophyllin 
(15) and artonin J (16), which were shown to possess improved anti-proliferative 
activity as compared to the crude extract (Tables 4.1 and 4.2). This observation could 
potentially be due to the presence of other secondary metabolites present within the 
extract that might have caused antagonistic interactions with the biologically active 
flavonoids. For instance, unwanted interactions due to tannins within a herbal 
concoction were previously found to hinder absorption of active constituents, thus 
affecting the overall bioavailability and resulting in a negative impact on the therapeutic 
effect.
192
  
Of the three prenylflavonoids tested, 13 showed the most potent activity (IC50 
values range from 2.80 – 4.15 µg/mL, followed by 15 (IC50 values range from 8.85 – 
25.6 µg/mL) while 16 is essentially inactive. Although cudraflavone C (13) seems to 
possess appreciable cytotoxicity, the SI values calculated show 13 to be a non-selective 
anti-proliferative agent based on the four cancer cell lines and the non-cancerous MRC-
5 cell line tested. Previously, 13 have also been found to show cytotoxicity against 
hepatocellular carcinoma (SMMC-7721), gastric carcinoma (BGC-823 and SGC-7901) 
and B-16 melanoma carcinoma cell lines.
55,193
 The anti-proliferative activities shown by 
flavonoids 13, 15 and 16 broadly confirm the SAR proposed by Arung et al., 
55 
which 
suggested the importance of the prenyl side chain at C-3 for activity. The presence of an 
intact prenyl side chain at C-3 in 13 is consistent with its superior anti-proliferative 
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activity compared to 15 and 16, in which the prenyl side chains at C-3 are part of the 
pyranoflavone and furanoxanthone ring systems, respectively. 
The crude extract of M. hypoleuca showed weak anti-proliferative activity against 
MCF-7 and A549, while the two quercetin-3-O-α-L-arabinopyranoside (18) and 
quercetin-3-O-β-D-galactoside (20) tested are devoid of anti-proliferative activity 
against all the tested cell lines. The lack of activity for both 18 and 20 can be attributed 
to the presence of the sugar substituents in the molecules where the sugar moieties were 
believed to have significantly reduced the hydrophobicity of the molecules and hence 
reduce their ability to permeate through the cellular membrane.
91,107
 Therefore, it can be 
assumed that the growth inhibition observed for the crude extract was not due to 
flavonoid glycosides but the cumulative effects of the aglycones, such as quercetin and 
kaempherol, present within the extract of M. hypoleuca. 
Overall, this screening effort has identified three phenanthroindolizidine alkaloids 
(4, 5 and 6) and flavonoid 13 to be most potent in cancer cell growth inhibition among 
the tested compounds. These compounds were generally found to be especially active 
towards MCF-7 and HCT-116 cell lines and were therefore selected for further 
apoptotic study using these two cell lines the two most succeptible cell lines, MCF-7 
and HCT-116. 
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Table 4.1: Anti-proliferative activity of selected isolated pure compounds using the NR uptake assay against selected cancer cell lines. 
Compounds Mean IC50 values (µg/mL) 
A549 MCF-7 MDA-MB-231 HCT 116 MRC-5 
1 37.30 ± 5.28 24.70 ± 0.46 41.00 ± 3.75 12.20 ± 1.50 - 
2 0.45 ± 0.03 (3.0) 0.18 ± 0.01 (6.9) 1.15 ± 0.01 (1.0) 0.13 ± 0.02 (9.6) 1.21 ± 0.28 
4 7.39 ± 0.58 (8.0) 3.69 ± 0.45 (4.5) 4.62 ± 1.59 (3.6) 3.46 ± 0.35 (4.8) 16.5 ± 5.37 
5 7.33 ± 0.59 (2.9) 5.27 ± 0.68 (4.1) 8.54 ±0.52 (2.8) 4.70 ± 0.67 (4.6) 16.3 ± 3.96 
6  0.056 ± 0.003 (0.7) 0.0003 ± 0.0001 (190) 0.015 ± 0.003 (2.6) 0.006 ± 0.001 (6.3) 0.038 ± 0.008 
10 > 50.0 > 50.0 > 50.0 25.20 ± 6.42 - 
11 > 50.0 33.80 ± 3.85 29.60 ± 5.71 25.20 ± 2.74 - 
12 > 50.0 > 50.0 25.20 ± 6.48 > 50.0 - 
13 3.76 ± 0.15 (0.7) 2.80 ± 0.13 (0.9) 4.15 ± 0.16 (0.7) 3.68 ± 0.84 (0.7) 2.70 ± 0.28 
15 18.60 ± 5.04 20.40 ± 0.34 25.60 ± 4.89 8.85 ± 0.40 - 
16 > 50.0 > 50.0 > 50.0 > 50.0 - 
18 > 50.0 > 50.0 > 50.0 Nil - 
20 > 50.0 > 50.0 > 50.0 Nil - 
Vinblastine 
(positive control) 
 
0.009 ± 0.001 
(229) 
0.0010 ± 0.0001  
(206) 
0.0010 ± 0.0001  
 (206) 
(0.400 ± 0.003) x 10
-5
 
(515000) 
2.070 ± 0.800 
Nil: no inhibition; Selectivity index (SI) value indicated in brackets. Data represents mean IC50 values ± SE, n = 3 and selectivity index (SI) where applicable. Bold 
values indicate isolated pure compound with good  – moderate potency which conforms to NCI guidelines as shown in Figure 4.1. 
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Table 4.2: Anti-proliferative activity of crude extracts using the NR uptake assay against selected cancer cell lines. 
 
 
 
 
 
 
Data represents mean IC50 values ± SE, n = 3. Bold values indicate crude extracts with good – moderate potency which conforms to 
NCI guidelines as shown in Figure 4.1. 
 
 
Plant extracts Mean IC50 values (µg/mL) 
A549 MCF-7 MDA-MB-231 HCT 116 
A. heterophyllus x 
integer (Bark)  
279.0 ± 68.7 471.0 ± 3.5 841.0 ± 193.0 186.0 ± 7.4 
M. hypoleuca  
(Leaves)  
30.05 ± 4.81 14.40 ± 2.78 92.30 ± 6.89 36.20 ± 2.67 
F.fistulosa 
(Leaves) 
0.025 ± 0.003 0.012 ± 0.002 0.161 ± 0.05 0.007 ± 0.002 
F. fistulosa 
(Bark) 
0.060 ± 0.010 0.033 ± 0.006 1.410 ± 0.089 0.027 ± 0.006 
F. hispida 
(Leaves) 
0.047 ± 0.003 0.003 ± 0.001 0.168 ± 0.032 0.011 ± 0.004 
F. hispida 
(Bark) 
0.047 ± 0.003 0.003 ± 0.001 0.167 ± 0.033 0.010 ± 0.003 
F. schwarzii 
(Leaves) 
0.297 ± 0.085 5.270 ± 3.500 0.060 ± 0.014 0.051 ± 0.001 
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4.3  Morphological observation of apoptosis   
Apoptosis is an ordered and orchestrated cellular process that occurs in 
physiological and pathological conditions. It is one of the most studied topics among 
cell biologists. In this study, the anti-proliferative effect evaluated by the NR assay in 
the previous section, showed concentration dependent growth inhibition with treatment 
of the active compounds (Table 4.1, Appendices 71-72). On the basis of these data, 
morphological observation of the cellular nuclei was carried out to determine if the 
growth inhibitory effects upon treatment with the active compounds, i.e., 4, 5, 6 and 13, 
were associated with apoptosis.  
The induction of apoptosis was determined by acridine orange-ethidium bromide 
(AO/EB) double staining of untreated cells (control) and cells treated with the four 
selected active compounds for 24 hours. AO/EB double staining can distinguish 
apoptotic cells from viable and necrotic cells on the basis of membrane integrity. 
Acridine orange permeates through the cell membrane and emits a green fluorescence 
when intercalated with cellular DNA in viable cells, while ethidium bromide is only 
taken up by necrotic cells with compromised membrane integrity, which then emits a 
red fluorescence. Therefore, viable cells will appear uniformly dull green, while the 
onset of apoptosis is indicated by the presence of bright green spots in cells due to 
morphological changes such as nuclear condensation and fragmentation.
194,195
 On the 
other hand, necrotic cells will have uniform red or orange nucleus morphology.
194,195
 
Other morphological hallmarks that can be observed which are associated with 
apoptosis include cell shrinkage, membrane blebbing and disassembly of apoptotic 
bodies.
194,196
  
HCT-116 and MCF-7 cells were treated with compounds 4, 5, 6 and 13 at two 
concentrations, namely, IC50 and 2 x IC50 (Table 5.3), for 24 hours to determine if these 
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compounds induced apoptosis compared to the untreated cells. Cells treated with 
vinblastine were used as a positive control. Vinblastine was selected as a suitable 
control because it is an anti-cancer drug derived from plant alkaloid and is well 
documented for its cytotoxic activity. 
Upon observation, chromatin condensation and membrane blebbing was seen in 
HCT-116 treated population among viable cells (Figures 4.2 - 4.5a,b). Similarly was 
observed in MCF-7 treated cells however, without the occurrence of membrane 
blebbing (Figures 4.2 – 4.4d,e). Although these are notable characteristics of apoptosis, 
cells treated with 4, 5 and 6 did not show a stark contrast when compared to the control 
population, with only a minute number of treated cells expressing such traits. Higher 
treatment concentrations (2 x IC50) with these compounds did show more cells 
displaying apoptotic changes however, the emergence of cells undergoing necrosis was 
also observed among the treated populations. Although unfavorable, literature states 
that apoptosis and necrosis may coexist depending on the concentration of the anti-
cancer agents, where lower and higher concentrations induce apoptosis and necrosis, 
respectively.
197
 Similar biphasic response was also reported in prominent anti-cancer 
drugs such as Taxol
®
 (paclitaxel).
198
  This is in contrast to HCT-116 and MCF-7 cells 
treated with 13 where chromatin condensation was clearly observable in cells treated at 
IC50 concentrations and 2 x IC50 without the presence of necrotic cells.  
Although observations resembling the presence of apoptotic characteristic such 
as chromosome condensation and membrane blebbing were made, the amount of cells 
exhibiting these changes were not substantial when compared to the control. Therefore, 
the induction of apoptosis by compounds 4, 5 and 6 were not conclusive. Furthermore, 
the lack of apoptotic bodies which are the end product and the concluding factor of 
apoptosis are not present within the treated population renders the induction of 
apoptosis by compounds 4, 5 and 6 ambiguous. Moreover, literature suggests that the 
 174 
induction of apoptosis may not necessarily be the primary mode of growth inhibition for 
compounds 4, 5 and 6 as phenanthroindolizidines have been reported to be generally 
non-apoptotic.
116,199
 This comes to suggest of the possibility of non-apoptotic 
chromosome condensation
200
 and membrane blebbing
201
 as a result of stress-induced 
response. 
In regards to 13, apoptotic bodies were also not observed however, AO/EB 
staining showed strong characteristics of chomatin condensation and membrane 
blebbing (HCT-116 cells) almost comparable to apoptotic changes seen on vinblastine 
treated cells. The absence of apoptotic bodies in cells treated with 13 could be due to 
insufficient treatment time for the completion of the apoptotic process. Figure 4.5b 
shows membrane blebs packed with condensed chromatin (seen as bright green) ready 
to be disposed, which may later appear as apoptotic bodies. This is not the argument for 
cells treated with 4, 5 and 6 because of the emergence of necrotic cells even at 24 hours 
treatment.  
Out of the four tested compounds, 13 appears to be the best potential as an 
apoptotic agent as literature have acknowledged flavonoids for their anti-cancer 
activities through the induction of apoptosis.
112,120–122
 Further assessment of apoptosis is 
needed to confirm the induction of apoptosis by 13 and to determine if the apoptotic 
traits observed is indeed apoptotic related. 
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Figure 4.2: Morphological observation with AO/EB double staining by 
flourescence microscope (200 x) of control cells and cells treated with fistulopsine 
A (4) for 24 hours. Cells showing condensed chromatin, membrane blebbing and 
necrosis within the observed population are indicated by white, yellow and red 
arrowheads, respectively. Images are representative of one of three similar experiments. 
Chromatin condensation and membrane blebbing at higher magnification are shown in 
Appendix 73. 
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Figure 4.3: Morphological observation with AO/EB double staining by 
fluorescence microscope (200 x) of control cells and cells treated with fistulopsine 
B (5) for 24 hours. Cells showing condensed chromatin, membrane blebbing and 
necrosis within the observed population are indicated by white, yellow and red 
arrowheads, respectively. Images are representative of one of three similar experiments. 
Chromatin condensation and membrane blebbing at higher magnification are shown in 
Appendix 74. 
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Figure 4.4: Morphological observation with AO/EB double staining by 
fluorescence microscope (200 x) of control cells and cells treated with 13a(R)-(-)-
3,6-didemethylisotylocrebrine (6) for 24 hours. Cells showing condensed chromatin, 
membrane blebbing and necrosis within the observed population are indicated by white, 
yellow and red arrowheads, respectively. Images are representative of one of three 
similar experiments. Chromatin condensation and membrane blebbing at higher 
magnification are shown in Appendix 75. 
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Figure 4.5: Morphological observation with AO/EB double staining by 
fluorescence microscope (200 x) of control cells and cells treated with cudraflavone 
C (13) for 24 hours. Cells showing condensed chromatin, membrane blebbing and 
necrosis within the observed population are indicated by white, yellow and red 
arrowheads, respectively. Images are representative of one of three similar experiments. 
Population of cells showing chromatin condensation and membrane blebbing in 
different viewing fields are shown in Appendix 76. 
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Figure 4.6: Morphological observation with AO/EB double staining by 
fluorescence microscope (200 x) of control cells and cells treated with vinblastine 
for 24 hours. Cells showing condensed chromatin, membrane blebbing, apoptotic 
bodies and necrosis are indicated by white, yellow, brown and red arrowheads, 
respectively. (a) Inset shows digital magnification of apoptotic features indicated by 
respective colored arrows. Images are representative of one of three similar 
experiments. 
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4.4  Cell cycle analysis 
The cell cycle is a series of events that takes place in a cell leading to its division 
and duplication. The cell cycle consists of four phases: G1, S, G2 and M and is 
mediated by growth factors (Figure 4.7). Progression through the cell cycle involves 
checkpoint pathways that monitor for DNA damage (G1, S and G2 checkpoints), proper 
chromosome replication (G2 checkpoint) and chromosome attachment to the spindle (M 
checkpoint, between metaphase and anaphase), transiently halting progression through 
the cell cycle at various points if conditions are not suitable for continuing. The driving 
force for ongoing proliferation can be traced to defective cell cycle control in cancer 
cells, largely by excessive production of growth factor signaling components coupled 
by the loss of restriction point control and failures in checkpoint pathway
202
  
 
Figure 4.7: Cell cycle phases and checkpoints.  
(Diagram adapted from Kleinsmith, L. J. 2005
202
) 
 
The analysis of different phases in the cell cycle was made possible by using 
flow cytometry. This approach of analysis of cellular DNA content following staining 
with intercalating DNA dye such as propidium iodide (PI), which fluoresces when 
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bound to DNA, reveals distribution of cells in three major phases of the cell cycle (G1 
vs S vs G2/M). This is under the assumption that the DNA content of an individual cell 
is proportional to the fluorescence intensity of the excited PI (blue laser 488 nm). All 
cells in G1 have uniform DNA content, as do cells in G2/M where the latter is described 
as having twice the normal G1 DNA content. Apoptotic cells are also detected with its 
fractional DNA content (fragmented low MW DNA) represented on the histogram by 
“sub-G1” peak. A histogram of DNA content of cells in a population can be used to 
derive the percentage of cells in each phase of the cell cycle and any perturbation 
caused by the test compounds.  
Due to time constrain, cell cycle analysis was focused on novel compounds 
fistulopsines A (4) and B (5). Herein, cell cycle perturbation of the two novel 
phenanthroindolizidine alkaloids, fistulopsines A (4) and B (5), were studied by flow 
cytometry on HCT-116 and MCF-7 cell lines following treatment at approximate IC50 
concentration (Table 5.3) of these compounds at 24, 48 and 72 hours. Figures 4.8 and 
4.9 show the effects of 4 and 5 on the cell cycle of the two cell lines. As shown in 
Figures 4.8 and 4.9, the treatment with 4 and 5 for 24, 48, and 72 hours resulted in 
significant increase of cells in the G1 phase of the cell cycle, accompanied by reduction 
of cells in the S and G2/M phases of the cell cycle in both cell lines. Taken together, 
these data suggest that the induction of G1 arrest in HCT-116 and MCF-7 cells by 4 and 
5 might be responsible for cell growth inhibition.
116
 Cell cycle arrest at G1 is commonly 
associated with the modulation of multiple cell cycle regulatory proteins. Among the 
regulatory proteins which is associated with G1 arrest is the downregulation of CDK2, 
CDK4 and CDK6, cyclins D1 and D2,  and the upregulation of CDK inhibitors p21 and 
p27.
116,203–205
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Figure 4.8: Effects of fistulopsines A (4) and B (5) at IC50 concentration on the cell 
cycle of HCT-116 cells after 24 (a), 48 (b) and 72 (c) hours treatment. Data are 
representative of three experiments. Significant differences were compared between 
control and treated cells - asterisk indicates significant (p<0.05) increase or decrease in 
events with respect to control (Appendix 77 and 78).  
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Figure 4.9: Effects of fistulopsines A (4) and B (5) at IC50 concentration on the cell 
cycle of MCF-7 cells after 24 (a), 48 (b) and 72 (c) hours treatment.  Data are 
representative of three experiments. Significant differences were compared between 
control and treated cells - asterisk indicates significant (p<0.05) increase or decrease in 
events with respect to control (Appendix 77 and 79).  
 184 
 
Additionally, HCT-116 showed trends of recovery from the G1 arrest induced by 
fistulopsine A (4) (Figure 4.8c) at 72h where the treated cells did not show any 
significant difference in cell population as compared to the control. At the same time 
point, HCT- 116 cells treated with fistulopsine B (5) still showed significant increase in 
G1 cell population. However, the reduction in S phase cell population was no longer 
significant hence suggesting that the onset of recovery from the G1 arrest is underway 
(Figure 4.8c). Literature states that this observation could be attributed to the decrease 
in intracellular drug accumulation and/or loss of cell sensitivity.
206
 A higher 
concentration of 4 and 5 could circumvent this problem and prevent recovery at least for 
the 72 hour time exposure. 
It was also interesting to note that the two cell lines did not exhibit significant 
accumulation of pre-G1 events, which is indicative of apoptosis. These results are in 
agreement with those obtained from the AO/EB double staining which did not show the 
presence of apoptotic bodies among the observed cell population as a conclusive 
indicator of apoptosis. Furthermore, the findings of this study is supported by previous 
studies on structurally similar compounds such as tylophorine (8)
116
 and antofine (50)
199
 
which rendered this class of compounds as generally non-apoptotic.  
Taken together, the NR results from this study found that 
phenanthroindolizidine alkaloids 4 and 5 are growth inhibitory agents. Growth 
inhibition may be cytostatic or cytotoxic through apoptosis or necrosis. Although 
morphological observation for apoptosis by AO/EB staining showed signs of 
chromosome condensation and membrane blebbing, the lack of apoptotic bodies among 
the observed population rendered the induction of apoptosis by 4 and 5 as inconclusive. 
It is however apparent that these compounds induced their growth inhibitory effect 
through cytostasis by G1 phase arrest in the cell cycle. 
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Majority of the genetic mutation in cancers involve genes that regulate 
progression through G1 phase in the cell cycle.
207,208
 Key regulators for progression 
through G1 to S phase are cyclins D and E. The roles in which these proteins play in 
regulating the transition of cells throughout the G1/S phase is shown in Figure 4.10 
 
 
Figure 4.10: Regulation of G1 cell cycle progression. 
(Diagram adapted from Kleinsmith, L. J., 2005
202
 and Foster, D. A. et al., 2010
207
) 
 
G1 cell cycle progression is triggered by the coupling of Cyclin D with CDK4  
or CDK6 and cyclin E with CDK2 to form complexes which initiate the 
phosphorylation of retinoblastoma tumor suppressor protein (Rb) to its 
hyperphosphorylated state.
208
 Prior to this, Rb in its unphosphorylated form is 
associated with transcription factor, E2F to form a Rb-E2F complex which keeps E2F in 
an inactive state.
207
 When Rb is hyperphosporylated, E2F disassociates from Rb and is 
able to activate genes that are necessary for progression into the S phase.
207
 Among the 
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genes activated by E2F include cyclin E
209
,  which generates a positive feedback loop 
allowing cells to move past the G1 restriction point and simultaneously increasing the 
production of cyclin A2
210,211
 which facilitates the transition of cells from G2 to M 
phase in the cell cycle. Cell cycle progression can be inhibited by cyclin-dependent 
kinase inhibitors (CKIs) such as p21
212
 and p27
213
 which are involved in cell cycle 
arrest at G1 phase.  
As in the case of compounds 4 and 5, tylophorine (8) was previously found to 
induce G1 arrest in HepG2, HONE-1 and NUGC-3 carcinoma cells, which was linked 
to the suppression of cyclin A2 expression.
116
 Therefore, given that compounds 4, 5 and 
8 share structural similarities, it is possible that compounds 4 and 5 exhibit its G1 phase 
arrest in a similar manner as 8. Therefore, the effect of compounds 4 and 5 on CKIs, 
cyclins D and E, CDKs 2, 4, or 6, which may eventually lead to the downregulation of 
cyclin A2 and G1 phase arrest cannot be ruled out. 
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Chapter 5: Experimental 
 
5.1  General experimental procedures 
Melting points were determined on a Stuart SMP-10 melting point apparatus and 
were uncorrected. Optical rotations were determined on a JASCO P-1020 automatic 
digital polarimeter. IR spectra were recorded on a Perkin Elmer Spectrum RX1 FT-IR 
Spectrophotometer. UV spectra were obtained on a GE Ultrospec 8000 
spectrophotometer. CD spectra were obtained on a J-815 Circular Dichroism 
Spectrometer. 
1
H and 
13
C NMR spectra were recorded in CDCl3 or acetone-d6 using 
TMS as internal standard on a JEOL JNL-LA400, JNM-ECA 400 or Bruker Avance III 
400 spectrometers, at 400 and 100 Hz, respectively or on a Bruker Avane III 600 
spectrometer at 600 and 150 MHz, respectively. Coupling constants (J) were reported in 
Hz and chemical shifts (δ) in ppm. X-ray diffraction analysis was carried out on a 
Bruker SMART APEX II CCD area detector system equipped with a graphite 
monochromator and a Mo Kα fine-focus sealed tube (λ=0.71703 Å), at 100K. The 
structure was solved by direct methods (SHELXS-97) and redefined with full-matrix 
least-squares on  F
2 
(SHELXL-97). ESIMS and HRESIMS were obtained on an Agilent 
6530 Q-TOF mass spectrometer. Fluorescent microscopic images were viewed using 
Nikon Eclipse 80i (Nikon, NY). NMR, X-ray diffraction, ESIMS and HRESIMS was 
carried out by collaborators at the Chemistry Department of University Malaya under 
the supervision of Prof. T. S. Kam.  
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5.2  Chromatographic methods 
5.2.1  Column chromatography 
Column chromatography was performed using silica gel 60 (Merck 9385, 230-
400 mesh) unless otherwise stated. The weight ratio of silica gel to sample was 
approximately 30:1 for crude samples. The gel was made into slurry with the eluting 
solvent system before being packed into a glass column. In separations by size 
exclusion, LH-20 sephadex gel was soaked in MeOH overnight to allow the gel to 
expand prior to column packing. Fractions collected were monitored by TLC and 
similar fractions were combined and subjected to further separation by column or 
preparative centrifugal thin layer chromatography where needed. 
5.2.2  Thin layer chromatography (TLC) 
TLC was used for detection and monitoring of targeted flavonoids and alkaloids 
in the crude extracts and fractions. The samples were loaded on to a TLC aluminum 
sheet pre-coated with silica gel 60 F254 0.20 mm thickness and developed in saturated 
chromatographic chambers with appropriate solvent systems. The developed spots were 
visualized by examination of the TLC plates under UV254, followed by spraying with 
Dragendroff‟s reagent (Section 5.3.1) or 1% ethanolic aluminium chloride solution 
(Section 5.3.2). Flavonoids appeared as bright yellow spots under UV365 while orange 
spots formed by reaction with Dragendroff‟s reagent indicated the presence of alkaloids. 
5.2.3  Preparative Centrifugal TLC (CTLC) 
Preparative centrifugal TLC was carried out using a round chromatographic 
plate measuring 24 cm in diameter. Preparation of the chromatographic plate was 
carried out by securing the edge of the plate with cellophane tape to form a mould. 
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Sillica gel slurry (Merck 7759, 50g in 110 mL cold distilled water) was then poured on 
to the previously prepared mould while rotating the plate to obtain an even setting. The 
plate was then left to air dry prior to being dried in an oven at 80 °C overnight. The 
newly prepared plate was then shaved to the desired thickness of 1, 2 or 4 mm before 
being attached to a centrifugal thin layer apparatus (Chromatotron). 
 Separation of compounds was carried out by dissolving the sample in a 
minimum volume of a suitable solvent and loaded on the centre of the spinning silica 
plate to form a thin band. Elution was then carried out with the appropriate solvent 
system. Fractions were collected, concentrated by rotary evaporation, monitored by 
TLC and combined where appropriate. Solvents systems used as eluents were: 
1. Chloroform 
2. Chloroform : Hexanes 
3. Chroloform saturated in ammonia vapor 
4. Chroloform : Methanol 
5. Diethyl ether 
6. Diethyl ether : Hexanes 
7. Diethyl ether : Methanol 
8. Diethyl ether saturated in ammonia vapor 
9. Ethyl acetate 
10. Ethyl acetate : Hexanes 
11. Ethyl acetate : Methanol 
12. Ethyl acetate saturated in ammonia vapor 
13. Acetone 
14. Acetone : Hexanes 
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5.3  Spraying Reagent 
5.3.1  Dragendorff’s Reagent 
Solution A: 0.85 g of bismuth nitrate was dissolved in a mixture of 10 mL glacial acetic 
acid and 40 mL of distilled water. 
Solution B: 8 g of potassium iodine was dissolved in 20 mL of distilled water. 
A stock solution was prepared by mixing equal volumes of solutions A and B. 
One mL of stock solution was then mixed with 2 mL of glacial acetic acid and 10 mL of 
distilled water.  
5.3.2  Aluminium chloride solution 
Aluminium chloride spray reagent was prepared by dissolving 5 g aluminium 
chloride hexahydrate into 500 mL absolute ethanol. 
5.4  Plant materials 
Plant materials were collected from various locations in Malaysia and were 
authenticated by Dr Yong Kien Thai (Institute of Biological Sciences, University of 
Malaya (UM), and Kuala Lumpur). Voucher specimens were deposited at the 
Herbarium University of Malaya, Kuala Lumpur. 
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Table 5.1: Source and authentication of plant materials 
Specimen 
No. 
Locality Plant species 
Date of 
collection 
Herbarium 
UNMC 60 Melaka Artocarpus heterophyllus 
x integer 
Aug 2009 UM 
 
UNMC 70 Semenyih, 
Selangor 
Macaranga hypoleuca June 2011 UM 
UNMC 68 Rawang, 
Selangor 
Ficus fistulosa Dec 2011 UM 
UNMC 77 Semenyih, 
Selangor 
Ficus hispida July 2012 UM 
UNMC 87 Gombak, 
Selangor 
Ficus schwarzii July 2013 UM 
 
5.5 Extraction of plant material 
The stem-bark and leaves (3 kg each) of F. hispida were extracted with 95% 
EtOH (40 L). The concentrated ethanolic extracts were slowly added into 3% tartaric 
acid solution with constant stirring. The acidic solutions were then filtered through 
kieselguhr to remove the non-alkaloidal substances and then basified with concentrated 
NH3 to approximately pH 10. The liberated alkaloids were exhaustively extracted with 
CHCl3, washed with water, dried over anhydrous Na2SO4 and concentrated to furnish 
the crude alkaloidal mixtures (0.67 g; 0.02% and 1.67 g; 0.06%, respectively). The 
stem-bark and leaves of F. fistulosa (8 kg each) and leaves of F. schwarzii (4 kg) were 
extracted in the same manner as described for F. hispida to produce the crude alkaloidal 
mixtures (1.87 g; 0.02%, 8.38 g; 0.1%, and 0.88 g; 0.02% respectively). 
The dried ground bark (4 kg) of A. heterophyllus x integer was sequentially 
extracted with n-hexane (30 L) followed by ethyl acetate (30 L)  and then 95% ethanol 
(30 L) at room temperature (25 °C) for 72 hours. The ethyl acetate extracts were filtered 
and the extractions were repeated twice by adding fresh ethyl acetate and soaked for 24 
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hours at 25 °C. The ethyl acetate filtrates were combined and concentrated to dryness 
under reduced pressure using a rotary evaporator to afford the ethyl acetate crude 
extract (60 g; 1.5%).  
The dried and ground leaf material of M. hypoleuca (2.2 kg) was sequentially 
extracted with n-hexane (20 L), ethyl acetate (20 L) and 95% ethanol (20 L). The three 
different extracts were concentrated to dryness under reduced pressure using a rotary 
evaporator. The concentrated ethyl acetate extract was re-dissolved in minimal amount 
of methanol and then partitioned with hexane to afford a hexane soluble syrup and 
methanol soluble syrup. The methanol soluble syrup was evaporated to dryness under 
reduced pressure using a rotary evaporator to afford 54 g (2.45%) of ethyl acetate crude 
extract.  
5.6  Isolation of alkaloids 
5.6.1 General procedure 
The crude mixture obtained from the extraction procedure was initially 
frationated by vacuum liquid chromatography over silica gel. The column was eluted 
with chloroform, followed by a step-wise increase of methanol gradient. Based on TLC, 
the fractions obtained were pooled into several major fractions which were then 
subjected to further fractionation by vacuum liquid chromatography or CTLC. 
5.6.2 Isolation of alkaloids from the bark and leaves of F. hispida 
The stem-bark crude alkaloid mixture (0.67 g) was initially fractionated by silica 
gel column chromatography (4 x 20 cm) eluted with CHCl3 with increasing proportions 
of MeOH to afford eight combined fractions. Fraction-3 (F3) was re-chromatographed 
using preparative centrifugal thin layer chromatography (CTLC) eluted with CHCl3 
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(NH3-saturated) followed by CH2Cl2/MeOH (NH3-saturated) to yield 13a(R)-(+)-
deoxypergularinine (3) (5 mg; 0.0002%). Fraction-8 (F-8) was re-chromatographed 
using centrifugal preparative TLC (CTLC) with CHCl3 (NH3-saturated) to yield 
hispidacine (1) (33 mg; 0.001%). 
 The leaf crude alkaloid mixture (1.67 g) was initially fractionated by silica gel 
column chromatography (4 x 20 cm) eluted with CHCl3 with increasing proportions of 
MeOH to afford six combined fractions. Fraction-4 (F4) was re-chromatographed using 
CTLC eluted with CH2Cl2/MeOH (NH3-saturated) followed by EtOAc/Hexane (NH3-
saturated) to yield hispilosine (2) (7 mg; 0.0002%). 
5.6.3 Triacetate derivative of hispidacine (1a) 
A mixture of hispidacine (1) (5 mg, 0.010 mmol), acetic anhydride (10 mole eq.), 
pyridine (10 mole eq.), 4-dimethylaminopyridine (cat. amount) in CH2Cl2 (3 mL) was 
stirred under N2 at (25 °C) temperature for 20 min. The mixture was then poured into 
saturated Na2CO3 solution and extracted with CH2Cl2. Removal of the solvent, followed 
by purification by preparative centrifugal TLC over silica gel (Et2O-MeOH) afforded 4 
mg (65%) of the triacetate derivative 1a. 
5.6.4  Isolation of alkaloids from the bark and leaves of F. fistulosa 
The stem-bark crude alkaloid mixture of F. fistulosa (1.87 g) was initially 
fractionated by silica gel column chromatography (2.5 x 20 cm), eluted with CHCl3- 
CHCl3/MeOH (4:1) (in the order of gradual increase in polarity) to produce ten fractions 
(F1 – F10). Fraction-3 (F3) (0.48 g) was re-chromatographed using CTLC eluted with 
Et2O/Hexane (1:2) (NH3-saturated) to yield 13a(S)-(+)-tylocrebrine (7) (4 mg; 
0.00005%). Fraction-4 (F4) (1.77 g) was re-chromatographed by column 
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chromatography (4 x 12 cm) eluted with CH2Cl2 and CH2Cl2/MeOH (NH3-saturated) 
and further purified by CTLC using Et2O/Hex (4:1) to yield 13a(S)-(+)-septicine (9) 
(5.9 mg; 0.00007%). Fraction-5 (F5) (0.11 g) was re-chromatographed by CTLC eluted 
with CHCl3/Hex (1:1) to yield fistulopsine A (4) (7.1 mg; 0.00009%). 
The leaf crude alkaloid mixture (8.38 g) was subjected to silica gel column 
chromatography (7 x 20 cm) eluted with CH2Cl2 and CH2Cl2/MeOH (4:1) (in the order 
of gradual increase in polarity) to produce 11 fractions (F1 - F11). Fraction-2 (F2) (0.05 
g) was purified by CTLC using Et2O (NH3-saturated) to yield 13a(S)-(+)-tylophorine 
(8) (11.8 mg; 0.0001%) as white precipitate. Fraction-5 (F-5) (0.75 g) was re-
chromatographed by CTLC, eluted with CH2Cl2/Hex (1:1) (NH3-saturated) to yielded 
eight sub-fractions (F5-1 – F5-8). F5-1 yielded vomifoliol (10) (7 mg; 0.00006%) as 
colourless needles. F5-5 (0.13 g) formed precipitates which was further purified by 
CTLC, eluted with CH2Cl2 (NH3-saturated) to yield fistulopsine B (5) (20.9 mg; 
0.0003%) and 13a(R)-(-)-3,6-didemethylisotylocrebrine (6) (24.9 mg; 0.0003%). 
Crystallisation of 10 and 5 occurred spontaneously upon isolation of these compounds. 
5.6.5  Isolation of alkaloids from the leaves of F. schwarzii 
The leaf crude alkaloid mixture (0.88 g) was initially fractionated by silica gel 
column chromatography (4 x 20 cm) eluted with CHCl3/Hexane (3:7) and 
CHCl3/MeOH (19:1) to afford nine semi-purified fractions. Fraction-1 (F1) (0.28 g) was 
re-chromatographed using CTLC eluted with Et2O/Hexane (NH3-saturated) to yield 
schwarzinicine A (11) (106.3 mg; 0.003%). Fraction-4 (F4) (0.11 g) was re-
chromatographed using CTLC eluted with Et2O (NH3-saturated) to yield schwarzinicine 
B (12) (213.8 mg; 0.005%). 
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5.7 Isolation of flavonoids 
5.7.1  General procedure 
The ethyl acetate crude extracts of A. heterophyllus x integer and M. hypoleuca 
was fractionated by vacuum chromatography over silica gel eluted with EtOAc/hexane, 
followed by a step-wise decrease of hexane and continually a gradual increase of 
methanol gradient. Fractions obtained were pooled into several major fractions based on 
the TLC profiles and was then subjected to further fractionation by vacuum 
chromatography or CTLC. 
5.7.2  Isolation of flavonoids from the bark of A. heterophyllus x integer 
The ethyl acetate bark extract of A. heterophyllus x integer (60 g) was subjected 
to silica gel column chromatography (8 x 12 cm), eluted with EtOAc/hexane (5:1) and 
EtOAc/MeOH (4:1) (in the order of gradual increase in polarity) to produce 12 
fractions. Fraction-5 (F5) (2.6 g) was re-chromatographed using CTLC eluted with 
EtOAc/Hex(1:4) (in the order of gradual increase in polarity) to produce 11 sub-
fractions (F5-1 –F5-11). Sub-fraction F5-5 (0.4 g) was purified by CTLC eluted with 
CHCl3/hexane (1:1) to yield cycloheterophyllin (15) (45.3 mg; 0.001%). Sub-fraction 
F5-6 was re-chromatographed using CTLC, eluted with Et2O/Hex (2:1) followed by 
Acetone/hexane (1:4) with gradual decrease of hexane to yield lichexanthone crystals 
(17) (1.7 mg; 0.00004%). Fraction-7 (F7) (4.48 g) was re-chromatographed by column 
chromatography (4 x 12 cm) eluted with EtOAc/hexane (1:4) and EtOAc/MeOH (4:1) 
to afford one flavonoid containing sub-fraction which was further purified by CTLC 
eluted with Et2O/hexane (1:1) and Et2O/MeOH (4:1) followed by acetone/hexane (1:1) 
to produce artonin J as yellowish crystals (16) (100 mg; 0.003%). Fraction-9 (F9) (4.5 
g) was chromatographed by column chromatography (4 x 12 cm) to afford four 
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flavonoid containing sub-fractions (F9-2 to F9-5). Sub-fraction F9-2 was purified by 
CTLC eluted with CHCl3/hexane (4:1) and CHCl3/MeOH (4:1) to yield cudraflavone C 
(13) (20 mg; 0.0005%), while sub-fraction F9-5 was re-chromatographed by CTLC 
eluted with CHCl3/MeOH (4:1) followed by purification by LH-20 sephadex column 
chromatography (1 x 44 cm, MeOH) to yield artocarpetin A (14) (4 mg; 0.0001%). 
Crystallisation of 16 and 17 occurred spontaneously upon isolation of these compounds. 
5.7.3  Isolation of flavonoids from the leaves of M. hypoleuca 
The ethyl acetate leaf extract of M. hypoleuca (54 g) was subjected to silica gel 
column chromatography (8 x 12 cm) eluted with EtOAc/hexane (1:4) and 
EtOAc/MeOH (4:1) (in the order of gradual increase in polarity) to produce 11 
fractions. Fraction-2 (F2) (3.4 g) was re-chromatographed by CTLC, eluted with 
CHCl3/hexane (1:4) and CHCl3/MeOH (4:1) to yield 3-epi-taraxerol (24) (3.0 mg; 
0.0001%) as colorless crystals and a flavonoid containing sub-fraction (F2-7) which 
was purified by LH-20 sephadex column chromatography to produce 5,7-dihydroxy-2-
(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one (23) (2.3 mg; 0.0001%). 
Fraction-6 (2.6 g) was re-chromatographed by CTLC and eluted with CHCl3 to produce 
quercetin (21) (17.1 mg; 0.0008%) and kaempherol (22) (38 mg; 0.002%). Fraction-9 
(F9) (4.6 g) produced yellow needles which were identified as quercetin-3-O-α-L-
arabinopyranoside (18) (22.5 mg; 0.001%). Re-chromatography of fraction-10 (F10) 
(4.5 g) by CTLC, eluted with CHCl3 afforded two flavonoid containing sub-fractions 
(F10-2 and F10-3). Precipitation of sub-fraction F10-2 was identified as quercetin-3-O-
α-L-arabinofuranoside (19) (26.2 mg; 0.001%) while purification of sub-fraction F10-3 
by LH-20 sephadex column chromatography produced quercetin-3-O-β-D-galactoside 
(20) (40.0 mg; 0.002%). Crystallisation of 18 and 24 occurred spontateously upon 
isolation of these compounds. 
 197 
5.8 Compound data  
Hispidacine (1): Light yellowish oil; []D
25
 20 (c 0.28, CHCl3); CD (CH3CN, 0.058 
nM),  (): 206 (+1.29), 237 (-2.58), 273 (+1.55) nm; UV (EtOH) max (log ) 228 
(3.86), 271 (3.60) nm; IR (dry film) max 3385, 1585, 1505 cm
1
; 
13
C NMR and 
1
H 
NMR data, see Table 2.2; ESIMS m/z 494 [M H]+; HRESIMS m/z 494.2380 (calcd 
for C25H35NO9 + H
+
, 494.2390). 
Triacetate derivative of hispidacine (1a): Light yellowish oil; CD (CH3CN, 0.046 
nM),  (): 204 (+1.32), 235 (-5.79), 275 (+3.48) nm; IR (dry film) max 3325, 1738, 
1585, 1505 cm
1
; 
13
C NMR and 
1
H NMR data, see Table 2.2; ESIMS m/z 620 [M H]+; 
HRESIMS m/z 620.2691 (calcd for C31H41NO12 + H
+
, 620.2707). 
Hispiloscine (2): Light yellowish oil; []D
25
 1 (c 0.40, CHCl3); UV (EtOH) max (log 
) 260 (3.67), 286 (3.51), 313 (3.06), 338 (2.66) nm; IR (dry film) max 1736  cm
1
; 
13
C 
NMR and 
1
H NMR data, see Table 2.3; ESIMS m/z 422 [M H]+; HRESIMS m/z 
422.1957 (calcd for C25H27NO5 + H
+
, 422.1968). 
13a(S)-(+)-Deoxypergularinine (3): Colourless oil; []D
25 (c 0.11, CHCl3); UV 
(EtOH) max (log ) 228 (3.63), 261 (3.88), 287 (3.80) nm; IR (dry film) max 2963, 
1609, 1512 cm
1
; 
1
H NMR data, see Table 2.4; HRESIMS m/z 364.1909 [M + H]
+ 
 
(calcd. for C23H25NO3 + H
+
, 364.1913). 
Fistulopsine A (4): Colourless oil; []D
25
 = -47 (c 0.30, CHCl3); UV (EtOH) max (log 
) 225 (4.16), 265 (3.94) and 282 (3.86) nm; UV (EtOH + NaOH) max (log ) 226 
(4.18), 247 (4.02), 269 (3.93) and 280 (3.88) nm; IR (KBr) vmax 3375 (OH), 1583, 1515 
cm
-1
; 
1
H NMR and 
13
C NMR data, see Table 2.5; HRESIMS m/z 412.2099 [M + H]
+ 
 
(calcd. for C24H29NO5 + H
+
, 412.2125). 
 198 
Fistulopsine B (5): Colourless needles (CHCl3/MeOH); mp: 209-210˚C; []D
25
 +18 (c 
0.32, MeOH); UV (EtOH) max (log ) 225 (4.11), 239 (4.01), 263 (3.90), and 286 
(3.89) nm; UV (EtOH + NaOH) max (log ) 226 (4.15), 250 (4.02), and 300 (3.87) nm; 
IR (KBr) vmax 3350 (OH), 1594, 1508 cm
-1
; 
1
H NMR and 
13
C NMR data, see Table 2.5; 
HRESIMS m/z 368.1868 [M + H]
+ 
(calcd. for C22H25NO4 + H
+
, 368.1862). 
Crystalographic data of fistulopsine B (5): Colourless needles, C22H25NO4, Mr = 
367.24, monoclinic, space group P21/n, a = 10.5986(17) Å, b = 11.447(2) Å, c = 
15.756(3) Å, α = γ = 90°, β = 102.895(3)°, V = 1863.4(5) Å3, T = 100 k, Z = 4, Dcald= 
1.170 g/cm
3
, crystal size 0.39 × 0.26 × 0.19 mm, F(000) = 700. The final R1 value is 
0.1781 (wR2 = 0.4323) for 4663 reflections [I ≥ 2σ (I)]. 
13a(R)-(-)-3,6-Didemethylisotylocrebrine (6): Light yellowish oil, with []D
25
 -113 (c 
0.13, CHCl3/MeOH). UV (EtOH) max (log ) 262 (4.81), 279 (4.43), 304 (4.04), and 
317 (4.03) nm; IR (KBr) vmax 3385 cm
-1
(OH), 1601, 1514; 
1
H NMR and 
13
C NMR data , 
see Table 2.6; HRESIMS m/z 366.1690 [M + H]
+ 
 (calcd. for C22H23NO4 + H
+
,  
366.1705). 
 13a(S)-(-)-Tylocrebrine (7): Light yellowish oil; []D
25
 +19 (c 0.15, CHCl3); UV 
(EtOH) max (log ) 244(3.21), 264 (3.57), 276 (1.29), 309 (3.03), 321 (2.31); IR (KBr) 
vmax 1600, 1515 cm
-1
; 
1
H NMR and 
13
C NMR data, see Table 2.6; HRESIMS m/z 
394.1938 [M + H]
+ 
(calcd. for C24H27NO4 + H
+
,  394.2018). 
13a(S)-(+)-Tylophorine (8): White amorphous; mp: 290-295˚C; []D
25
 +44 (c 0.12, 
CHCl3); UV (EtOH) max (log ) 240 (3.21), 257 (3.61), 288 (3.34), 304 (3.07) and 399 
(3.87) nm; IR (KBr) vmax 1619, 1515 cm
-1
; 
1
H NMR and 
13
C NMR data, see Table 2.7; 
HRESIMS m/z 394.2011 [M + H]
+ 
(calcd. for C24H27NO4 + H
+
, 394.2018). 
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13a(S)-(+)-Septicine (9): Light yellowish oil; []D
25
 +7 (c 0.28, CHCl3); UV (EtOH) 
max (log ) 204(3.83), 235(3.89), 263 (3.94), 280 (3.97), 353 (4.07) nm; 
1
H NMR and 
13
C NMR data , see Table 2.7; HRESIMS m/z 396.2152 [M + H]
+ 
(calcd. for C24H29NO4 
+ H
+
, 396.2175). 
Vomifoliol (10):  Colourless needles; mp: 98-104˚C; []D
25
 +117 (c 0.41, CHCl3); UV 
(EtOH) max (log ) 237 (3.78) nm; IR (KBr) vmax 3369, 1663 cm
-1
 ; 
1
H NMR and 
13
C 
NMR data , see Table 2.8; HRESIMS m/z 225.1505 [M + H]
+ 
(calcd. for C13H20O3 + 
H
+
, 255.1491). 
Schwarzinicine A (11): Light yellowish oil; []D
25 (c 0.50, CHCl3); UV (EtOH) 
max (log ) 228 (3.30), 280 (3.85) nm; 
1
H NMR and 
13
C NMR data, see Table 2.9; 
HRESIMS m/z 524.3006 [M + H]
+ 
(calcd. for C31H41NO6 + H
+
, 524.3012). 
Schwarzinicine A (12): Light yellowish oil; []D
25  (c 0.45, CHCl3); UV (EtOH) 
max (log ) 230 (3.09), 281 (2.66) nm; IR (KBr) vmax 3587 cm
-1
; 
1
H NMR and 
13
C NMR 
data, see Table 2.9; HRESIMS m/z 396.2152 [M + H]
+ 
(calcd. for C30H39NO6 + H
+
, 
510.2856). 
Cudraflavone C (13): Light orange oil, UV (EtOH) max (log ) 201 (4.51), 232 (4.21), 
261 (4.49), 314 (3.93) nm; IR (KBr) vmax 3364, 1649 cm
-1
; 
1
H NMR and 
13
C NMR data, 
see Table 3.2; HRESIMS m/z 423.1811 [M + H]
+ 
(calcd. for C25H26O6  + H
+
, 423.1808). 
Artocarpetin A (14): Light yellowish powder, mp: 268-273 ˚C; UV (EtOH) max (log 
) 208 (4.21), 253 (3.65), 269 (3.89), 286 (3.62) and 360 (3.83) nm; IR (KBr) vmax 3400, 
1651, 1602 cm
-1
; 
1
H NMR and 
13
C NMR data, see Table 3.2; HRESIMS m/z 369.1348 
[M + H]
+ 
(calcd. for C21H21O6 + H
+
, 369.1338). 
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Cycloheterophyllin (15): Light yellowish powder; mp: 220-222 °C; UV (EtOH) λmax 
(log ): 273 (3.99), 299 (4.15), and 405 (3.88); IR (KBr) vmax: 3346, 1652, 1375 and 
1346 cm
-1
; 
1
H NMR and 
13
C NMR data, see Table 3.3; ESIMS m/z 501.2 [M - H]
-
 
(calcd. for C30H30O7 - H
+
, 501.1913). 
Artonin J (16): Light yellowish crystals; mp: 280-285 °C; UV (EtOH) λmax (log ): 380 
(3.41), 264 (3.84), 231 (3.98) and 210 (4.20); IR (KBr) vmax: 3399, 1713, 1651 cm
-1
; 
1
H 
NMR and 
13
C NMR data, see Table 3.3; ESIMS m/z 437.3 [M + H]
+
 (calcd. for 
C25H24O7 + H
+
, 437.1600). 
Crystallographic data of artnoin J (16): Light yellowish crystals, C25H24O7, Mr = 
340.36, monoclinic, space group P21/c, a = 7.0568(4) Å, b = 17.6285(8) Å, c = 
18.3043(8) Å, α = γ = 90°, β = 97.818(3)°, V = 2255.90(19) Å3, T = 100 k, Z = 4, Dcald= 
1.002 g/cm
3
, crystal size 0.62 × 0.22 × 0.12 mm, F(000) = 720. The final R1 value is 
0.1001 (wR2 = 0.2534) for 16953 reflections [I ≥ 2σ (I)] 
Lichexanthone (17): Yellow needles; mp: 185-190 °C, 
1
H NMR (400MHz, CDCl3): δH 
2.83 (3H, s, H-8), 3.84 (3H, s, OMe), 3.88 (3H, s, OMe). 6.28 (1H, d, J = 2.8 Hz, H-2), 
6.31 (1H, d, J = 2.8 Hz, H-4), 6.64 (1H, s, H-5), δ 6.66 (1H, s, H-7). 
Crystallographic data of Lichexanthone (17): Colourless needles, C16H14O5, Mr = 
286.27, monoclinic, space group P21/c, a = 11.6219(4) Å, b = 7.5059(2) Å, c = 
15.1606(5) Å, α = γ = 90°, β = 102.282(2)°, V = 477.62(11) Å3, T = 100 K, Z = 4, Dcald= 
1.471 g/cm
3
, crystal size 0.48 × 0.08 × 0.04 mm, F(000) = 600. The final R1 value is 
0.0478 (wR2 = 0.1119) for 11753 reflections [I ≥ 2σ (I)]. 
Quercetin-3-O-α-L-arabinopyranoside (18): Yellow needles; mp: 242-244 °C; UV 
(EtOH) λmax (log ): 256 (4.21), 357 (4.47); IR (KBr) vmax: 3476, 2903, 1654, 1618, 
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1508  cm
-1
; 
1
H NMR and 
13
C NMR data, see Table 3.5; HRESIMS m/z 435.0922 [M + 
H]
+
 (calcd. for C20H18O11 + H
+
, 435.0927). 
Crystalographic data of Quercetin-3-O-α-L-arabinopyranoside (18): Yellow 
needles, C20H18O11.2H2O, Mr = 470.246, triclinic, space group P1, a = 4.7435(6) Å, b = 
10.2235(13) Å, c = 11.1721(14) Å, α = 109.622(11)°, β = 100.161(10)°, γ = 
103.176(10)°, V = 477.62(11) Å
3
, T = 100 K, Z = 1, Dcald= 1.673 g/cm
3
, crystal size 
0.10 × 0.02 × 0.01 mm, F(000) = 241.0. The final R1 value is 0.2664 (wR2 = 0.6524) for 
3512 reflections [I ≥ 2σ (I)]. 
Quercetin-3-O-α-L-arabinofuranoside (19): Yellow amorphous; mp: 204-206 °C; UV 
(EtOH) λmax (log ): 258 (4.61), 292 (4.14), 358 (4.52); IR (KBr) vmax: 3400, 2920, 
1613, 1594, 1460 cm
-1
; 
1
H NMR and 
13
C NMR data, see Table 3.5; HRESIMS m/z 
435.0877 [M + H]
+
 (calcd. for C20H18O11 + H
+
, 435.0927). 
Quercetin-3-O-β-D-galactoside (20): Yellow amorphous; mp: 229-231 °C; UV (EtOH) 
λmax (log ): 258 (4.0), 306 (4.05), 316 (3.55), 363 (3.94); IR (KBr) vmax: 3400, 1608, 
1496, 1363, 1300, 1201 cm
-1
; 
1
H NMR and 
13
C NMR data, see Table 3.5; HRESIMS 
m/z 465.1030 [M + H]
+
 (calcd. for C21H20O12 + H
+
, 465.1033). 
Quercetin (21): Yellow powder; mp: 279-283 °C; UV (EtOH) λmax (log ): 257 (4.61), 
303 (4.31), 374 (4.76); IR (KBr) vmax: 3476, 1614, 1519 cm
-1
; 
1
H NMR and 
13
C NMR 
data, see Table 3.6; HRESIMS m/z 303.0498 [M + H]
+
 (calcd. for C15H10O7 + H
+
, 
303.0505). 
 
Kaempherol (22): Yellow powder; mp: 274-279 °C; UV (EtOH) λmax (log ): 265 
(294), 367 (322); IR (KBr) vmax 3476, 1614 cm
-1
; 
1
H NMR and 
13
C NMR data, see 
Table 3.6; ESIMS m/z 287.1 [M + H]
+
 (calcd. for C15H10O6 + H
+
, 287.0556). 
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5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one (23): 
Yellow crystals, mp: 215-218 °C; UV (EtOH) λmax (log ): 219 (4.69), 296 (4.48), 336 
(3.87); IR (KBr) vmax: 3241, 1643, 1516 cm
-1
; 
1
H NMR and 
13
C NMR data, see Table 
3.7; HRESIMS m/z 355. 1504 [M + H]
+
 (calcd. for C21H22O5 + H
+
, 355.1546). 
3-Epi-taraxerol (24): Colourless crystals; mp: 260-263 °C; IR (KBr) vmax: 3400, 848 
cm
-1
; 
1
H NMR (400MHz, CDCl3): δH 0.81(3H, s, H-24), 0.86 (3H, s, H-28), 0.91(3H, s, 
H-30), 0.94 (3H, s, H-27), 0.95 (3H, s, H-29), 1.09 (3H, s, H-23), 1.25 (3H, s, H-20), 
3.40 (1H, t , J = 2.28 Hz,  H-3), 5.50 (H, dd, J = 8.2, 3.1 Hz, H-15). 
Crystalographic data of 3-epi-taraxerol (24): Colourless needles, C30H50O, Mr = 
426.70, triclinic, space group P1, a = 6.2860(4) Å, b = 13.5426(9) Å, c = 15.7104(10) 
Å, α = 110.801(4)°, β = 90.366(4)°, γ = 93.318(4)°, V = 1247.62(14) Å3, T = 100 K, Z = 
2, Dcald= 1.136 g/cm
3
, crystal size 0.52 × 0.41 × 0.23 mm, F(000) = 476. The final R1 
value is 0.0641 (wR2 = 0.1530) for 11001 reflections [I ≥ 2σ (I)]. 
 
5.9 Cell culture 
Human cell lines used in this study were A549 (human lung carcinoma), MCF-7 
(human breast adenocarcinoma-estrogen receptor positive), MDA-MB-231 (human 
breast adenocarcinoma-estrogen receptor negative), HCT-116 (human colon carcinoma) 
and MRC-5 (normal human lung fibroblast), which were purchased from American 
Type Culture Collection (ATCC), USA. A549 and MRC-5 were cultured in RPMI 1650 
medium supplemented with sodium pyruvate (Sigma, UK), MCF-7 and MDA-MB-231 
cells were cultured in Dubelcco‟s modified Eagle‟s medium (DMEM) (Sigma, UK), 
whereas HCT-116 was cultured in McCoy‟s 5A medium (Sigma, UK). All media were 
supplemented with 10% (v/v) fetal bovine serum (Gibco, USA), 100 U/mL of 
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penicillin, 100 µg/mL streptomycin and 50 µg/mL amphotericin B (Gibco, UK). All 
cells were maintained at 37°C in a humidified 5% CO2 incubator (ESCO, USA). 
5.9.1 Preparation of treatment extracts and test compounds 
 Stock crude extract and test compounds were dissolved in DMSO to a 
concentration of 20 mg/mL and 10 mg/mL, respectively. The stock solutions were then 
further diluted to the required concentrations (Table 5.2) with culture media.  
5.9.2 Neutral red uptake assay  
Neutral red (NR) uptake assay was carried out according to methods reported by 
Guillermo et al.
188
 Ninety- six well plates (Nunc, Denmark) were seeded with 5 x 10
3
 
cells per well and allowed to adhere for 24 hours prior to treatment with test samples. 
Seeded cells were treated with test samples at concentrations of 10-1000 µg/mL for 
crude extracts, while pure compounds were treated within the range as indicated in 
Table 5.2 for the duration of 72 hours. Wells containing untreated cells were regarded 
as a negative control, while cells treated with vinblastine (1 x 10
-2
 – 1 x 10-7 µg/mL) 
served as a positive control.  
After 72 hours, the media in the wells were replaced with NR medium (50 µg/mL 
NR stock in culture media) and allowed to incubate for 3 hours. Then, the NR medium 
was removed and the wells were rinsed with (phosphate Buffered Saline; pH7.4) PBS. 
The dye accumulated within the cells was extracted with a solution containing acetic 
acid, ethanol and water (1:50:49). Absorbance (A) was measured at 540 nm using a 
multiwall plate reader (Thermo Fisher Scientific, USA). 
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Table 5.2: NR treatment concentrations for isolated compounds. 
Compounds  A549, MCF-7, 
MDA-MB-231, HCT-116 
MRC-5 
 Treatment range (µg/mL) 
1, 10, 11, 12, 15, 18, and 20  3.25 – 50.0 1.5 -25.0 
2, 4, 5, and 13  0.01 – 10.0 
6  1 x 10
-5 – 0.1 1 x 10-5 – 0.1 
  
 
 Percentage of inhibition was expressed as NR uptake of treated cells as 
compared to untreated cells, calculated as: [(Auntreated – Atreated)/(Auntreated) x 100%].
195
 
Results were presented as mean ± SE of triplicate wells from three independent 
experiments. IC50 (concentration required to reduce the growth by 50% as illustrated in 
Figure 5.1) values were then calculated by Prism Graphpad software (Version 5.0, 
GraphPad Software, Inc., California USA). Dose response curves in which IC50 values were 
derived from are shown in Appendices 70-72. Compounds deemed active (IC50 less than 
5 µg/ml) were tested against the non-cancerous cell line, MRC-5, to investigate cell type 
selectivity. The selectivity index (SI) was calculated as IC50 against MRC-5 cells/IC50 
against cancer cells) where samples with SI greater than 3 were considered highly 
selective towards cancer cells.
191
 
 
 
Figure 5.1:  Illustration of concentration-response graph indicating the definitive values 
of IC50 
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5.9.3 Acridine orange-ethidium bromide staining  
Cell morphological changes were assessed by differential staining using DNA-
intercalate fluorescent dyes, acridine orange (AO) and ethidium bromide (EB). Cells 
(HCT-116 and MCF-7) were seeded into six-well tissue culture plates (7 x 10
4
 
cells/well) for 24 hours prior to treatment with relevant compounds at approximate IC50 
and two times IC50 concentrations  for 24 hours (Table 5.3). Untreated cells served as a 
negative control while cells treated with vinblastine at IC50 served as a positive control. 
After incubation, the control and treated cells were detached, pelleted and suspended in 
25 µL of PBS pH 7.4. Prior to microscopic viewing, one µL of AO/EB solution (1% 
AO in PBS; 1 % EB in PBS) was added to each sample. The stained cell suspension (15 
µg/mL) was then placed on a glass slide and covered with a glass coverslip. The slide 
was then observed under a microscope (Nikon, Japan) and photographed under 
fluorescent illumination (FITC, Cy3 and DAPI filters). Images were analysed by 
Nikon’s imaging software, NIS-Elements. 
Table 5.3: Approximate IC50 and 2 IC50 treatment concentrations (µg/mL) for tested 
compounds. 
Compounds IC50 2IC50 
MCF-7 HCT-116 MCF-7 HCT-116 
4 3 6 3 6 
5 0.002 0.004 0.006 0.012 
6 6 12 4 8 
13 2 4 4 8 
 
5.9.4 Cell cycle analysis by flow cytometry 
Cell cycle analysis was carried out by a collaborator at the Centre for 
Biomolecular Sciences, University of Nottingham, UK according to the method by 
Nicoletti et al.
214
 A total of 1 x 10
6
 cells (HCT-116 and MCF-7) were seeded into a six-
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well plate and incubated for 24 hours at  37 
o
C, after which treatment with compounds 4 
and 5 were applied at approximate IC50  concentration (Table 5.3) for 24, 48 and 72 
hours. At the end of the designated time point, the medium was collected into individual 
centrifuge tubes and the adherent cells were rinsed with PBS, detached and pelleted by 
centrifugation at 1200 rpm (5 minutes, 4 
o
C). Cell pellet obtained was re-suspended in 
0.4 ml fluorochrome solution (50 g/mL of propidium iodide (PI), 0.1 mg/mL of 
ribonuclease A, 0.1% v/v Triton X-100, and 0.1% w/v sodium citrate in dH2O) and 
stored overnight in the dark at 4 
o
C. A single cell suspension was achieved by passing 
the cells through a 23 g needle immediately prior to analysis by flow cytometry 
machine (Beckamn Coulter Ltd, UK) for cell cycle analysis. Data was analysed using 
EXPO 32 software (Beckman Coulter Ltd, UK). 
5.9.5  Statistical analysis 
Statistical calculations of cell cycle analysis were carried out with Prism 
Graphpad 6 software. Results are expressed as mean ± SD of 3 independent 
experiments. Significant differences between untreated (control) and treated groups at 
varying time points were determined by using the two-way analysis of variance 
(ANOVA) with significant differences between groups determined by Duncan‟s 
multiple range tests (DMRT) at 95 % significant difference (p>0.05) using Graphpad 
Prism software (Version 5.0, GraphPad Software, Inc., California USA). 
  
 207 
Chapter 6: Research Limitations, Future Studies and 
Conclusion  
 
6.1  Research Limitations 
The research has successfully yielded six new and 18 known compounds, some 
of which were shown to possess interesting biological activity, several limitations and 
difficulties encountered throughout the research period need to be considered and are 
discussed as follows: 
1. The phytochemical investigation of the leaves of F. schwarzii was only carried 
out on preliminary basis and as such only a very small amount of plant material 
was used. This study has resulted in the isolation of two novel tri-nor-
sesquilignan alkaloids 11 and 12, which are the major alkaloids present in the 
alkaloid crude extract. Several minor alkaloids that were faintly noticeable by 
TLC were however not isolable due to insufficient amount of the alkaloid crude 
extract. Furthermore, due to limited resources and time constraints the absolute 
configuration of 11 and 12 was also not established. 
2. Several of the new and known compounds were only isolated in minute 
amounts, which in many instances have hindered further biological evaluation. 
This can be overcome by re-collecting the plant materials at a larger scale so that 
more pure compounds can be obtained for further studies. 
3. It was unexpected that the research was unable to uncover any new flavonoids 
from A. heterophyllus x integer and M. hypoleuca although screening efforts 
(total flavonoid content, TLC) showed that the crude extracts are rich in 
flavonoids. However, the many flavonoids present in the extracts are believed to 
be in minute quantities hence not all were isolable.  
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4. Preliminary biological evaluations found that some of the compounds isolated 
showed compelling bioactivity, however limitations due to unavailability of 
equipment and time constrains have limited the depth of study for the bioactive 
compounds. 
5. The time taken to carry out structure elucidation has been longer than expected 
mainly due to the unavailability of NMR facility within the University of 
Nottingham Malaysia Campus. NMR spectra for pure compounds were acquired 
from Chemistry Department, University of Malaya. 
6.2  Future studies 
The novel oxyneolignan alkaloid hispidacine (1) and tri-nor-sesquilignan 
alkaloids, schwarzinicines A (11) and B (12) did not show any cytotoxic effect towards 
the tested cancer cells but were however found in a separate study by Dr K. N. Ting‟s 
research group (School of Biomedical Sciences, University of Nottingham Malaysia) 
that these alkaloids exhibited potent vasorelaxant activity (unpublished data). A detailed 
investigation to uncover the underlying mechanism that is responsible for the observed 
effect is underway. Findings from this study may be potentially useful for the treatment 
of asthma, cardiovascular and other related diseases. On the other hand, a more 
thorough phytochemical study on the leaves of Ficus schwarzii will be implemented by 
Dr K. H. Lim‟s group with the intention to uncover more schwarzinicine-type alkaloids 
which may also possess useful vasorelaxant activity. 
Fistulopsines A (4) and B (5) showed potentially active anti-cancer properties 
that can be further exploited. This study found that compounds 4 and 5 induced cell 
cycle perturbation at G1 phase of the cell cycle. Based on literature, 
phenanthroindolizidine tylophorine (8) also showed G1 phase cell cycle arrest, which 
was linked to the down regulation of cyclin A2. However, the point of initiation that led 
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to this was not explored. Given that 4 and 5 are of the same class of metabolites as 8, it 
is highly possible that these two compounds share similar modes of action. The down 
regulation of cyclin A2 is a downstream event that occurred as a result of perturbation 
in the G1 phase machinery which encompasses many other players particularly cyclins 
D and E. As both these regulatory cyclins are activated independently of each other, it is 
advantageous to explore the specific targets in which these compounds exert its effects. 
As majority of genetic mutation that occur in human cancers encodes proteins that 
regulate through the G1 phase of the cell cycle
207,208
, understanding the key regulatory 
points of potential cytostatic agents may allow rational targeting of regulatory sites in 
G1 phase of the cell cycle in most cancers, if not all. 
The anti-cancer potential of cudraflavone C (13) has yet to be fully explored even 
though there were several previous studies that reported the cytotoxicity of it towards 
B16 melanoma cells, hepatocellular and gastric cancer cells.
55,193
 In a recent 
collaborative effort with Dr C. W. Mai and Dr C. O. Leong from International Medical 
University (IMU), it has been disclosed that 13 showed selective inhibition towards 
colon cancer cell proliferation but not towards normal colon epithelial cells 
(unpublished data). This has further sparked the interest on this compound to explore 
the underlying anti-cancer mechanism at the molecular and genomic levels. Among the 
proposed studies include identification of gene expression as well as genomic mapping 
of inter-related genes involved in the activity by means of qPCR and microarray 
analysis, followed by quantification of the protein of interest by immunoblotting.  
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6.3  Conclusion 
A total of 11 alkaloids, six of which are new, were isolated from three Ficus 
species, namely, Ficus hispida, F. fistulosa and F. schwarzii. As far as alkaloid content 
is concerned only phenanthroindolizidine and aminocaprophenone alkaloids were 
previously reported from three Ficus species, namely F. septica, F. fistulosa and F. 
hispida.  
The novel alkaloid hispidacine (1) was isolated from the stem-bark of F. hispida 
as an 8,4'-oxyneolignan that has unusually incorporated a 2-hydroxyethylamine moiety 
and therefore represents the third alkaloid class isolated from Ficus. Hispiloscine (2), 
which was obtained from the leaves of F. hispida, represents the first naturally 
occurring phenanthroindolizidine alkaloid with acetoxy substitution and exhibited 
appreciable anti-proliferative activity against breast, lung and colon cancer cell lines.  
The two new alkaloids obtained from Ficus fistulosa, namely, fistulopsines A 
(4) and B (5); represent the second and third septicine-type alkaloids to be isolated from 
the same species. Fistulopsines A (4) and B (5), showed appreciable in vitro anti-
proliferative activities in HCT-116 and MCF-7 cell lines with IC50 ranging from 2 – 7 
μg/ml. Furthermore, these alkaloids were found to predominantly arrest cells at G1 
phase of the cell cycle without the induction of apoptosis. The known 
phenanthroindolizidine alkaloid 13a(R)-(-)-3,6-didemethylisotylocrebrine (6) also 
isolated from Ficus fistulosa was shown to be potent anti-proliferative agents with IC50 
values in the nanogram range towards the cell lines tested. As in the case of 4, 5 and 
13a(S)-(+)-tylophorine (8), it could be assumed that 6 exerted its growth inhibitory 
activity by means of cell cycle arrest.  
Ficus schwarzii, which was chemically, investigated for the first time, yielded 
two new alkaloids, namely, schwarzinicines A (11) and B (12), which represents the 
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first members of a novel class of plant alkaloids, i.e., tri-nor-sesquilignan alkaloids. 
Schwarzinicines A (11) and B (12) did not show any growth inhibitory effect against 
cancer cell lines. However, a separate study carried out by our collaborators found that 
these alkaloids showed pronounced relaxation effects on rat isolated aorta and trachea. 
Four known prenylated flavonoids and a known xanthone were obtained from 
the bark of A. heterophyllus x integer. On the other hand, the leaves of M. hypoleuca 
provided seven known compounds, of which three are flavonoid glycosides, three 
flavonoid aglycones and one triterpenoid compound. Of the flavonoids tested for 
growth inhibitory activity, only the known prenylflavonoid cudraflavone C (13) showed 
appreciable activity against the cancer cell lines tested, while cycloheterophyllin (15) 
was only shown to be weakly active.  
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Appendices 
 
Appendix 1: Comparison of total phenolic content and total flavonoid content among 
Artocarpus and Macaranga plants.  
 
Table 1a: Total phenolic content (TPC) using Folin-Ciocalteu reagent 
215
 
Plant  
(ethyl acetate extracts) 
Part Total Phenolics 
(mg quercetin equivalents/ g plant 
extract) 
A. heterophyllus x integer Bark 29.60 ± 0.06 
M. hypoleuca Leaves 50.34 ± 0.01 
Total phenolic compounds was determined from regression equation of calibration curve (y = 0.0582x + 
0.0151, R
2
= 0.98) and expressed in mg gallic acid equivalents. Data represent mean ± SD of 5 replicates 
(n=5). 
 
Table 1b: Total flavonoid content (TFC) using ethanolic aluminium chloride solution
216
 
Plant  
(ethyl acetate extracts) 
Part Total flavonoids 
(mg quercetin equivalents/ g plant 
extract) 
A. heterophyllus x integer Leaves 8.63±0.04 
 Bark 46.23±0.05 
 
A. heterophyllus Leaves 8.81±0.06 
 Bark 52.96±0.03 
 
A. integer Leaves  1.28±0.01 
 Bark 17.63±0.04 
 
M. hypoleuca Leaves 47.68 ± 0.09 
 
M. griffithiana Leaves 18.018. ± 0.19 
Total content of flavonoid compounds was determined from regression equation of calibration curve (y = 
0.00166x + 0.0731, R
2
= 0.9769) and expressed in mg quercetin equivalents. Data represent mean ± SD of 
5 replicates (n=5). 
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Appendix 2: Comparison of anti-proliferative activity of the ethyl acetate bark extracts 
of A. heterophyllus, A. integer and the hybrid A. heterophyllus x integer 
 
Table 2: Anti-proliferative activity of crude extracts against various cell lines using 
MTT assay  
Plant extracts Mean IC50 values (µg/ml) 
A549 MCF-7 MDA-MB-231 HCT 116 
A. heterophyllus x 
integer  
46.77  60.26  >100 34.67 
A. heterophyllus 2.11 10.96 >100 3.39 
A. integer 6.81 20.89 >100 15.49 
Data represents mean of IC50 values of triplicate samples conducted in three independent experiments 
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Appendix 3: COSY spectrum of hispidacine (1) 
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Appendix 4: HSQC spectrum of hispidacine (1) 
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Appendix 5: HMBC spectrum of hispidacine (1) 
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Appendix 6: NOESY spectrum of hispidacine (1) 
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Appendix 7: UV spectrum of hispidacine (1) 
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Appendix 8: IR spectrum of hispidacine (1) 
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Appendix 9: COSY spectrum of hispidacine triacetate (1a) 
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Appendix 10: HSQC spectrum of hispidacine triacetate (1a) 
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Appendix 11: HMBC spectrum of hispidacine triacetate (1a) 
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Appendix 12: IR spectrum of hispidacine triacetate (1a) 
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Appendix 13: COSY spectrum of hispiloscine (3) 
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Appendix 14: HSQC spectrum of hispiloscine (3) 
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Appendix 15: HMBC spectrum of hispiloscine (3) 
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Appendix 16: IR spectrum of hispiloscine (3) 
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Appendix 17: COSY spectrum of fistulopsine A (4) 
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Appendix 18: HSQC spectrum of fistulopsine A (4) 
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Appendix 19: HMBC spectrum of fistulopsine A (4) 
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Appendix 20: NOESY spectrum of fistulopsine A (4) 
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Appendix 21: UV spectrum of fistulopsine A (4) 
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Appendix 22: IR spectrum of fistulopsine A (4) 
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Appendix 23: COSY spectrum of fistulopsine B (5) 
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Appendix 24: HSQC spectrum of fistulopsine B (5) 
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Appendix 25: HMBC spectrum of fistulopsine B (5) 
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Appendix 26: NOESY spectrum of fistulopsine B (5) 
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Appendix 27: UV spectrum of fistulopsine B (5) 
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Appendix 28: IR spectrum of fistulopsine B (5) 
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Appendix 29: COSY spectrum of 13a(R)-(-)-3,6-didemethylisotylocrebrine (6) 
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Appendix 30: HSQC spectrum of 13a(R)-(-)-3,6-didemethylisotylocrebrine (6) 
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Appendix 31: HMBC spectrum of 13a(R)-(-)-3,6-didemethylisotylocrebrine (6) 
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Appendix 32: COSY spectrum of 13a(S)-(+)-tylocrebrine (7) 
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Appendix 33: COSY spectrum of 13a(S)-(+)-tylophorine (8) 
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Appendix 34: HSQC spectrum of 13a(S)-(+)-tylophorine (8) 
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Appendix 35: HMBC spectrum of 13a(S)-(+)-tylophorine (8) 
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Appendix 36: COSY spectrum of 13a(S)-(+)-septicine (9) 
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Appendix 37: HSQC spectrum of 13a(S)-(+)-septicine (9) 
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Appendix 38: HMBC spectrum of 13a(S)-(+)-septicine (9) 
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Appendix 39: COSY spectrum of schwarzinicine A (11) 
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Appendix 40: HSQC spectrum of schwarzinicine A (11) 
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Appendix 41: HMBC spectrum of schwarzinicine A (11) 
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Appendix 42: UV spectrum of schwarzinicine A (11) 
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Appendix 43: IR spectrum of schwarzinicine A (11) 
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Appendix 44: COSY spectrum of schwarzinicine B (12) 
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Appendix 45: HSQC spectrum of schwarzinicine B (12) 
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Appendix 46: HMBC spectrum of schwarzinicine B (12) 
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Appendix 47: UV spectrum of schwarzinicine B (12) 
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Appendix 48: IR spectrum of schwarzinicine B (12) 
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Appendix 49: COSY spectrum of cudraflavone C (13) 
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Appendix 50: HSQC spectrum of cudraflavone C (13) 
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Appendix 51: HMBC spectrum of cudraflavone C (13) 
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Appendix 52: COSY spectrum of artocarpetin A (14) 
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Appendix 53: HSQC spectrum of artocarpetin A (14) 
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Appendix 54: HMBC spectrum of artocarpetin A (14) 
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Appendix 55: COSY spectrum of cycloheterophyllin (15) 
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Appendix 56: HSQC spectrum of cycloheterophyllin (15) 
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Appendix 57: HMBC spectrum of cycloheterophyllin (15) 
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Appendix 58: COSY spectrum of artonin J (16) 
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Appendix 59: COSY spectrum of quercetin-3-O-α-L-arabinopyranoside (18) 
 2
8
3
 
 
Appendix 60: HSQC spectrum of quercetin-3-O-α-L-arabinopyranoside (18) 
 2
8
4
 
 
Appendix 61: HMBC spectrum of quercetin-3-O-α-L-arabinopyranoside (18) 
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Appendix 62: COSY spectrum of quercetin-3-O-α-L-arabinoanofuranoside (19) 
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Appendix 63: HMBC spectrum of quercetin-3-O-α-L-arabinoanofuranoside (19) 
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Appendix 64: COSY spectrum of quercetin-3-O-β-D-galactopyranoside (20) 
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Appendix 65: HSQC spectrum of quercetin-3-O-β-D-galactopyranoside (20) 
 2
8
9
 
 
Appendix 66: HMBC spectrum of quercetin-3-O-β-D-galactopyranoside (20) 
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Appendix 67: COSY spectrum of 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one (23) 
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Appendix 68: HSQC spectrum of 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one (23) 
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Appendix 69: HMBC spectrum of 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one (23) 
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Appendix 70: Concentration-response curves of crude extracts against selected cancer cell lines. 
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Appendix 71: Concentration-response curves of isolated compounds (1-10) against selected cancer cell lines. 
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Appendix 72: Concentration-response curves of isolated compounds (10-20) against selected cancer cell lines.
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Appendix 73: HCT-116 and MCF-7 cells observed with AO/EB double staining after 
24 hours treatment with fistulopsine A (4) in comparison to untreated cells as control. 
 
 
 
(a)-(f): Treated and control cells at 200x magnification; (g)-(h): Treated cells showing 
apoptotic features under 400x magnification. Cells showing condensed chromatin, 
membrane blebbing, apoptotic bodies and necrosis are indicated by white, yellow and 
red arrowheads, respectively; (i): Untreated/control cells as comparison under 400 x 
magnifications. Images are representative of one of three similar experiments. 
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Appendix 74: HCT-116 and MCF-7 cells observed with AO/EB double staining after 
24 hours treatment with fistulopsine B (5) in comparison to untreated cells as control. 
 
 
 
(a)-(f): Treated and control cells at 200x magnification; (g)-(h): Treated cells showing 
apoptotic features under 400x magnification. Cells showing condensed chromatin, 
membrane blebbing, apoptotic bodies and necrosis are indicated by white, yellow and 
red arrowheads, respectively; (i): Untreated/control cells as comparison under 400 x 
magnifications. Images are representative of one of three similar experiments. 
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Appendix 75: HCT-116 and MCF-7 cells observed with AO/EB double staining after 
24 hours treatment with 13a(R)-(-)-3,6-didemethylisotylocrebrine (6) in comparison to 
untreated cells as control. 
 
 
 
(a)-(f): Treated and control cells at 200x magnification; (g)-(h): Treated cells showing 
apoptotic features under 400x magnification. Cells showing condensed chromatin, 
membrane blebbing, apoptotic bodies and necrosis are indicated by white, yellow and 
red arrowheads, respectively. (i): Untreated/control cells as comparison under 400 x 
magnifications. Images are representative of one of three similar experiments. 
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Appendix 76: HCT-116 and MCF-7 cells observed with AO/EB double staining after 
24 hours treatment with cudraflavone C (13) in comparison to untreated cells as control. 
 
 
 
(a)-(f): Treated and control cells at 400x magnification; (g)-(h): Treated cells showing 
apoptotic features under 400x magnification. Cells showing condensed chromatin, 
membrane blebbing, apoptotic bodies and necrosis are indicated by white, yellow and 
red arrowheads, respectively; (i): Untreated/control cells as comparison under 400 x 
magnifications. Images are representative of one of three similar experiments. 
 
  
 
3
0
0
 
Time Sample HCT-116  
  
Pre-G1     G1     S     G2/M     
    Mean SD N Mean SD N Mean SD N Mean SD N 
24 hours Control 3.01 1.86 8 39.23 4.18 8 23.15 2.67 8 34.75 2.29 8 
 
Fistulopsine A 3.55 0.60 4 51.63 2.15 4 19.08 1.57 4 26.13 1.49 4 
 
Fistulopsine B 4.63 2.01 4 50.15 0.95 4 17.98 1.04 4 27.48 2.53 4 
              48 hours Control 2.64 1.20 8 41.54 2.49 8 25.06 2.50 8 30.85 1.68 8 
 
Fistulopsine A 2.81 0.74 4 44.30 1.68 4 18.40 2.18 4 25.59 2.65 4 
 
Fistulopsine B 2.68 0.64 4 56.53 1.23 4 16.88 0.53 4 23.98 0.83 4 
              72 hours Control 3.95 2.79 6 55.53 3.54 6 12.05 1.73 6 28.72 7.37 6 
 
Fistulopsine A 4.55 1.50 4 58.38 3.39 4 11.90 1.15 4 25.28 5.98 4 
 Fistulopsine B 6.48 1.27 4 61.80 1.56 4 11.60 1.47 4 20.40 2.66 4 
              
              Time Sample MCF-7                       
  
Pre-G1     G1     S     G2/M     
    Mean SD N Mean SD N Mean SD N Mean SD N 
24 hours Control 0.31 0.12 8 39.69 3.59 8 23.48 1.87 8 36.74 4.26 8 
 
Fistulopsine A 0.33 0.19 4 56.55 8.10 4 17.65 0.73 4 25.70 7.85 4 
 
Fistulopsine B 0.25 0.17 4 61.03 10.39 4 15.90 0.85 4 23.00 10.00 4 
              48 hours Control 0.49 0.54 8 39.69 4.47 8 25.99 2.26 8 33.88 2.79 8 
 
Fistulopsine A 0.43 0.15 4 56.85 2.99 4 13.30 2.68 4 29.38 5.43 4 
 
Fistulopsine B 0.43 0.10 4 54.58 1.24 4 16.40 3.04 4 28.75 4.15 4 
              72 hours Control 1.01 0.59 8 46.75 2.86 8 20.46 1.63 8 32.15 1.73 8 
 
Fistulopsine A 1.88 1.36 4 67.28 4.95 4 8.98 1.49 4 22.00 7.19 4 
  Fistulopsine B 3.13 2.65 4 66.33 5.54 4 11.05 4.38 4 19.60 2.19 4 
 
Appendix 77: Percentage of events at each phases of the cell cycle after treatment with fistulopsine A (4) and fistulopsine B (5) at IC50 concentration. 
(Data is expressed as mean value of more than more than three experiments (N).)
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Appendix 78: Two-way ANOVA of cell cycle analysis of HCT-116 cells treated with 
fistulopsines A (4) and B (5) for 24, 48 and 72 hours.  
(Generated using GraphPad Prism 6 software from mean values generated from more than three 
independent experiments). 
 
 
 
 
 
 
 
 
 
Number of families 4 
Number of comparisons per family 2 
Alpha 0.05 
 Time HCT-116         
  
Dunnett's multiple  
comparisons test 
Mean 
Diff. 
95% CI of diff. Significant
? 
Summary 
24 hours Pre-G1     
 
Control vs. Fistulopsine A -0.54 -3.881 to 2.806 No ns 
 
Control vs. Fistulopsine B -1.61 -4.956 to 1.731 No ns 
 
     
 
G1     
 
Control vs. Fistulopsine A -12.40 -15.74 to -9.056 Yes **** 
 
Control vs. Fistulopsine B -10.93 -14.27 to -7.581 Yes **** 
      
 
S     
 
Control vs. Fistulopsine A 4.08 0.7314 to 7.419 Yes * 
 
Control vs. Fistulopsine B 5.18 1.831 to 8.519 Yes ** 
      
 
G2/M     
 
Control vs. Fistulopsine A 8.63 5.281 to 11.97 Yes **** 
 
Control vs. Fistulopsine B 7.28 3.931 to 10.62 Yes **** 
      48 hours Pre-G1     
 
Control vs. Fistulopsine A -0.17 -2.692 to 2.357 No ns 
 
Control vs. Fistulopsine B -0.04 -2.562 to 2.487 No ns 
      
 
G1     
 
Control vs. Fistulopsine A -2.76 -5.286 to -0.2378 Yes * 
 
Control vs. Fistulopsine B -14.99 -17.51 to -12.46 Yes **** 
 
     
 
S     
 
Control vs. Fistulopsine A 6.66 4.137 to 9.185 Yes **** 
 
Control vs. Fistulopsine B 8.19 5.663 to 10.71 Yes **** 
      
 
G2/M     
 
Control vs. Fistulopsine A 5.26 2.732 to 7.781 Yes **** 
 
Control vs. Fistulopsine B 6.88 4.351 to 9.399 Yes **** 
      72 hours Pre-G1     
 
Control vs. Fistulopsine A -0.60 -5.958 to 4.758 No ns 
 
Control vs. Fistulopsine B -2.53 -7.883 to 2.833 No ns 
      
 
G1     
 
Control vs. Fistulopsine A -2.84 -8.199 to 2.516 No ns 
 
Control vs. Fistulopsine B -6.27 -11.62 to -0.9091 Yes * 
 
     
 
S     
 
Control vs. Fistulopsine A 0.15 -5.208 to 5.508 No ns 
 
Control vs. Fistulopsine B 0.45 -4.908 to 5.808 No ns 
      
 
G2/M     
 
Control vs. Fistulopsine A 3.44 -1.916 to 8.799 No ns 
 Control vs. Fistulopsine B 8.32 2.959 to 13.67 Yes ** 
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Appendix 79: Two-way ANOVA of cell cycle analysis of MCF-7 cells treated with 
fistulopsines A (4) and B (5) for 24, 48 and 72 hours.  
 (Generated using GraphPad Prism 6 software from mean values generated from more than three 
independent experiments). 
 
 
 Time MCF-7         
  
Dunnett's multiple 
comparisons test 
Mean 
Diff. 
95% CI of diff. Significant? Summary 
      24 hours Pre-G1     
 
Control vs. Fistulopsine A -0.01 -6.843 to 6.818 No ns 
 
Control vs. Fistulopsine B 0.06 -6.768 to 6.893 No ns 
  
    
 
G1     
 
Control vs. Fistulopsine A -16.86 -23.69 to -10.03 Yes **** 
 
Control vs. Fistulopsine B -21.34 -28.17 to -14.51 Yes **** 
      
 
S     
 
Control vs. Fistulopsine A 5.83 -1.005 to 12.66 No ns 
 
Control vs. Fistulopsine B 7.58 0.7446 to 14.41 Yes * 
      
 
G2/M     
 
Control vs. Fistulopsine A 11.04 4.207 to 17.87 Yes ** 
 
Control vs. Fistulopsine B 13.74 6.907 to 20.57 Yes **** 
      48 hours Pre-G1     
 
Control vs. Fistulopsine A 0.06 -4.046 to 4.171 No ns 
 
Control vs. Fistulopsine B 0.06 -4.046 to 4.171 No ns 
      
 
G1     
 
Control vs. Fistulopsine A -17.16 -21.27 to -13.05 Yes **** 
 
Control vs. Fistulopsine B -14.89 -19.00 to -10.78 Yes **** 
      
 
S     
 
Control vs. Fistulopsine A 12.69 8.579 to 16.80 Yes **** 
 
Control vs. Fistulopsine B 9.59 5.479 to 13.70 Yes **** 
      
 
G2/M     
 
Control vs. Fistulopsine A 4.50 0.3914 to 8.609 Yes * 
 
Control vs. Fistulopsine B 5.13 1.016 to 9.234 Yes * 
      72 hours Pre-G1     
 
Control vs. Fistulopsine A -0.86 -5.290 to 3.565 No ns 
 
Control vs. Fistulopsine B -2.11 -6.540 to 2.315 No ns 
      
 
G1     
 
Control vs. Fistulopsine A -20.53 -24.95 to -16.10 Yes **** 
 
Control vs. Fistulopsine B -19.58 -24.00 to -15.15 Yes **** 
      
 
S     
 
Control vs. Fistulopsine A 11.49 7.060 to 15.91 Yes **** 
 
Control vs. Fistulopsine B 9.41 4.985 to 13.84 Yes **** 
      
 
G2/M     
 
Control vs. Fistulopsine A 10.15 5.723 to 14.58 Yes **** 
 Control vs. Fistulopsine B 12.55 8.123 to 16.98 Yes **** 
 
 
Number of families 4 
Number of comparisons per family 2 
Alpha 0.05 
